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Aims and Summary
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With this thesis I wish to contribute to evidence based practice in Neph-rology. Not so much by expanding the theory of evidence based medi-cine (EBM), but by applying currently accepted methods to various 
aspects of evidence synthesis and guideline development. The validity of such an 
approach rests on the premise that the methodology used is supported by theo-
retic and empiric evidence, and provides more accurate and trustworthy informa-
tion than any other method. For this reason this thesis starts (Chapter 2) by outlin-
ing definition and purpose of clinical practice guidelines, and discusses some of the 
methods central to their development. Throughout, it was not the intention to be 
exhaustive or even comprehensive but rather to provide the necessary rationale and 
background for a better understanding of the research presented in this thesis and 
the limitations thereof. In Chapter 3, we apply standard Cochrane methods for as-
sessing the benefits and harms of interventions for primary vesicoureteric reflux in 
children through a systematic review of randomized controlled trials. In Chapter 4, 
we continue by extending the criteria to include non-randomized comparative and 
pharmacokinetic studies in a systematic review of antidepressants for depression in 
stage 3–5 chronic kidney disease. The two projects served as a preface to a larger 
one which had as its primary aim the development a clinical practice guideline on 
the diagnosis and treatment of hyponatraemia. In Chapter 5, we present a system-
atic review of guidance documents on this topic, followed by a systematic review 
of randomised trials assessing the benefits and harms of interventions for chronic 
non-hypovolaemic hypotonic hyponatraemia in Chapter 6. The guideline itself is 
presented in Chapter 7. Chapter 8 summarizes the main implications for practice of 
the presented research and discusses some of the limitations of the methodology 
we used. Finally, Chapter 9 is devoted to some personal reflections on what has been 
an exciting journey that has brought me to new lands and has taught me a more 
rational way of practising medicine. I hope readers will enjoy reading this thesis as 
much as I have enjoyed writing it.
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Introduction:
Development of clinical practice guidelines 
in the care of people with kidney disease
Webster AC, Nagler EV, Gallagher M
Paper accepted for publication by the American Journal of Kidney Diseases
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Definition, purpose and effectiveness of clinical practice guidelines
Definition and purpose
The Institute of Medicine defines clinical practice guidelines – hereafter referred to as guidelines - as ‘statements that include recommendations intended to optimize patient care, which are informed by a systematic review of evidence and an assess-
ment of the benefits and harms of alternative care options.’  
The use of guidelines began and expanded in response to issues all healthcare systems 
continue to face. Increasing amounts of information were gradually overwhelming clini-
cians who were finding it increasingly difficult to evaluate new information in context, and 
provide the best possible care, supported by the latest scientific developments. Healthcare 
costs were continuously rising, service delivery varied among providers and at least some of 
this variation reflected inappropriate care (both overuse and underuse of services) with re-
sultant impacts upon patient outcomes. Guidelines were developed in an attempt to reme-
dy these problems by providing a quality control tool for standardising and optimizing care. 
Use, expected benefits and possible harms 
The ultimate aim of guidelines is to improve patient outcomes by optimizing medical de-
cision making. Initially, guidelines were conceived primarily to help individual clinicians to 
digest new research, and to facilitate evidence-based management decisions. By present-
ing contemporary evidence summaries and treatment recommendations, guideline enti-
ties aimed to improve effective practice by encouraging treatments with proven benefit 
and discouraging ineffective or harmful treatments.
Guidelines also serve other purposes. Guidelines may have a general educational role, 
teaching patients, care-givers and the media about best healthcare practices. Knowledge 
of a guideline may empower the individual patient to make better informed healthcare 
choices, by promoting shared decision making between users and providers of healthcare. 
Guidelines generated for conditions with little or no research evidence may be useful in 
additional ways. Rather than emphasizing what we know, these guidelines may predomi-
nantly serve to highlight what we don’t know, and so provide justification for new research 
plans, and encourage stake holders and funding agencies to support new research that will 
close evidence gaps. Guidelines may also be used as an implementation tool, to promote 
translation of research evidence into everyday clinical practice. Healthcare service provid-
ers may use guidelines as a tool for standardising care, aiming to increase efficiency with a 
view to reducing costs. Guidelines may be used to derive measurable clinical performance 
indicators which can be used in quality assurance initiatives, or form the basis of financial 
reimbursement schemes by rewarding the use of best evidence-based practice. Publication 
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Chapter 2
16
of guidelines may raise public awareness of previously under-recognised health burden, 
and inform decisions by policy makers in allocation of healthcare resources. Finally, clini-
cians may turn to guidelines for medico-legal protection in case of malpractice litigation.
The potential benefits of guidelines rest on the premise that guidelines are valid and 
their recommendations are a credible distillation of the evidence. History has often chal-
lenged this assumption. Recommendations may simply be wrong if guideline panels do not 
appraise all the existing evidence, give undue weight to certain findings or if the available 
evidence is misleading or misinterpreted. Recommendations within guidelines may be po-
larised if development groups fail to convene multi-stakeholder, multi-disciplinary panels, 
or if panel members are biased through financial or intellectual conflicts of interest. 
Valid recommendations are never applicable to every single patient. It is a common mis-
conception that guideline developers intend them to be so. If guideline recommendations 
are applied injudiciously, the frequently advertised benefit of more consistent practice and 
reduced variation in care may come at the cost of reducing individualised care for peo-
ple with special needs. If guidelines are misused by auditors, there is risk of inappropriate 
evaluation of clinicians who purposefully deviate from the recommendations for legitimate 
reasons. Reimbursement incentives and fear of legal ramifications when acting outside of 
recommendations may prompt physicians to adhere to recommendations even when a 
specific clinical situation may require a practice variation. Finally even where recommenda-
tions are applicable for the individual patient, the treatment may not represent the best use 
of limited healthcare resources. 
Evidence of effectiveness
Guidelines are able to improve care in theory, but whether they do in practice requires 
evaluation. Research into the effectiveness of guidelines remains limited and their effect 
is often hard to separate from that of other research and initiatives in the area. Examples 
of guidelines that have been associated with widespread and beneficial changes in prac-
tice include the National Kidney Foundation - Kidney Disease Outcome Quality Initiative 
(NKF-KDOQI) guidelines on vascular access and the NKF-KDOQI update of anemia guide-
lines. The vascular access guideline was an important catalyst for a number of changes that 
have seen significant increases in the use of native arterio-venous fistulae and the anaemia 
update, along with clinical trial evidence from the year before, has seen significant changes 
in haemoglobin levels in the ensuing years. Whether this translates into improved patient 
outcomes– e.g. fewer infections, longer and better lives - rests entirely on the evidence that 
underpins the relevant guidelines. 
Entities providing guidelines relevant to nephrologists
There are numerous entities producing guidelines relevant to nephrology clinical prac-
tice. These include international and national nephrology entities, international and na-
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Table 2.1. Examples of entities producing clinical practice guidelines relevant to nephrology.
Acronym – 
Guideline body 
Countries Website
Nephrology
CSN
Committee for Clinical Practice Guidelines -
Canadian Society of Nephrology
Canada www.csnscn.ca/committees/clinical-practice-
guidelines/library
UK-RA
United Kingdom Renal Association
UK www.renal.org/guidelines/
KHA-CARI
Kidney Health Australia – Caring for Australasians with 
Renal Impairment
Australia – 
New Zealand
www.cari.org.au/
NKF-KDOQI
National Kidney Foundation - Kidney Disease Outcomes 
Quality Initiative
USA www.kidney.org/professionals/KDOQI/guide-
lines_commentaries
ERBP
European Renal Best Practice
Europe www.european-renal-best-practice.org/
SLANH
Latin-American Society of Nephrology and Hypertension
Latin America www.slanh.org/
KDIGO
Kidney Diseases Improving Global Outcomes
Global www.kdigo.org/
ISPD
International society for peritoneal dialysis
Global www.ispd.org/ispd-guidelines/
Diabetes
CDA
Canadian Diabetes Association
Canada www.guidelines.diabetes.ca/
ADA
American Diabetes Association
USA www.professional.diabetes.org/ResourcesForPro-
fessionals.aspx?cid=84160
AACE USA www.aace.com/publications/algorithm
American Association of Clinical Endocrinologists
EASD
European Association for the Study of Diabetes
Europe www.easd.org/index.php?option=com_content&v
iew=article&id=93&Itemid=508
IDF
International Diabetes Federation
Global www.idf.org/guidelines
Hypertension
ASH
American Society of Hypertension
USA www.ash-us.org/About-Hypertension/Hyperten-
sion-Guidelines.aspx
ESH
European Society of Hypertension
Europe www.eshonline.org/guidelines/arterial-hyperten-
sion/
ISH
International Society of Hypertension
Global www.ish-world.com/activities/guidelines.htm
General
NICE
National Institute for Health and Care Excellence
England www.nice.org.uk/guidancemenu/conditions-and-
diseases/ kidney-conditions
SIGN
Scottish Intercollegiate Guidelines Network
Scotland www.sign.ac.uk/guidelines/index.html
WHO
World Health Organisation
Global www.who.int/publications/guidelines/en/
Guideline Databases
GIN
Guidelines International Network
Global www.g-i-n.net/
NGC
National Guideline Clearinghouse
USA www.guideline.gov/
NHMRC Guidelines portal
National Health and Medical Research Council
Australia https://www.clinicalguidelines.gov.au/
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tional disease-focussed societies, and government-linked organisations. There are also sev-
eral useful guideline databases, permitting users to search for guidelines by topic or entity. 
Some of these are listed in Table 2.1.
Additional readings
1. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential ben-
efits, limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527-530. 
2. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guide-
line dissemination and implementation strategies. Health Technol Asses. 2004;8(6):iii-iv, 
1-72.
3. Lenzer J. Why we can’t trust clinical guidelines. BMJ. 2013;346:f3830. http://www.bmj.
com/bmj/346/bmj.f3830. Accessed March 14, 2015. 
Methods for developing guidelines
The expected benefits of guidelines are heavily dependent upon the quality of the devel-
opment process. The next sections capture the various aspects of guideline development, 
including topic selection; guideline group composition and group process; systematic re-
view, synthesis and grading of the evidence; moving from evidence to recommendations; 
reporting and peer review. 
Additional readings
1. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical 
Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington DC: The Na-
tional Academies Press; 2011. http://www.ncbi.nlm.nih.gov/books/NBK209539.
2. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward inter-
national standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525-531.
3. Schunemann HJ, Wiercioch W, Etxeandia I, et al. Guidelines 2.0: systematic development 
of a comprehensive checklist for a successful guideline enterprise. Can Med Assoc J. 
2014;186(3):E123-142.
4. WHO. WHO Handbook for Guideline Development. Geneva: World health organization; 
2015.
Topic selection
Priority setting
Developing guidelines is labour-intensive and, therefore, costly. There is no empiric 
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evidence to guide the choice of specific methods for prioritising topics, the major (renal) 
guideline development bodies take similar criteria into account: 
1. Domain specificity – covering topics relevant to people with kidney diseases and their 
carers;
2. Importance – conditions affecting many people or with great burden of illness to an 
individual, families, communities or society as a whole;
3. Need – perceived necessity of a guideline, as indicated by relevant stakeholders;
4. Cost – monetary cost per person of managing the health condition;
5. Variation in practice – as a proxy for clinical uncertainty over best practice; 
6. Expected benefits on health outcomes from successful implementation of the guideline 
- potential to improve healthcare decision making for patients and providers, to improve 
mismatch between actual and appropriate care, to enhance care by improving patients’ 
quality of life, reduce avoidable morbidity, or reduce avoidable premature death;
7. Availability of evidence – clinical research suggesting management strategies can pro-
duce a difference in outcomes.
The relative importance of these criteria in topic prioritisation is unclear. Most often, deci-
sions are made implicitly. Nephrology guideline entities that use specific criteria to prioritize 
guideline topics, do not provide written documentation of the information which informed 
the specific criteria, or how this influenced judgments on relative priority of different topics. 
In a review of methods for priority setting commissioned by the World Health Organisation, 
Oxman and colleagues suggested that: 
1. Criteria for establishing priorities should be applied using a systematic and transparent 
process.
2. Because data to inform judgements are often lacking, unmeasured factors should also 
be considered – explicitly and transparently.
3. The process should include consultation with potential end users and other stakehold-
ers, including the public, using well-constructed questions, and possibly using Delphi-
like procedures.
4. Groups that include stakeholders and people with relevant types of expertise should 
make decisions. Group processes should ensure full participation by all members of the 
group.
5. The process used to select topics should be documented and open to inspection.
Updating published guidelines 
As medical practice develops and advances, guidelines inevitably become outdated. 
Successful priority setting should reveal whether updating a previously published guide-
line takes preference over developing a new topic. Whether an update is needed will largely 
be determined by the extent to which new evidence has emerged, indicating that a change 
in the previously advocated practice strategies could lead to better outcomes or possibly 
reduce cost. 
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Guideline adaptation and appraisal
Adapting guidelines is a means used by some guideline entities of integrating one or 
more guidelines produced by other entities. This may be as an alternative to developing 
a guideline anew, and adaptation may reduce duplication of effort and increase efficiency 
of guideline entities working in the same clinical arena. Adaptation may also aid collabora-
tion between discrete guideline entities, thereby enhancing efficiency further. Adaptation 
might be desirable over simple endorsement, where treatment recommendations need to 
change to suit jurisdiction-specific constraints in delivery of care. The ADAPTE collaboration 
details in their manual a systematic approach to identify, appraise, and endorse or modify 
recommendations to suit the local context. Every guideline is assessed for quality of devel-
opment and reporting using the Appraisal of Guidelines Research & Evaluation (AGREE) II 
instrument. AGREE II is an internationally validated, rigorously developed tool using 23 sig-
nalling questions to evaluate the quality of six domains, and provides a means for making 
explicit judgments about guideline quality. The structure of AGREE II is shown in Table 2.2.
Additional readings
1. Oxman AD, Schunemann HJ, Fretheim A. Improving the use of research evidence in 
guideline development: 2. Priority setting. Health Res Policy Syst. 2006;4:14-21.
2. Field MJ, ed. Setting Priorities for Clinical Practice Guidelines. Washington DC: National 
Academy of Sciences; 1995. 
3. Vernooij R, Sanabria A, Sola I, Alonso-Coello P, Martinez Garcia L. Guidance for updating 
clinical practice guidelines: a systematic review of methodological handbooks. Imple-
ment Sci. 2014;9(1):3.
4. The ADAPTE collaboration. The Adapte Process: Resource Toolkit for Guideline Adap-
tation. Version 2.0. http://www.g-i-n.net/document-store/working-groups-documents/
adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf. Accessed March 14, 
2015.
5. AGREE Collaboration. Development and validation of an international appraisal instru-
ment for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf 
Healthcare. 2003;12(1):18-23.
6. Brouwers M, Kho ME, Browman GP, Cluzeau F, Feder G, Fervers B, Hanna S, Makarski J on 
behalf of the AGREE Next Steps Consortium. AGREE II: Advancing guideline develop-
ment, reporting and evaluation in healthcare. Can Med Assoc J. 2010, 182 (18): E839-842.
Guideline development group composition and processes
Group composition
Guideline development is not an individual’s task. A multidisciplinary team is necessary 
for ensuring adequate consideration of the breadth of evidence and the different values at-
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Table 2.2. Structure of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument, used for 
appraising the quality of Clinical Practice Guidelines.
Domain Questions within domain
Scope and 
purpose
The overall objective(s) of the guideline is (are) specifically described.
The health question(s) covered by the guideline is (are) specifically described.
The population (patients, public, etc.) to whom the guideline is meant to apply is specifically de-
scribed.
Stakeholder 
involvement
The guideline development group includes individuals from all relevant professional groups.
The views and preferences of the target population (patients, public, etc.) have been sought.
The target users of the guideline are clearly defined.
Rigor of 
development
Systematic methods were used to search for evidence.
The criteria for selecting the evidence are clearly described.
The strengths and limitations of the body of evidence are clearly described.
The methods for formulating the recommendations are clearly described.
The health benefits, side effects, and risks have been considered in formulating the recommenda-
tions.
There is an explicit link between the recommendations and the supporting evidence.
The guideline has been externally reviewed by experts prior to its publication.
 A procedure for updating the guideline is provided.
Clarity  of 
presentation
The recommendations are specific and unambiguous.
The different options for management of the condition or health issue are clearly presented.
Key recommendations are easily identifiable.
Applicability The guideline describes facilitators and barriers to its application. 
The guideline provides advice and/or tools on how the recommendations can be put into practice.
The potential resource implications of applying the recommendation have been considered.
The guideline presents monitoring and/or auditing criteria.
Editorial 
independence
The views of the funding body have not influenced the content of the guideline.
Competing interests of guideline development group members have been recorded and addressed.
Adapted and abbreviated from http://www.agreetrust.org/ , accessed 30th March 2015
tached to possible outcomes, as well as for securing ownership and support among target 
audiences. Teams ideally represent the clinicians taking care of patients (e.g. nephrologists, 
but also other specialty disciplines, primary care physicians, nurses and paramedical staff ), 
and other stakeholders potentially affected by implementation of the guideline (policy 
makers making decisions about resource use, patients and their care-givers). Guideline 
groups ideally also include people with expertise in epidemiology and statistics, guideline 
development or implementation. However, the desire for wide representation needs to be 
balanced against timelines and costs for bringing groups together and the challenges of 
effectively managing groups beyond 15 participants. 
Conflict of interest
Guidelines should be based on scientific evidence, critical appraisal of the potential bias-
es of that evidence, and objective clinical judgment in linking the evidence to what patients 
value. Financial or other ties to companies that are impacted by a guideline, may negatively 
influence the panellist’s ability to approach a scientific question with an open mind. Con-
flict of interest may bias the interpretation of evidence, but also determine what questions 
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a guideline seeks to answer and unduly influence the recommendation generating pro-
cess. An example that became the source of heated debate is the 2006 KDOQI guideline for 
the management of anaemia in people with chronic kidney disease. One recommendation 
therein proposed to increase the previously supported haemoglobin target concentrations 
from 11-12 to 11-13 g/dL, even though the available evidence indicated such an approach 
was not associated with better survival or reduced risk of cardiovascular events. At the time, 
14 of the 16 guideline development team members reported having received consultant 
fees or research funds from at least one of the companies, which would potentially benefit 
from the guideline change. In addition, both the chair and co-chair had financial relation-
ships with the company that funded the guideline and stood to benefit from its recom-
mendations. 
Much less acknowledged, and possibly far more difficult to deal with is intellectual con-
flict of interest. We often believe science to be a dispassionate pursuit of facts, and that 
researchers willingly change their minds as new evidence emerges. In reality, human be-
ings often find it extraordinarily difficult to look at their own results through the eyes of a 
detached observer or to change their prevailing beliefs. For most entities developing renal 
guidelines, public disclosure of financial interests has become commonplace, but intellec-
tual interests are rarely considered and declared intellectual conflicts rarely limit the extent 
to which people are permitted to participate in the guideline development process. Many 
experts are sceptical that disclosure alone minimizes the bias. In its standards for develop-
ing trustworthy guidelines, the Institute of Medicine has advocated exclusion of those with 
conflict of interest from leadership positions. The World Health Organization has adopted 
increasingly rigorous management strategies, excluding altogether those with conflict of 
interest from the recommendation generating process. Ideally, a guideline development 
panel would only include individuals free from conflict of interest, be it financial or intellec-
tual. It would also include the most knowledgeable and those best able to convince others 
to implement the recommendations in practice. Unfortunately well-known ‘experts’ often 
have the most sweeping competing interests. Excluding them entirely from the process 
may not be possible without losing important insights into specific content or necessary 
support for effective implementation. The Institute of Medicine recognized this; rather than 
demanding all guideline development members be free from any competing interest, it 
advocated keeping their participation to a minimum. 
Group processes
Although a multidisciplinary team is necessary for valid guideline development, this 
does not guarantee success. Successful guideline development relies on functioning group 
processes. What can go wrong? If one person dominates the discussion, resulting recom-
mendations may diverge from the evidence or may not represent the opinion of the group 
(known as minority influence). Likewise, a desire to reach agreement may override concerns 
about accuracy and drive people away from the evidence (known as group think). Multidis-
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ciplinary groups are especially at risk here, as established authorities are often the most ac-
tive participants, and may exert undue influence over other members of lower professional 
status. 
Group process biases may be reduced by careful selection of the group leader, who 
should have the authority to enforce any ground rules; ensure complete group participa-
tion by providing equal opportunities for contribution from all members; give group mem-
bers’ arguments proper attention when articulating recommendations; maintain construc-
tive dynamics; and check consensus attainment while guarding their own neutrality. In the 
UK, the NICE guidelines entity seeks to appoint guideline working group chairs from non-
topic specialties:
“The Chair is appointed for their expertise and skill in chairing groups, and although they 
may have some knowledge of the topic, this is not their primary role in the group. Specialist 
knowledge is provided by other Committee members....”
More formal group process methods include formal consensus building strategies such 
as nominal group techniques and Delphi methods which tend to surpass informal methods 
in achieving agreement. The nominal group technique is structured group brainstorming 
involving problem identification, solution generation, and decision making. The Delphi 
method is a widely used group communication process which aims to achieve a conver-
gence of opinion from topic experts by two or more rounds of anonymous data gathering 
with subsequent statistical feedback.
Patient and public involvement
Quality standards increasingly stress the value of patient and public involvement in 
guidelines. Involving patients, their carers or advocates is necessary to ensure that their 
views and experiences are reflected, that the guideline is patient-centred and that it cov-
ers issues and outcomes important to them. However, best methods of adequately solicit-
ing consumer perspectives are not clear, and take time and money. If done without proper 
thought to the aims and required methods for achieving integration of consumer perspec-
tives, attempts risk remaining tokenistic, leaving consumers with a marginal role at best. 
In 2012, G-I-N PUBLIC, a workgroup of the Guidelines International Network devoted to 
effective patient and public involvement in the development and implementation of guide-
lines, identified three strategies important for patient and public involvement. These were:
1.  Consultation – aiming to collect views regarding needs, experiences, and expectations. 
This can happen at the scoping stage or when the draft guideline has been developed, 
be targeted to relevant consumer groups or open to the public, or both. Consultation 
may include inviting comment on draft documents, centre on systematic reviews of pa-
tient and public perspectives, and include surveys, focus groups or individual interviews. 
2. Participation – aiming to have active involvement in deliberation, to foster a collective 
perspective on guideline development and to agree on common group decisions over 
guideline content. Although in theory, participation can facilitate compromise between 
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people with varying perspectives, adequate support is required for it to be effective. 
3. Communication - aiming to provide patients and public with understandable infor-
mation on diagnostic or treatment recommendations, enabling joint decision-making 
based on the best available evidence.  
For nephrology guidelines groups, the engagement of patients and the broader commu-
nity with their work remains limited and in need of development.
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Systematic literature review/Development processes
Scoping/Determining key questions and outcomes
This is possibly the most important phase of the guideline development process, but 
team impetus to move forwards to evidence review is sometimes at odds with spending 
time deliberating guideline questions and outcomes.  Arriving at an evidence-based recom-
mendation requires understanding which questions must be answered to get there, what 
evidence is available for consideration, and what outcomes need to be assessed. Typically, 
questions include identification of groups at risk of a health problem, diagnostic test accu-
racy, benefits and harms of different treatments, significance of prognostic factors, etc. For 
example, to develop a recommendation for or against screening for cardiovascular disease 
in kidney transplant candidates, one would need to know; if there are effective treatments 
to improve outcomes in candidates with severe asymptomatic coronary artery disease; if 
tests can accurately diagnose the condition: the potential harms of testing and treatment; 
and who should be screened. Failure to articulate these key questions and to define which 
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evidence is admissible to answer them can result in time, effort and money wasted at gath-
ering and analysing data that is ultimately irrelevant to the recommendations being devel-
oped.   
Consider an example; if you tried answering a question on ‘how best to screen for car-
diovascular disease in kidney transplant recipients?’ How would you go about finding an 
answer? You could turn to an internet browser and search the question verbatim. In Google 
it would take 0.37 seconds to retrieve 179,000 citations (as of 6th April 2015), including 
guidelines and consensus statements and, if lucky, these would be at the top of the list and 
provide trustworthy advice. More likely is that these were buried among many other entries, 
more or less relevant to the topic. There may be a few systematic reviews and hundreds 
of individual studies investigating the incidence of cardiovascular disease among kidney 
transplant candidates; the risk factors associated with having asymptomatic coronary artery 
disease; the diagnostic accuracy of various non-invasive tests in detecting disease; the as-
sociation between asymptomatic coronary disease before and the outcome after transplan-
tation; and benefits and harms of treatments for asymptomatic disease before transplanta-
tion. Most of the retrieved studies regarding a given question will cover different patient 
groups. In addition, there will be thousands of citations unrelated to the problem. Finally, 
you may have missed crucial information not picked up by the browser’s search algorithm. 
The example above illustrates that efficiently generating evidence-based advice requires 
understanding i) which questions need to be answered in what order ii) what evidence is 
required and ii) how to adopt a systematic strategy that will allow its retrieval.  
Guideline development team members must unambiguously define which outcomes 
and which measurement time-points they consider pivotal for decision making. This step 
forces the team to articulate in advance to what extent particular outcomes need to be 
affected to support a particular recommendation. Outcomes must reflect what is impor-
tant to patients. In the example of screening for cardiovascular disease, it is likely that pa-
tient-centred outcomes would include all-cause and cardiovascular death as well as severe 
complications such as acute myocardial infarction. Important outcomes may also include 
indicators of physical or emotional well-being such as functional status or health-related 
quality of life. Data on these health-outcomes are often harder to ascertain, as clinical trial 
investigators tend to measure surrogates outcomes to reduce the cost, sample size and du-
ration of trials. However, assumptions about proximity of surrogates to clinically important 
outcomes are often not well informed. For example, it is tempting to assume benefits of 
lipid-lowering treatment on total cholesterol will result in downstream reduction in cardio-
vascular death, but this may not be the case for people with ESKD. 
Framing questions for systematic review: PICOM
Individual key questions must be framed such that relevant evidence can be systemati-
cally searched and selected. Framing is facilitated by addressing each part of the mnemonic 
PICOM. 
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• P - Patient and/or Problem. How would one define a group of patients akin to the ones 
of interest? What are key common characteristics of these people? 
• I – Intervention or Indicator. Which main interventions should be contemplated?  What 
diagnostic test or exposure?  
• C – Comparison. What is the main alternative with which the intervention/indicator is to 
be compared? Is this about a comparison between two medications, a medication and 
no treatment, or two diagnostic tests? 
• O – Outcomes. What is/are the outcome(s) of most interest in this clinical setting? Are 
clinicians or patients seeking benefit or reduced adverse events?
• M – Methodology. What is the best feasible study design to answer this question? Which 
study design will offer the least biased results? 
Table 2.3 shows how the clinical question on screening for coronary artery disease in 
kidney transplant candidates can be divided in sequential specific questions and converted 
into a focused format more readily answerable by research evidence, by applying the above 
PICOM strategy.
Systematic searching and study selection 
Information sources
Once the precise guideline questions have been framed into an answerable format, the 
next step is to determine where to best look for an answer. Medical research data are most 
effectively accessed through queries of electronic databases which offer citations and ab-
stracts of journal articles and books. There is a wide variety of such databases available and 
the ‘best’ choice will largely depend on the type of question being asked and the optimal 
study design to answer that question. There are many databases with overlapping, com-
plementary or unique content areas and each has its strengths and weaknesses. It is be-
yond the scope of this paper to cover all options. Hence, discussion will be limited here to 
the databases most immediately useful to guideline developers: The Cochrane Database 
of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effects (DARE), the 
Cochrane Central Register of Controlled Trials (CENTRAL), the Medical Literature Analysis 
and Retrieval System (MEDLINE), and the Excerpta Medica Database (EMBASE) platform. 
Table 2.4 shows the specific databases most useful to search for the clinical questions 
developed earlier in this paper, organised by question type and optimal study design.
Search strategy structure 
Executing an effective search to identify all studies relevant to the specific question at 
hand is a critical and often challenging step in the guideline development process. Identify-
ing the totality of evidence for a question must appreciate the quantity of published and 
unpublished material is vast; much research remains unpublished; there are limitations in 
indexing systems within electronic databases, and in the scope of individual databases; sen-
sitive searching has to come at the cost of retrieving irrelevant studies, and specific searches 
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may miss important evidence and individuals who are experts in the content area may be-
lieve they already know all the relevant research within a particular field. 
A typical search strategy consists of a logical combination of terms referring to the pop-
ulation; the intervention, index test or exposure; possibly the comparator; the outcomes; 
and finally the study design. For each of the components, relevant search terms include a 
combination of keywords database providers use to index the publications and documents 
listed within their database. These keywords make up the controlled vocabulary thesaurus 
(e.g. MeSH for MEDLINE and the Cochrane Library; EMTREE for EMBASE) and allow simulta-
neous retrieval of similar articles without specifying each synonym and spelling variation 
used by authors. Because indexing is at times subjective and incomplete, systematic search 
strategies typically include free text words (in title and abstract) to ensure important cita-
tions are not missed. Table 2.5 shows an example of a framed question translated into a 
sensitive search strategy. 
Systematic evidence review including bias appraisal of included studies
What is bias and why should it be considered? 
A bias is a systematic error or deviation from the truth, in results or inferences which can 
lead to either over- or underestimation of the causal relationship between an intervention, 
an exposure or a diagnostic test, and an outcome. Bias results from factors which may be 
known or unkown, which provide a possible alternative explanation for the result attributed 
to the relationship between the intervention of interest and the outcome. Such factors have 
three features: i) they affect the outcome, e.g. age; ii) they are unequally distributed be-
tween the experimental and control group; iii) they do not represent an intermediate step 
in the causal chain between the exposure and outcome. In practice it is impossible to know 
to what extent biases affect the results of any individual study, but there is substantial evi-
dence that specific shortcomings in the design, conduct or analysis of studies result in bias. 
Some study designs are inherently more vulnerable to the introduction of bias than others. 
For example, the RCT differs from an observational cohort study in that the randomization 
aims to protect against selection bias whilst the blinding of participants and personnel tries 
to minimise performance bias. However, not all RCTs produce equally trustworthy results, 
as not all are conducted and reported optimally. RCTs produce treatment effect estimates 
that are; exaggerated by 11% if the sequence generation is inadequate or unclear; exagger-
ated by 7% if the allocation concealment is inadequate or unclear; and exaggerated by 13% 
if blinding of participants and researchers does not occur. Estimates of exaggeration are 
greatest for meta-analyses assessing subjective outcome measures. 
Because each type of study (e.g. RCT versus cohort study) has different opportunities for 
introducing bias, any assessment tool aiming to distinguish studies providing more or less 
trustworthy results, needs to be tailored to the particular study design under evaluation. 
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Tools for assessing risk of bias in studies
Risk of bias can be used interchangeably with internal validity or the extent to which 
design and conduct of a study are likely to have prevented biases. Many tools have been 
developed to aid the assessment of potential bias in studies of different designs, each with 
their own strengths and weaknesses. Table 2.6 lists a suggested bias assessment tool for 
each study design. Without exception these tools are the result of consensus between stat-
isticians, epidemiologists and review authors, based on systematic review of empirical evi-
dence. 
Appraising a body of evidence for individual outcomes across studies
Regardless of the primary aim of the guideline literature review (comparing interven-
tions, assessing the accuracy of a test or estimating the average effect of a risk factor), the 
next step is to examine the totality of evidence for each outcome across studies and draw 
conclusions about the summary effect. The degree of confidence in these conclusions will 
depend on several factors. The reliability of results of the individual studies is not the only 
determinant. Other features include evaluating the consistency and precision of the results 
across studies, applicability of results to the targeted population and whether publication 
bias is likely. 
Consistency of evidence relates to heterogeneity of findings across studies. Study results 
can vary due to differences in key aspects of the design (e.g. trials with lower or higher risk of 
bias) or of the study participants (e.g. those treated versus those not yet treated with dialy-
sis), interventions (e.g. doses, duration of treatment, co-interventions) and outcomes (e.g. 
definitions and measurement time-point). If important variability among studies remains 
unexplained, it will reduce the confidence in any resulting inferences. Assessing the impor-
tance of a level of variability remains a matter of judgement of the assessors. 
Directness of evidence is also referred to as applicability or external validity. Examples 
of features that can reduce the applicability of evidence to a guideline include differences 
between the study participants and the population for which the guideline is meant to 
apply. This might be driven by difference in baseline risk, in culture, lifestyle, delivery of 
care, or in the availability of technologies and resources. Directness is also compromised if 
measured study outcomes differ from those the guideline development team see as criti-
cally important (e.g. Kt/V versus health-related Quality of Life); or if surrogate outcomes are 
used instead of important patient outcomes (e.g. 30% decrease in glomerular filtration rate 
versus need for renal replacement therapy). 
Precision relates to confidence in the magnitude of an estimated effect. Precision is usual-
ly represented by the 95% confidence interval, which can be interpreted as the range within 
which the effect plausibly lies.  The confidence interval needs to be sufficiently narrow, and 
to encompass the minimal effect considered clinically important. 
Publication bias occurs if ‘negative studies’ remain unpublished or unidentified. When 
only published studies are considered, interventions appear more effective, tests more ac-
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Table 2.6. Tools for assessing risk of bias/Critical appraisal tools.
Study 
design
Tool Bias Mechanism 
Ran-
domised 
controlled 
trials
Cochrane risk of bias 
tool for randomised 
controlled trials
Selection bias
Selection bias
Performance bias
Detection bias
Attrition bias
Reporting bias
Other bias
1 Bias due to inadequate random sequence generation
2 Bias due to inadequate allocation concealment
3 Bias due to inadequate blinding of participants and researchers
4 Bias due to inadequate blinding of outcome assessment?
5 Bias due to incomplete outcome data
6 Bias due to selective reporting
7 Bias due to other mechanisms
Non-ran-
domised 
studies of 
interven-
tions
A Cochrane risk of 
bias assessment 
tool: for non-rand-
omized studies of 
interventions
(ACROBAT – NRSI)
Confounding bias
Selection bias
Misclassification bias
Performance bias
Attrition bias
Detection bias
Reporting bias
1 Bias due to confounding
2 Bias in selection of participants into the study
3 Bias in measurement of interventions
4 Bias due to departures from intended interventions
5 Bias due to missing data
6 Bias in measurement of outcomes
7 Bias in selection of the reported result
Cohort 
studies
Newcastle-Ottawa 
quality assessment 
scale cohort studies 
(NOS – Cohort)
Selection bias
Selection bias
Misclassification bias
Detection bias
Selection bias
Detection bias
Detection bias
Attrition bias
1 Representativeness of exposed cohort
2 Selection of the non-exposed cohort
3 Ascertainment of exposure
4 Demonstration that outcome was not present at start of study
5 Comparability of cohorts on basis of the design and analysis
6 Assessment of outcome
7 Adequacy length of follow-up for outcome occurrence
8 Adequacy of follow-up of cohorts
Case-
control 
studies
Newcastle-Ottawa 
quality assessment 
scale cohort studies 
(NOS – Case-control)
Selection bias
Selection bias
Selection bias
Selection bias
Selection bias 
Detection bias
Detection bias
Attrition bias
1 Adequacy of case definition
2 Representativeness of cases
3 Selection of controls
4 Definition of controls
5 Comparability of cases and controls on the basis of the design or 
analysis
6 Ascertainment of exposure
7 Same method of ascertainment for cases and controls
8 Non-response rate
Cross-
sectional 
diagnos-
tic test 
accuracy 
studies
Quality assess-
ment of studies of 
diagnostic accuracy 
(QUADAS-II)
Selection bias
Spectrum bias
Performance bias
Detection Bias
Performance bias
Performance Bias
Attrition bias
1 Bias in selection of participants into the study
2 Applicability of test results to target population of interest 
3 Bias in conduct or interpretation of the index test (blinding)
4 Applicability of index test, its conduct, or interpretation to 
review question
5 Bias in conduct or interpretation of reference standard
6 Applicability of target condition as defined by reference standard 
to review question
7 Bias through patient flow
Systematic 
review
Assessing the meth-
odological quality of 
systematic reviews 
(AMSTAR)
Reporting bias
Selection bias
Selection bias
Publication bias
Publication bias
Selection bias
Information bias
Information bias
Detection bias
Publication bias
Conflict of interest 
bias
1 Was an ‘a priori’ design provided?
2 Was there duplicate study selection and data extraction?
3 Was a comprehensive literature search performed?
4 Was the status of publication (i.e. grey literature) used as an 
inclusion criterion?
5 Was a list of studies (included and excluded) provided?
6 Were the characteristics of the included studies provided?
7 Was the scientific quality of the included studies assessed and 
documented?
8 Was the scientific quality of the included studies used appropri-
ately in formulating conclusions?
9 Were the methods used to combine the findings of studies ap-
propriate?
10 Was the likelihood of publication bias assessed?
11 Was the conflict of interest included?
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curate and risk factors more important. It is difficult to formally assess for publication bias 
outside of the systematic review setting, and statistical methods for estimating the magni-
tude of the problem all have their limitations. 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
working group, provides a framework to facilitate formal evaluation of the reliability of a 
body of evidence (Table 2.7). 
Additional readings
1. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and 
deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. 
2. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assess-
ing risk of bias in randomised trials. BMJ. 2011;343:d5928. 
3. Sterne JAC, Higgins JPT, Reeves BC, et al. A Cochrane Risk Of Bias Assessment Tool: for 
Non-Randomized Studies of Interventions (ACROBAT- NRSI), Version 1.0.0. http://www.
riskofbias.info. Accessed March 14, 2015.
4. Savovic J, Jones HE, Altman DG, et al. Influence of reported study design characteris-
tics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 
2012;157(6):429-38.
5. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the 
quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clini-
cal_epidemiology/oxford.asp. Accessed March 14, 2015.
6. Whiting P, Rutjes A, Westwood M, et al. QUADAS-2: a revised tool for the quality assess-
ment of diagnostic accuracy studies. Ann Int Med. 2011;155(8):529-536.
7. Shea B, Grimshaw J, Wells G, et al. Development of AMSTAR: a measurement tool to 
assess the methodological quality of systematic reviews. BMC Med Res Methodol. 
2007;7(1):10-16. 
8. Scottish Intercollegiate Guidelines Network (SIGN). Chapter 5: Assessing the quality of 
evidence. In: SIGN 50: a guideline developer’s handbook. Edinburgh, Scotland. SIGN; 
2014:89-106. http://www.sign.ac.uk.
9. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines 3: rating the quality of 
evidence - introduction. J Clin Epidemiol. 2011;64(4):401-406.
10. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a 
new series of articles in the Journal of Clinical Epidemiology. Journal of clinical epidemi-
ology. 2011;64(4):380-382.
Generating recommendations
Rating strength of recommendations and quality of the evidence across key outcomes
A recommendation is an individual statement proposing the best course of action for a 
given situation. It can be for or against a strategy with varying degrees of conviction. The 
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strength of a recommendation is determined by the quality of the evidence across key out-
comes, but also by judgments related to the balance between the desirable and undesir-
able effects of a strategy, the variability in values and preferences and the associated costs. 
Clear communication of both the intended message and the value judgements that influ-
ence the recommendation generating process is key.  
Guideline developers apply formal approaches for separately rating the strength of rec-
ommendations and the overall quality of the underlying evidence, resulting in the assign-
ment of categorical scores. The GRADE system is currently the most widely used and has 
been adopted by all major renal guidelines organisations. It categorizes recommendations 
as ‘strong’ if benefits or harms clearly outweigh one another, the confidence in the evidence 
for important health outcomes is high, healthcare consumers agree on the value of differ-
ent outcomes and the proposed strategy represents a wise use of resources. It categorizes 
recommendations as ‘weak’ if the trade-offs between benefits and harms are less certain, 
because of low quality evidence, because high quality evidence suggests that wanted and 
Table 2.7. GRADE method of rating the quality of the evidence.
Step 1: Starting grade 
according to study 
design
Step 2: Lower if Step 3: Higher if Step 4: determine final 
grade for quality of 
evidence
Randomized trials 
= High
Observational Studies 
= Low
Risk of Bias
-1 Serious 
-2 Very Serious 
Inconsistency
-1 Serious
-2 Very Serious
Indirectness
-1 Serious
-2 Very Serious
Imprecision
-1 Serious
-2 Very Serious
Publication Bias
-1 Likely
-2 Very likely
Large effect
+1 Large
+2 Very Large
Dose response
+1 Evidence of a gradient
All plausible confounding
+1 Would reduce a demon-
strated effect
+1 Would suggest a spurious 
effect when results show no 
effect
High (four plus: ⊕⊕⊕⊕)
Moderate (three plus: 
⊕⊕⊕○)
Low (two plus: ⊕⊕○○)
 
Very Low (one plus: ⊕○○○)
GRADE specifies four categories for the quality of a body of evidence: from high to very low. The quality of evidence for an outcome 
is initially rated high if it originates predominantly from randomised controlled trials and low if it originates from observational data. 
These ratings can be subsequently downgraded or upgraded if any of a number of additional criteria are met Adapted from Balshem 
H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. 
J Clin Epidemiol. 2011;64(4):401–406.
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unwanted effects are closely balanced, because healthcare consumers have diverging ideas 
on which outcomes matter most to them, or because the proposed strategy may is very 
costly. Although, the discrete approach to rating recommendations can be criticised for cat-
egorizing what in in reality is a continuum, it has the benefit not only of simplicity, but also 
of direct associations to actions on the part of patients and policy makers To communicate 
the overall quality of the evidence supporting a recommendation, a summary rating, rang-
ing from ‘high’ to ‘very low’ is assigned representing the lowest quality of evidence for any 
of the outcomes that are critical to decision making. Figure 2.1 provides a worked example 
about how the GRADE approach works in practice. 
Articulating recommendations
It is reasonable to assume specific wording influences how statements are interpreted 
and whether or not they can be implemented consistently by clinicians. Most renal guide-
line organizations use the specific terminology proposed by GRADE to confer the strength 
of a recommendation: ‘we recommend’ (either in favour or disfavour) for a strong statement, 
and ‘we suggest’ (either in favour or disfavour) for a weak statement. This standardisation 
of language and methods is a positive evolution, as it increases consistency in how rec-
ommendations are to be interpreted. Often however, recommendations have been criti-
cized for being non-specific, failing to indicate precisely under which conditions to do what. 
Vague recommendations using structures such as ‘patients with condition A should receive 
treatment B if considered necessary’, are usually not very useful in clinical practice as they 
are dependent upon the interpretation of what constitutes necessity. A well worded recom-
mendation should specify the population as well as the specific conditions under which it 
applies. Unless it is obvious, it should also specify the comparator. Consider for example the 
following statement: “In patients at increased risk of contrast-induced acute kidney injury, 
we recommend intravenous volume expansion with isotonic saline or sodium bicarbonate”. 
Here, the strength of this recommendation may differ depending on whether the alterna-
tive is oral hydration or no hydration at all. 
Additional readings
1. Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of 
confidence in effect estimates for a single outcome and for all outcomes. J Clin Epide-
miol. 2012;66(2):151-157.
2. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to 
recommendations: the significance and presentation of recommendations. J Clin Epide-
miol. 2013;66(7):726-735.
Reporting and peer review
Reporting refers to how a guideline will be made public (e.g., print, online), and the level 
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of detail contained within the guideline document. Peer review refers to how the guideline 
document will be reviewed before its publication and how the guideline can be assessed 
both internally, as well as externally by stakeholders who were not members of the guide-
line development team.
Reporting a guideline
The user casts the ultimate verdict on a guideline’s trustworthiness. An informed deci-
sion requires detailed description of the methods used for developing the guideline includ-
ing all items covered in the other sections (above and below) in this paper.  In addition, 
in reporting a guideline it is essential to provide a narrative rationale describing the link 
between every recommendation and its supporting evidence in order for a user to judge 
the extent to which the recommendations can be justified. The narrative should cover both 
anticipated benefits and potential risks associated with implementation of the guideline 
recommendations. In 2003, a conference on guideline standardisation proposed a list of 
18 core items to report for a guideline. The major organisations producing guidelines for 
patients with kidney diseases currently use similar formats, covering the majority of the 
expected items. 
External review
A guideline development group is limited in the knowledge it can bring to the table and 
the perspectives it can offer. External review helps to ensure balance, comprehensiveness, 
accuracy of the scientific evidence, validity of the rationale for recommendations, allows 
feedback on the clarity and feasibility of recommendations and contributes to engagement 
of stakeholders. There are several types of external review, serving different purposes and 
requiring input from different people. 
Reviewers can be specifically invited, usually for their perceived ability to contribute. 
They may include leading clinical researchers or key opinion leaders, asked to identify miss-
ing research, and mistakes in the description of studies, interpretation of their quality, or re-
porting of their results. In addition, expert peer-reviewer contribution may increase a sense 
of ownership and support of those who are most influential. Invited reviewers may include 
methodologists, specifically to identify possible biases, asymmetry in the presentation of 
evidence or flaws in the logic applied in translating the evidence into recommendations. 
Invited reviewers may also include targeted practicing clinicians, with the aim of identifying 
any ambiguities in the recommendations when they are used in practice or effects on work-
Figure 2.1. (opposite page) From framing the question to generating the recommendation, a worked example 
of whether and how to screen for coronary artery disease in potential kidney transplant recipients. 
CABG – Coronary Artery Bypass Grafting; GRADE—Grading of Recommendations, Assessment, Development and Evaluation; 
PCI – Percutaneous Coronary Intervention; QOL – quality of life.
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flow that may hamper implementation. Other peer reviewers may include representatives 
from federal agencies, professional organizations, specialty societies, healthcare provid-
ers, peer review journals, and relevant guideline panels authoring related guidelines. They 
may include representatives from advocacy organizations, community groups, and public 
health organizations whose constituents may be affected by the guideline; and representa-
tives businesses and industries, pharmaceutical or device manufacturers impacted by the 
guideline.
A draft guideline may also be put up for public consultation. In this case, typically the 
guidelines are posted on the internet for a defined time period, and open for comment by 
any interested party. Public consultation provides an opportunity to create a sense of part-
nership, which may increase acceptability of the guideline as a whole and help in promot-
ing awareness and adoption of the recommendations. 
Finally, guideline developers can also choose to include peer review through publication 
in a peer-reviewed journal. This may have the advantage of obtaining scientific credibility 
and facilitate implementation through outreach to the readership of the journal. Disadvan-
tages include delays due to the peer-review process, and external control over guideline 
release dates. A possible drawback is the potential for Editors to exert undue influence over 
the guideline content, insisting on changes based on comments of a few reviewers which 
may or may not be substantiated by the evidence and agreed methodology. 
Regardless of the type of external review, methods for dealing with criticism should com-
ply with development methodology, and criticism can never simply be ignored. Groups 
need to adopt a system for recording, discussing and processing elicited comments. Care 
needs to be taken that responses are adequately communicated, given guideline imple-
mentation resistance often comes from insufficient understanding of the methodology 
used.
Additional readings
1. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standard-
ized Reporting of Clinical Practice Guidelines: A Proposal from the Conference on Guide-
line Standardization. Ann Int Med. 2003;139(6):493-498.
2. Shekelle P, Woolf S, Grimshaw JM, Schunemann HJ, Eccles MP. Developing clinical prac-
tice guidelines: reviewing, reporting, and publishing guidelines; updating guidelines; 
and the emerging issues of enhancing guideline implementability and accounting for 
comorbid conditions in guideline development. Implement Sci. 2012;7:62-68.
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Implementation of guidelines
Producing a guideline does not change practice. The next step is guideline implementa-
tion. Detailed exposition on implementation science is beyond the scope of this paper, but 
a brief overview is warranted. The aphorism that “guidelines don’t implement themselves” 
poses a challenge for guideline developers, as implementation requires quite a different 
set of skills and resourcing from those required to develop the guideline. Implementation 
of guidelines requires that clinicians or patients are aware of the guideline, understand the 
guideline and its implications for their service and patient care, and consider it important 
enough to invest in changing their practice to more closely reflect the guideline recommen-
dations. Within this voyage from evidence summation to implementation there are many 
potential barriers at the various layers of the healthcare delivery system, such that is it not 
surprising that most guideline development groups concede the responsibility of imple-
mentation to health service delivery organisations.
Dissemination
The easiest part of guideline implementation is dissemination. There are numerous por-
tals through which guidelines can be publicised, with most renal guidelines groups publish-
ing their guidelines in peer-reviewed journals as well as on their websites (Table 2.1). Many 
guidelines groups also publicise their products using the more usual tools that researchers 
employ, such as in the proceedings of Scientific Meetings, as well as publicising document 
though local specialty societies. With the increasing availability of mobile internet devices, 
smartphone applications that summarise clinical guidelines are also becoming more widely 
used (eg: KDIGO, NICE). However, dissemination alone is not a very effective tool for driving 
practice change.
Additional implementation challenges
Beyond informing clinicians about the guideline, the more effective guideline imple-
mentation tools share common ground with healthcare quality improvement and assur-
ance methods. These use methodologies including audit and feedback, barrier analyses, 
involvement of key opinion leaders and extend to the use of reminder systems and multi-
faceted interventions delivered at multiple levels of the healthcare system. The commonest 
approach used to address guideline–practice gaps in healthcare is the Plan-Do-Study-Act 
cycle, designed to be applied in iterative cycles, to generate and analyse data from a health-
care process, use results to develop interventions to alter that process and measure the ef-
fect of these interventions before developing further actions (Figure 2.2). However, devel-
opment of new implementation methods and evaluation of existing strategies is on-going, 
and is likely to evolve further in coming years. Clearly these methods require quite different 
skill sets from the development of the guideline itself, as well as significant investment in 
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Figure 2.2. The plan do study act (PDSA) cycle for guideline 
implementation clinical level.

staff time and project infrastructure. Organisations that fund and manage health systems 
are likely to be best placed to drive such processes but may also be the groups least likely to 
be aware of the guideline evidence. 
Additional readings
1. Davis DA, Taylor-Vaisey A. Translating guidelines into practice. A systematic review of 
theoretic concepts, practical experience and research evidence in the adoption of clini-
cal practice guidelines. CMAJ. 1997;157(4):408-16.
2. Coleman J, Katz E, Menzel H. The diffusion of an innovation among physicians. Sociom-
etry. 1957;20(4):253-70.
3. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of 
change in patients’ care. Lancet. 2003; 362(9391):1225-30.
4. Gallagher MP, Cass A, Craig JC. Applying evidence into routine clinical care at a unit level: 
The exemplar of renal anaemia management. Nephrology. 2010;15(4):429-33.
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Abstract
Background. Vesicoureteric reflux (VUR) results in urine passing retrograde up the ureter. Uri-
nary tract infections (UTI) associated with VUR have been considered a cause of permanent 
renal parenchymal damage in children with VUR. Management of these children has been 
directed at preventing UTI by antibiotic prophylaxis and/or surgical correction of VUR. The 
optimum strategy is not clear.
Objectives. To evaluate the benefits and harms of different treatment options for primary VUR.
Search methods. In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened 
reference lists of papers and abstracts from conference proceedings.
Selection criteria. RCTs in any language comparing any treatment of VUR including surgical 
or endoscopic correction, antibiotic prophylaxis, non-invasive non-pharmacological tech-
niques and any combination of therapies.
Data collection and analysis. Two authors independently searched the literature, determined 
study eligibility, assessed quality, extracted and entered data. We expressed dichotomous 
outcomes as risk ratios (RR) and their 95% confidence intervals (CI) and continuous data 
as mean differences (MD) and their 95% CI’s Data were pooled using the random effects 
model.
Main results. Twenty RCTs (2324 children) were included. Long-term low-dose antibiotic 
prophylaxis compared to no treatment/placebo did not significantly reduce repeat symp-
tomatic UTI (846 children: RR 0.68, 95% CI 0.39 to 1.17) or febrile UTI (946 children: RR 0.77, 
95% CI 0.47 to 1.24) at two years. There was considerable heterogeneity in the analyses 
and only one study was adequately blinded. At one to three years, antibiotic prophylaxis 
reduced the risk of new or progressive renal damage on DMSA scan (446 children: RR 0.35, 
95% CI 0.15 to 0.80). Side effects were infrequent when reported, but antibiotics increased 
the likelihood of bacterial drug resistance threefold (132 UTIs: RR 2.94, 95% CI 1.39 to 6.25).
 When long-term antibiotic prophylaxis was compared with surgical or endoscopic correc-
tion of VUR plus antibiotics for one to 24 months (10 studies, 1141 children), the risk of 
symptomatic UTI was not significantly different at any time point. Combined surgical and 
antibiotic treatment caused a 57% reduction in febrile UTI by five years (2 studies, 449 chil-
dren: RR 0.43, 95% CI 0.27 to 0.70) but did not decrease the risk of new or progressive renal 
damage at any time point. Postoperative obstruction was seen in 0% and 7% of children in 
two surgical studies and 0% in one endoscopic study.
Authors’ conclusions. Compared with no treatment, use of long-term, low-dose antibiotics 
did not significantly reduce the number of repeat symptomatic and febrile UTIs in children 
with VUR. Considerable heterogeneity in the analyses and inclusion of only one adequately 
blinded study, made drawing firm conclusions challenging. Antibiotic prophylaxis signifi-
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cantly reduced the risk of developing new or progressive renal damage, but assuming an 
8% baseline risk, 33 children would need long-term antibiotic prophylaxis to prevent one 
more child developing kidney damage over the course of two to three years.
 The added benefit of surgical or endoscopic correction of VUR over antibiotic treatment 
alone remains unclear. Eight children would require combined surgical and antibiotic treat-
ment to prevent one additional child developing febrile UTI by five years, but it would not 
cause fewer children developing renal damage.
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Background 
Primary vesicoureteric reflux (VUR) is thought to be a maturational abnormality of the vesicoureteric junction, which results in retrograde passing of urine up the ure-ter during voiding. Although the exact prevalence in children is unknown, about 
a third investigated after a urinary tract infection (UTI), shows signs of VUR (Smellie 1994). 
UTI is common, affecting 5% to 10% of all children (Hellstrom 1991), with 30% to 50% of 
them likely to suffer a recurrence (Smellie 1994). VUR is thought to predispose for UTI, renal 
involvement during UTI and hence to potentially cause subsequent permanent renal dam-
age in 15% of patients (Montini 2007). Retrospective analyses of selected individuals with 
renal scarring, have reported hypertension and chronic kidney disease (CKD) in approxi-
mately 20% and 10% respectively (Martinell 1996; Smellie 1998). However recent data from 
a prospective cohort study have indicated, that possibly due to better treatment of acute 
infections, these adverse outcomes now occur considerably less frequently (Wennerstrom 
2000a; Wennerstrom 2000b).
As a result of the hypothesized causal link between VUR and renal scarring, VUR screen-
ing and treatment strategies have largely been directed towards avoidance of UTI induced-
damage (Belman 1995). To this end, both antibiotic prophylaxis with or without surgical 
VUR correction have been used. In addition to the common Politano-Leadbetter, Lich-Gre-
goir and Cohen surgical techniques, newer, less invasive techniques involving endoscopic 
periureteric injections of polydimethylsiloxane (Macroplastique), dextranomer/hyaluronic 
acid copolymer (Deflux) or glutaraldehyde cross-linked bovine collagen have been assessed 
(Capozza 2002; Frankenschmidt 1997; Frey 1997; Oswald 2002). Although VUR is a common 
problem in childhood, there has been no consensus regarding the optimal management 
strategy and practice varies widely.
Objectives
The aim of this review was to evaluate the available evidence for both benefits and harms 
of the currently available treatment options for primary VUR: operative, non-operative or no 
intervention.
Methods
Criteria for considering studies for this review
Types of studies 
Randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treat-
ment was obtained by alternation, use of alternate medical records, date of birth or other 
predictable methods) which evaluated any treatment for primary VUR were included.
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Types of participants 
Inclusion criteria 
Males and females of any age with primary VUR diagnosed by voiding cystourethrogram 
(VCUG) with or without UTI.
Exclusion criteria 
Patients with VUR associated with posterior urethral valves, spina bifida, other urological 
abnormalities or kidney transplants.
Types of interventions 
Treatments of VUR including surgery (open and endoscopic techniques), antibiotic 
prophylaxis of any duration, non-invasive techniques such as bladder training and any com-
bination of therapies.
Types of outcome measures 
Primary outcomes 
• Number of patients with symptomatic UTI, defined as symptoms consistent with a UTI 
together with a positive urine culture.
Secondary outcomes 
• Number of patients with UTI accompanied by fever (temperature > 38°C or > 100.4°F)
• Number of patients with at least one repeat positive urine culture during follow-up.
• Renal parenchymal abnormality, defined as new, progression from pre-existing damage, 
resolution, end-stage kidney disease (ESKD) and diagnosed by ultrasound, intravenous 
pyelography (IVP) or 99mTc-DMSA (dimercaptosuccinic acid) scintigraphy (DMSA scan).
• Number of previously unaffected subjects who developed hypertension, defined as 
greater than 140 mm Hg systolic, 90 mm Hg diastolic for adults and above the 95th per-
centiles for systolic and diastolic blood pressures in children.
• Renal function impairment was defined as an estimated glomerular filtration rate (eGFR) 
(measured either directly or calculated from serum creatinine) less than the 95th percen-
tile for age, or a decrease in renal function over the duration of the study.
• Correction of VUR, defined as the number of children and/or ureters without VUR on fol-
low up VCUG.
• Microbial resistance, obstruction following correction of VUR, death or serious injury re-
sulting from the anaesthetic, wound infection, fever, adverse effects of medication in-
cluding urticaria and gastro-intestinal reaction.
Search methods for identification of studies  
Initial search 
Relevant studies were obtained from the following sources (see Appendix 1 for Electron-
ic search strategies)
Nagler.indb   46 15/09/2015   16:14:36
Interventions for primary vesicoureteric reflux
47
• The Cochrane Renal Group Specialised Register (November 2003).
• Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, Issue 
4, 2003.
• MEDLINE (1966 to February 2003).
• EMBASE (1988 to February 2003).
• Reference lists of relevant articles, reviews and studies.
• Pharmaceutical industry representatives.
• Known authors in the field.
There were no language restrictions.
Review update search 
For the first and the current update, the Cochrane Renal Group’s specialised register 
(August 2010) and The Cochrane Central Register of Controlled Trials (CENTRAL, in The 
Cochrane Library Issue 8, 2010) were searched. CENTRAL and the Renal Group’s specialised 
register contain the handsearched results of conference proceedings from general and spe-
ciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both 
retrospective and prospective (Master List 2011). Please refer to The Cochrane Renal Review 
Group’s Module in The Cochrane Library for the complete list of nephrology conference 
proceedings searched (Renal Group 2011).
Data collection and analysis 
Selection of studies 
Titles and abstracts obtained from the above searches were screened for selection inde-
pendently by at least two authors. In all cases an overly inclusive selection was preferred 
to avoid losing relevant studies and to ensure additional studies could be identified from 
the reference lists. Where suitability was uncertain or no abstract available, the full article 
was obtained and screened by the same authors. Any disagreements were resolved by dis-
cussion with a third author. Authors were contacted to obtain raw or missing data where 
necessary.
Data extraction and management 
Data extraction was conducted independently by at least two authors, using a stand-
ardised data extraction form. All studies, reported in a non-English journal, were translated 
prior to assessment. Any further information required from the original author was request-
ed by written correspondence and any relevant information obtained in this manner was 
included in the review. Any disagreements were resolved by discussion with a third author.
Assessment of risk of bias in included studies 
The following items will be independently assessed by two authors using the risk of bias 
assessment tool (Higgins 2008) (see Appendix 2).
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• Was there adequate sequence generation?
• Was allocation adequately concealed?
• Was knowledge of the allocated interventions adequately prevented during the study?
• Were incomplete outcome data adequately addressed?
• Are reports of the study free of suggestion of selective outcome reporting?
• Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect 
Dichotomous outcomes 
For dichotomous outcomes, the risk ratio (RR) and corresponding 95% confidence inter-
val (CI) were chosen to describe the treatment effects and the precision of their point esti-
mates. Number needed to treat (NNT) estimates were calculated to compare the benefits 
and harms of each active treatment.
Continuous outcomes 
Where continuous scales of measurement were used to assess effects of treatment such 
as blood pressure and kidney function measured by eGFR, the mean difference (MD) and 
95% CI was used. Where summary statistics were missing, they were derived from accom-
panying P values.
Planned treatment comparisons 
• Antibiotics versus surgery or endoscopic treatment
• Antibiotics versus placebo or no treatment
• One antibiotic treatment versus another
• Surgical or endoscopic correction with no other treatment
• Any combinations of any active treatment
Assessment of heterogeneity 
Heterogeneity between studies was analysed using the Cochran’s Q statistic with the 
threshold for statistical significance set at alpha = 0.1 (Lau 1997). It was also tested by means 
of the I² test, reflecting the percentage of total variation across studies that could be as-
cribed to heterogeneity (Higgins 2003). Due to an insufficient number of studies, formal 
evaluation of the different sources of heterogeneity was not possible.
Assessment of reporting biases 
Publication bias was to be assessed using a funnel plot; there were insufficient studies 
to do so.
Data synthesis 
A random effects model was used, with subsequent testing for robustness of the analysis 
by applying a fixed effects model.
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Sensitivity analysis 
To determine the effect of study quality on the primary outcome’s pooled summary 
measure, sensitivity and subgroup analysis was performed to examine the influence of al-
location concealment and blinding on results.
Results 
Description of studies 
See: Characteristics of included studies; Characteristics of excluded studies; Characteris-
tics of ongoing studies.
Results of the search 
We originally identified 10 studies after full paper assessment (Wheeler 2004). The Inter-
national Reflux Study was reported in a European (IRS EUR 1981-2003) and an American arm 
(IRS USA 1992) and so we treated them as two separate studies. We captured two studies by 
screening reference lists of the authors. Both studies were published in conference proceed-
ings only (Morris 1991; Reddy 1997). During a second search in June 2006 (Hodson 2007), 
we found one new study (Garin 2006) and two additional reports of the European arm of the 
International Reflux Study. Finally, after a search in August 2010, we included an additional 
nine RCTs (Craig 2002; Dite 2007; Lee 2007; Montini 2008; Pennesi 2006; PRIVENT Study 
2009; Roussey-Kesler 2008; Scott 1968; Swedish Reflux Trial 2010). Craig 2002 was only pub-
lished as an abstract and Dite 2007 was originally published in Czech and translated before 
assessment. We found another three papers that belonged to previously included studies 
(Garin 2006; IRS EUR 1981-2003; IRS USA 1992). We also identified one ongoing study (RIVUR 
Study), which is scheduled to finish in October 2011. See Figure 3.1 for study selection dia-
gram.
Figure 3.1. Study flow diagram.
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Included studies 
In eight studies (1039 children) antibiotic treatment was compared with surveillance 
(Garin 2006; Montini 2008; Pennesi 2006; Reddy 1997; Roussey-Kesler 2008; Swedish Re-
flux Trial 2010) or with placebo (Craig 2002; PRIVENT Study 2009). In most of these studies, 
participants were recruited after at least one symptomatic UTI (Garin 2006; Montini 2008; 
Pennesi 2006; PRIVENT Study 2009; Roussey-Kesler 2008; Swedish Reflux Trial 2010), with 
subsequent exclusion of children with severe VUR, defined as grade IV (Garin 2006; Montini 
2008; Roussey-Kesler 2008) or grade V (Pennesi 2006). Overall, girls outnumbered boys, with 
a maximum reported ratio of 4:1 (Garin 2006). In three studies (Garin 2006; Montini 2008; 
PRIVENT Study 2009), the investigators included both children with and without VUR. For 
this review, we only included the data from children with VUR. In Reddy 1997 no treatment 
was compared with two antibiotic prophylaxis regimens (daily or intermittent antibiotic 
administration). Additionally, Lee 2007 (125 children) compared probiotics with antibiotic 
prophylaxis. Overall the duration of the antibiotic treatment varied from one to three years.
In 10 studies (1141 children) the effectiveness of low-dose antibiotic prophylaxis, given 
for one to five years, was compared with ureteric reimplantation by open surgery (BIRSG 
1987; Holland 1982; IRS EUR 1981-2003; IRS USA 1992; Morris 1991; Smellie 2001; Scott 
1968) or endoscopic subureteric injection of Deflux (Capozza 2002; Dite 2007; Swedish Re-
flux Trial 2010). All who underwent a surgical or endoscopic procedure received antibiotic 
prophylaxis for one to 24 months, with a variety of open surgical techniques being used to 
correct VUR. Generally, only children with higher (dilating) grades of VUR were included. The 
gender distribution was usually poorly reported. Outcomes were reported at three months 
to 10 years post randomisation.
One study had a three-arm design (203 children), and children were randomised to en-
doscopic VUR correction and antibiotic prophylaxis, antibiotic prophylaxis alone, or surveil-
lance (Swedish Reflux Trial 2010).
In two studies (88 children), researchers compared different materials for subureteric 
injection to correct VUR (Frey 1997; Oswald 2002). We did not find a single RCT in which 
an open surgical procedure was compared with endoscopic correction of VUR, nor one in 
which antibiotic use was compared with surgery alone, or with other treatment strategies 
such as management for voiding dysfunction.
In total, we have included 20 studies (58 reports) enrolling 2324 children under the age 
of 18 years from the USA, Europe, Australasia and South Korea. The number of participants 
varied between 10 and 321. Nine studies included less than 100, eight studies included 
between 100 and 200, and three studies enrolled more than 200 children. Data for at least 
one outcome was available from 2219 participants. Trimethoprim-sulphamethoxazole was 
the predominant chemoprophylactic drug of choice, but trimethoprim, nitrofurantoin, ce-
fadroxil or amoxicillin-clavulanic acid were also used for antibiotic chemoprophylaxis.
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Excluded studies 
We excluded nine studies (18 reports). There was one acute treatment study (Montini 
2003) and one study that was conducted in patients with ileal bladders (Osman 2004). There 
were two cohort studies (Cheskis 1995; Lindberg 1978) and one review (Becker 2004). One 
study was terminated before collection of outcome data because of inadequate patient 
recruitment (Ransley 2004). One study was omitted because it was impossible to separate 
the outcomes for randomised patients from those of a non-randomly selected group of chil-
dren reported in the same publication (Scholtmeijer 1993). Finally both COBSG 1978 and 
NCBRG 1981 had included patients with and without VUR, but provided insufficient data to 
allow for separate analysis of the children with VUR.
Risk of bias in included studies 
Before we conducted the current update, overall reporting of methodology in primary 
studies was generally not very detailed. In four of the most recently included studies, au-
thors adhered to a higher standard of both design and reporting (Montini 2008; Pennesi 
2006; PRIVENT Study 2009; Roussey-Kesler 2008). An overview is provided in Figure 3.2 and 
Figure 3.3.
Allocation 
The method of sequence generation and treatment allocation was satisfactory in nine 
studies (Capozza 2002; Craig 2002; IRS EUR 1981-2003; IRS USA 1992; Montini 2008; Pen-
nesi 2006; PRIVENT Study 2009; Swedish Reflux Trial 2010). The other eleven used a quasi-
random method or did not detail the applied procedure.
Figure 3.2. Methodological quality graph: review authors’ judgements about each methodological quality 
item presented as percentages across all included studies.
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Figure 3.3. Methodological quality summary: 
review authors’ judgements about each methodological quality item for each included study.
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Blinding 
Given the nature of the intervention, blinding of investigators and participants was not 
possible in studies comparing the potential benefits and harms of surgical and endoscopic 
treatments with antibiotic prophylaxis. Yet only four explicitly reported that assessment of 
radiological outcomes occurred without knowledge of the treatment groups (BIRSG 1987; 
IRS EUR 1981-2003; IRS USA 1992; Swedish Reflux Trial 2010). Overall, in only three studies 
all participants, caregivers, outcome assessors and data analysts were adequately blinded 
(Craig 2002; Frey 1997; PRIVENT Study 2009).
Incomplete outcome data 
Only seven studies re-included all cases for analysis that had been withdrawn during 
the course of follow-up (Craig 2002; Lee 2007; Montini 2008; Pennesi 2006; PRIVENT Study 
2009; Roussey-Kesler 2008; Swedish Reflux Trial 2010). In the remainder it was not possible 
to determine whether the analysis had been done on an intention-to-treat basis. Losses to 
follow-up over the short-term were however generally low: 0% and 10% at one to two years; 
11% at three years; 5% and 42% at five to 10 years.
Selective reporting 
Nine studies reported the most appropriate primary outcome, repeat symptomatic UTI 
(Garin 2006; Dite 2007; IRS EUR 1981-2003; Lee 2007; Montini 2008; PRIVENT Study 2009; 
Roussey-Kesler 2008; Swedish Reflux Trial 2010). Frey 1997 only described VUR correction; 
the other 10 described the less relevant primary outcome of repeat positive urine culture.
Other potential sources of bias 
For many studies it was difficult to discern who the children were and how many were 
reviewed for possible inclusion in the study protocol, thereby largely limiting the ability 
to evaluate the extent of selection bias. Only IRS EUR 1981-2003 and PRIVENT Study 2009 
clearly denoted the number of patients screened and the reasons for their exclusion or non-
enrolment.
Definitions and criteria for diagnosis of initial or recurrent UTI and renal abnormalities 
greatly differed between the various studies and, apart from in the most recent ones, were 
largely inadequately reported.
Effects of interventions 
Antibiotic prophylaxis versus surveillance/no treatment 
The data were analysed using a random and fixed effects model, without there being an 
appreciable difference between the summary estimates. Results are presented using the 
random effects model.
Nagler.indb   53 15/09/2015   16:14:37
Chapter 3
54
Symptomatic UTI and febrile UTI 
Of the eight studies that compared antibiotic prophylaxis with placebo or no treatment, 
six had repeat symptomatic UTI as the primary outcome and allowed distinction of febrile 
UTI as a separate entity. One and two year incidence of symptomatic UTI varied from 12% 
to 36% in the group treated with antibiotics and 2% to 41% in the surveillance group. The 
point estimate for overall effect favoured antibiotic prophylaxis, but the result was not sta-
tistically significant for either symptomatic UTI (Analysis 1.1.1 (5 studies, 846 children): RR 
0.68, 95% CI 0.39 to 1.17) or febrile UTI by one to two years of follow-up ( Analysis 1.1.2 (6 
studies, 946 children): RR 0.77, 95% CI 0.47 to 1.24). For both outcomes, there was a large 
amount of unexplained heterogeneity among studies. We could not identify systematic dif-
ferences in allocation mechanism, blinding or participant characteristics that would have 
explained the heterogeneity. For allocation concealment, heterogeneity appeared to be 
related to Garin 2006, however removing this study did not alter the statistical significance 
of the result (Analysis 1.2.1 (5 studies, 833 children): RR 0.69, 95% CI 0.45 to 1.05). One study 
was optimally designed with adequate blinding (PRIVENT Study 2009). Its point estimate 
again favoured antibiotic prophylaxis, but the result was not statistically significant and pa-
tient numbers were too small to give sufficient power to the analysis (Analysis 1.3).  
Repeat positive urine culture 
In six studies the outcome of repeat positive urine culture was reported for urine samples 
taken in asymptomatic subjects (Craig 2002; Garin 2006; Montini 2008; Pennesi 2006; Reddy 
1997; Roussey-Kesler 2008). The analysis did not show a significant reduction in routine 
positive urine cultures associated with the use of antibiotics (Analysis 1.1.3 (6 studies, 636 
children): RR 0.84, 95% CI 0.57 to 1.25). In addition to comparing a daily antibiotic regimen 
with surveillance, Reddy 1997 introduced an extra treatment arm to compare intermittent 
treatment three times/week, with no specific therapy. In the group treated with intermit-
tent antibiotics 2/14 participants (14%) had a positive urine culture, in the surveillance 
group the culture was positive for 5/16 patients (31%) (Analysis 1.1.4 (1 study, 30 children): 
RR 0.46, 95% CI 0.10 to 2.00).
Renal parenchymal abnormality 
In five studies, the acquisition of new renal abnormalities was evaluated by comparing 
DMSA scans, taken both at study commencement and completion of follow-up (Craig 2002; 
Montini 2008; Pennesi 2006; PRIVENT Study 2009; Swedish Reflux Trial 2010). Two studies 
had no events in either group and hence did not contribute to any of the analyses (Craig 
2002; Pennesi 2006). Overall there was no significant reduction in either the number of chil-
dren with new renal damage (Analysis 1.4.1 (5 studies, 782 children): RR 0.27, 95% CI 0.06 to 
1.23) or progression of existing renal abnormalities (Analysis 1.4.2 (3 studies, 446 children): 
RR 0.68, 95% CI 0.27 to 1.73), although the point estimates favoured antibiotic prophylaxis 
in both instances. When the number of children with new or progressive renal damage 
were considered as a single outcome measure, the reduction was statistically significant, al-
though only two studies contributed to the analysis ( Analysis 1.4.3 (3 studies, 446 children): 
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RR 0.35, 95% CI 0.15 to 0.80). All physicians evaluating the DMSA scans had been adequately 
blinded to the treatment group and there was no substantial heterogeneity.
Two additional studies also reported development of renal abnormality but had done 
the baseline DMSA scan either at the time of acute pyelonephritis (Garin 2006) or not at all 
(Reddy 1997). In both these studies it was impossible to distinguish those who had devel-
oped the abnormality as a result of the index UTI from those in whom antibiotic prophylaxis 
had failed to prevent the renal damage. Overall no appreciable difference was seen in either 
group at one to three years when combined in meta-analysis (Analysis 1.4.4 (2 studies, 142 
children): RR 1.70, 95% CI 0.36 to 8.07). Similarly, Reddy 1997 showed no meaningful differ-
ence in the risk of renal parenchymal injury between intermittent prophylaxis given three 
times/week and no prophylaxis (Analysis 1.4.5 (1 study, 30 children): RR 0.38, 95% CI 0.02 to 
8.59).
Other outcomes 
One small study (46 children), only published in abstract form, reported on estimated 
GFR, calculated with the MDRD equation, and renal growth at the end of a three year follow-
up period (Craig 2002). Results were only reported as means, but standard deviations could 
be derived from the accompanying P value. Neither the difference in estimated GFR, 119 
mL/min/1.73 m² in the group treated with antibiotics versus 108 mL/min/1.73 m² in the 
placebo group (Analysis 1.5 (1 study, 41 children): MD -11.00 mL/min/1.73 m², 95% CI -31.53 
to 9.53), nor the difference in renal growth, 2.42 cm versus 2.38 cm (Analysis 1.6 (1 study, 41 
children): MD 0.04 cm, 95% CI -0.04 to 0.12) was statistically significant at three years follow-
up. Three studies (Pennesi 2006; Reddy 1997; Swedish Reflux Trial 2010) reported the VUR 
status after a two year follow-up. Overall there was no significant difference in the number 
of children with persisting VUR (Analysis 1.7 (3 studies, 262 children): RR 1.46, 95% CI 0.71 
to 2.99).
Adherence 
Adherence was addressed in 4/7 studies (Montini 2008; Pennesi 2006; PRIVENT Study 
2009; Swedish Reflux Trial 2010).
• Pennesi 2006 tested the urine samples of children that developed a febrile UTI for pres-
ence of the prophylactic drug. He found all patients were compliant.
• Montini 2008 found 71% of participants were adherent when assessed by measuring 
antimicrobial activity in a sample of screened urine samples. The reported compliance 
was 86% according to the visual analogue questionnaire.
• PRIVENT Study 2009 was the only placebo-controlled study and investigators tested 
adherence by weighing the bottles at each clinic visit as well as by direct questioning 
of the parents. The authors reported no difference in the frequency of measured non-
adherence between the groups. In-depth analysis of the compliance data is currently 
under assessment and no numeric data were available.
• The Swedish Reflux Trial 2010 report stated that adherence to the antibiotic prophylaxis 
had been assessed by asking questions during every follow-up visit, but no findings were 
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provided.
Adverse events 
Only three studies reported side effects and the findings were very different for each 
study (Garin 2006; Montini 2008; PRIVENT Study 2009) (Analysis 1.8).
• Garin 2006 explicitly stated to have had ‘no reported side effects associated with the use 
of urinary antibiotic prophylaxis’.
• In PRIVENT Study 2009 two participants developed thrush while on antibiotics and five 
developed a rash while on placebo. 
• Montini 2008 reported 25 minor adverse events (out of 211 participants), mainly vomit-
ing or gastro-intestinal intolerance. These data however included patients without VUR 
and were not reported per treatment group.
Microbial resistance 
Four studies described bacterial resistance to the prophylactic drug in subsequent symp-
tomatic UTIs (Pennesi 2006; PRIVENT Study 2009; Roussey-Kesler 2008; Swedish Reflux Trial 
2010). Overall the estimated risk of prophylactic drug resistance in a repeat symptomatic 
UTI was three times higher for children that received antibiotics (Analysis 1.9.1 (4 studies, 
132 urine cultures): RR 2.94, 95% CI 1.39 to 6.25). In Garin 2006, in which both frequencies of 
symptomatic febrile and afebrile UTIs were collected, all of the seven pyelonephritis cases 
in children given antibiotics were caused by a resistant micro-organism, as opposed the one 
case in the no treatment group which was caused by a sensitive strain. This estimate how-
ever was based on the pooled data of only three studies, with high levels of heterogeneity 
and imprecision due to small numbers.
 Anatomic VUR correction with surgery or endoscopic injection plus antibiotics (1-24 months) 
versus antibiotics alone 
We had planned to analyse the results of studies comparing antibiotic prophylaxis (for 
one to five years) with surgical VUR correction together with studies comparing antibiotic 
prophylaxis with endoscopic VUR correction to obtain summary measures of treatment ef-
fects. However, we separated outcomes according to follow-up time (one to two, four to 
five, five to 10, and more than 10 years) and for none of the time-points did the analyses 
include both surgical and endoscopic interventions to estimate the treatment effect. There 
was no appreciable difference between the summary estimates using random and fixed ef-
fects models. There were insufficient studies to explore potential effect modification using 
subgroup analysis or meta-regression.
Symptomatic and febrile UTI 
The overall incidence of symptomatic UTI (febrile and non-febrile) was reported in three 
studies (Dite 2007; IRS EUR 1981-2003; Swedish Reflux Trial 2010). There was no significant 
difference at any time point up to 10 years between children who had undergone either 
surgical or endoscopic VUR correction on top of receiving antibiotics for up to 24 months 
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(Analysis 2.1.1 to Analysis 2.1.4). Two studies reported the number of children developing 
febrile UTI by two years of follow-up (Dite 2007; Swedish Reflux Trial 2010). Both were stud-
ies comparing subureteric injection of Deflux and the use of antibiotics with antibiotics 
alone. When combined, we found no significant difference in frequency of repeat symp-
tomatic UTI (Analysis 2.1.1 (2 studies, 179 children): RR 0.88, 95% CI 0.26 to 3.01) or febrile 
UTI (Analysis 2.1.5 (2 studies, 179 children): RR 0.73, 95% CI 0.15 to 3.60). Numeric results of 
the individual studies contradicted each other but both studies were small and CI’s wide. 
Both arms of the International Reflux Study (IRS EUR 1981-2003; IRS USA 1992) reported 
outcomes by five years of follow-up. In these studies children underwent surgical reimplan-
tation of the ureter. After five years, there were significantly fewer children developing a 
febrile UTI in the group that had undergone surgery and received prophylactic antibiotics 
(8% to 10%) than in the group only receiving antibiotics (22%) (Analysis 2.1.6 (2 studies, 429 
children): RR 0.43, 95% CI 0.27 to 0.70). The effect persisted for between five and 10 years 
(Analysis 2.1.7 (1 study, 252 children): RR 0.34, 95% CI 0.14 to 0.82) so that overall in children 
followed for 10 years there were significantly fewer febrile UTIs among children that had 
undergone surgical correction plus antibiotic treatment compared with children receiving 
only antibiotic treatment (Analysis 2.1.8 (1 study, 252 children): RR 0.54, 95% CI 0.32 to 0.92). 
Conversely, there tended to be fewer children with a repeat symptomatic afebrile UTI in the 
group treated antibiotics alone, but this result was not significant at any of the time-points.
Repeat positive urine culture 
Repeat positive urine culture was examined in eight studies (BIRSG 1987; Capozza 2002; 
Holland 1982; IRS EUR 1981-2003; IRS USA 1992; Morris 1991; Smellie 2001; Scott 1968). The 
number of children with a repeat positive urine culture did not significantly differ between 
the group treated with antibiotics alone and the group that underwent surgical VUR cor-
rection in addition to receiving antibiotic prophylaxis at one to three years (Analysis 2.1.9 (5 
studies, 388 patients): RR 0.89, 95% CI 0.55 to 1.44) and four to five years follow-up ( Analysis 
2.1.10 (3 studies, 479 children): RR 0.99, 95% CI 0.79 to 1.26).
Renal parenchymal abnormality 
Renal parenchymal abnormalities were examined in six studies (BIRSG 1987; Holland 
1982; IRS EUR 1981-2003; IRS USA 1992; Smellie 2001; Swedish Reflux Trial 2010). The fre-
quency of renal parenchymal abnormality (scars and renal parenchymal thinning) on IVP 
at study entry was 56% to 100% with no difference between children receiving antibiotic 
prophylaxis alone and those treated with surgery plus antibiotics. There was no difference 
in the number of children developing a new renal parenchymal abnormality, either at two 
years (Analysis 2.2.1 (2 studies, 171 children): RR 1.06, 95% CI 0.33 to 3.42) or at four to five 
years (Analysis 2.2.2 (4 studies, 572 children): RR 1.09, 95% CI 0.79 to 1.49). Similarly, there 
was no difference in the risk of progression of an existing abnormality either at two years 
(Analysis 2.2.3 (1 study, 10 children): RR 7.00, 95% CI 0.45 to 108.26) or at four to five years 
(Analysis 2.2.4 (3 studies, 468 children): RR 0.99, 95% CI 0.69 to 1.42). When the development 
of a new or a progressive abnormality were considered as a single outcome at four to five 
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years, there was no difference between the two groups ( Analysis 2.2.6 (3 studies, 468 chil-
dren): RR 1.05, 95% CI 0.85 to 1.29).
The European (IRS EUR 1981-2003) and US arms (IRS USA 1992) of the International Re-
flux Study differentiated renal scarring and renal parenchymal thinning on IVP. There was no 
significant difference in the number of patients with renal scars on IVP at zero to five years 
( Analysis 2.3.1 (2 studies, 418 children): RR 1.28, 95% CI 0.84 to 1.94), at five to 10 years ( 
Analysis 2.3.2 (1 study, 223 children): RR 1.03, 95% CI 0.07 to 16.22) or zero to 10 years in chil-
dren followed for 10 years in the European arm of the International Reflux Study ( Analysis 
2.3.3 (1 study, 223 children): RR 1.03, 95% CI 0.53 to 2.00). In the IRS EUR 1981-2003, renal 
scarring on IVP was present at entry in 49% of the 306 children originally treated and in 51% 
of 223 children studied by IVP at 10 years. During the first five years of follow-up, 40 children 
(surgery plus antibiotic group (21); antibiotic group (19)) developed new scars. Of these, 28 
were among the 223 followed radiologically at 10 years. Only two more children, one from 
each therapy group, developed new scars between five and 10 years. 
When the data were examined according to the total number of kidneys, there were 
also no significant differences at two years in new (Analysis 2.4.1 (2 studies, 235 children): 
RR 1.03, 95% CI 0.31 to 3.37), progressive (Analysis 2.4.2 (2 studies, 235 children): RR 1.56, 
95% CI 0.24 to 10.08) or total renal parenchymal abnormalities (Analysis 2.4.3 (2 studies, 235 
children): RR 1.54, 95% CI 0.24 to 9.95). Similarly, the risks for new abnormality (Analysis 2.4.4 
(2 studies, 319 children): RR 0.85, 95% CI 0.24 to 3.09), progression in abnormality (Analysis 
2.4.5 (2 studies, 319 children): RR 0.84, 95% CI 0.50 to 1.41) or total abnormality (Analysis 
2.4.6 (2 studies, 319 children): RR 0.84, 95% CI 0.53 to 1.34) did not differ at four to five years.
Two studies evaluated renal parenchymal abnormality with DMSA scan (IRS EUR 1981-
2003; Swedish Reflux Trial 2010). In the Swedish Reflux Trial 2010, the number of children 
developing new renal damage or deterioration of already existing damage did not signifi-
cantly differ between children that underwent endoscopic correction and received antibiot-
ics versus those receiving antibiotic prophylaxis alone ( Analysis 2.5.1 (1 study, 133 children): 
RR 2.09, 95% CI 0.66 to 6.61). In the IRS EUR 1981-2003, 97% of children had a scintigraphy 
performed at five years and 73% of children at 10 years. Parenchymal abnormalities were 
present in 83% of children at study entry. Relative to the antibiotics-only group, in the sur-
gical plus antibiotic treatment group there was no significantly increased risk of new or 
progressive DMSA scan abnormalities (Analysis 2.5.2 (1 study, 287 children): RR 0.97, 95% CI 
0.58 to 1.62) or of deterioration in DMSA scan appearance between five to 10 years (Analysis 
2.5.3 (1 study, 216 children): RR 0.71, 95% CI 0.31 to 1.58).
Finally in Capozza 2002, renal damage was evaluated with ultrasound. There was no 
significant difference in the risk of abnormality at one year between medically and surgi-
cally treated participants (Analysis 2.6.1 (1 study, 81 children): RR 0.36, 95% CI 0.04 to 3.31) 
though only four children developed abnormalities.
Renal growth was evaluated in four studies (BIRSG 1987; IRS EUR 1981-2003; IRS USA 
1992; Smellie 2001) at two to 10 years by measurements of changes in renal length standard 
deviation score (SDS) (3 studies, 510 children) or renal area (1 study, 82 children) on IVP. No 
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significant differences between groups were found at any time point or in any age group. 
Combining data in meta-analysis as not possible because of differences in reporting.
Other outcomes 
Five other outcomes were reported in 10 studies. The two outcomes of greatest clinical 
importance, ESKD and hypertension, were reported in three studies (BIRSG 1987; IRS EUR 
1981-2003; Smellie 2001). Six children developed ESKD and 14 developed hypertension 
during follow-up. There was no significant difference in the risk of ESKD (Analysis 2.7.1 (2 
studies, 154 children): RR 1.07, 95% CI 0.23 to 5.04) or hypertension (Analysis 2.7.2 (2 stud-
ies, 154 children): RR 0.93, 95% CI 0.25 to 3.42) between treatment groups at five years or for 
hypertension at 10 years (Analysis 2.7.3 (1 study, 252 children): RR 0.15, 95% CI 0.01 to 2.78).
Five studies (BIRSG 1987; Capozza 2002; IRS EUR 1981-2003; Morris 1991; Smellie 2001) 
reported on GFR but these were unable to be combined because of insufficiently reported 
point estimate and variance data. Individually, no study reported any significant difference 
between groups. Data from IRS EUR 1981-2003 showed no significant differences in GFR 
measured by the Schwartz formula at study entry (Analysis 2.8.1), at five years (Analysis 
2.8.2) and at 10 years (Analysis 2.8.3).
Growth was investigated in IRS EUR 1981-2003. There was no significant difference in 
height SDS at study entry (Analysis 2.9.1) or at 10 years ( Analysis 2.9.2).
Resolution of VUR was an outcome described in eight studies (BIRSG 1987; Capozza 
2002; Dite 2007; IRS EUR 1981-2003; IRS USA 1992; Smellie 2001; Scott 1968; Swedish Reflux 
Trial 2010). Combining individual study data was only possible for two studies examining 
endoscopic VUR correction. Unsurprisingly more children in the endoscopic group than in 
the antibiotics alone group had full VUR resolution after one to two years (Analysis 2.10.1 (2 
studies, 164 children): RR 2.69, 95% CI 1.57 to 4.63). But assuming a spontaneous resolution 
rate of 15% over one to two years when treated with antibiotics alone, two to three patients 
would have to be treated endoscopically for one additional patient to have a response com-
pared with antibiotic treatment alone. Capozza 2002 included VUR grade I in its definition 
of resolution. Still the success rate was lower than in the other two studies that evaluated 
endoscopic VUR correction (69% versus 38%).
We did not combine individual study data for the surgical studies, because of differences 
in reporting practices (patients and ureters), not all patients having had follow-up VCUGs 
and missing data. In four studies (BIRSG 1987; IRS EUR 1981-2003; IRS USA 1992; Smellie 
2001) the postoperative resolution rate at four to five years for ureters was 93% to 99%. Over 
a follow-up period of three to five years, 16% to 49% of patients had spontaneous resolution 
of VUR (BIRSG 1987; IRS EUR 1981-2003; IRS USA 1992; Smellie 2001; Scott 1968). In IRS EUR 
1981-2003, 130/155 children in the antibiotics-only group had persisting VUR at five years 
though in 50 other children VUR grade had diminished. Among 102 children undergoing 
voiding VCUGs at 10 years, VUR was still present in 27 children (22 with grade IV and five 
with grade III). In Scott 1968, 6/31 had persistent VUR three years postoperatively and 4/31 
had successful operations, but developed VUR in the opposite ureter at a later date.
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Adverse events 
Adverse events for either group were generally not well reported. Postoperative obstruc-
tion to the urinary tract occurred in 7% of children (10/151) in the European arm of the 
International Reflux Study. The Birmingham Reflux Study stated that no cases of postopera-
tive obstruction were found after five years. None of children treated with endoscopic injec-
tion in the Swedish Reflux Trial 2010 suffered vesicoureteric obstruction. The authors did 
report six other adverse events. One boy had transient ureteral and renal pelvic dilatation 
on ultrasound at one month, one boy developed urine retention after endoscopic injection, 
and one boy aspirated during anaesthesia and required overnight observation in the inten-
sive care unit. One girl suffered abdominal pain with pelvic dilatation and decreasing split 
function. The authors stated this resulted from a crossing vessel at the pelviureteral junc-
tion and was not related to the intervention. Finally, in one boy a fibrous narrowing of the 
bulbar urethra without obstruction was detected during the first endoscopic procedure. A 
weakening urine stream and obstructive flow curve pattern led to repeat endoscopic inves-
tigation, which revealed deterioration of bulbar narrowing. Ultimately internal urethrotomy 
was done. No other study referred to obstruction. No other adverse outcomes of surgery or 
endoscopy were reported.
Endoscopic VUR correction plus antibiotics (minimum of three months) versus no treatment 
Symptomatic and febrile UTI 
Being a three-arm study, the Swedish Reflux Trial 2010 allowed comparison of endo-
scopic correction versus no treatment. All children had received antibiotic prophylaxis for 
a period of at least three months after the endoscopic procedure when a follow-up VCUG 
was done. Only if this showed downgrading of the VUR status to grade I, prophylaxis was 
stopped. At two years follow-up, in the group who had undergone endoscopic interven-
tion, 45% fewer children developed symptomatic UTI (Analysis 3.1.1 (1 study, 134 children): 
RR 0.55, 95% CI 0.33 to 0.94). Similarly, fewer children developed febrile UTI, although this 
result did not reach statistical significance (Analysis 3.2 (1 study, 134 children): RR 0.58, 95% 
CI 0.33 to 1.01).
Renal parenchymal abnormality 
Although the point estimate was in favour of the combined treatment, the number of 
children with renal damage on DMSA scan was not significantly reduced for new damage 
( Analysis 3.3 (1 study, 133 children): RR 0.70, 95% CI 0.26 to 1.85), progressive damage ( 
Analysis 3.4 (1 study, 133 children): RR 0.52, 95% CI 0.14 to 2.00) or combined new and pro-
gressive damage ( Analysis 3.5 (1 study, 133 children): RR 0.70, 95% CI 0.30 to 1.60).
Other outcomes 
Endoscopic treatment significantly reduced the number of children with persistent VUR 
at two years of follow-up (Analysis 3.6.1 (1 study, 117 children): RR 2.50, 95% CI 1.28 to 4.86). 
However 14 children required at least a second subureteric injection and 21% of children in 
Nagler.indb   60 15/09/2015   16:14:37
Interventions for primary vesicoureteric reflux
61
the endoscopic group did not have repeat VCUG performed at the end of the study.
Different materials for subureteric injection to correct VUR 
Oswald 2002 compared endoscopic subureteric injections of Macroplastique with De-
flux. Although the data seemed to indicate a lower rate of persistent VUR beyond grade I at 
both three months (Analysis 4.1.1 (1 study, 114 children): RR 0.48, 95% CI 0.22 to 1.04) and 
one year (Analysis 4.1.2 (1 study, 73 children): RR 0.62, 95% CI 0.28 to 1.40), the results were 
not statistically significant. Conversely, patients injected with Deflux seemed less at risk for 
developing afebrile UTI during follow-up, although the difference was not significant and 
events in both groups were sparse (Analysis 4.1.3 (1 study, 72 children): RR 1.68, 95% CI 0.52 
to 5.44). Temporary pelvicaliceal dilatation however was more common following Macro-
plastique (Analysis 4.1.4 (1 study, 114 children): RR 1.85, 95% CI 1.02 to 3.35). No data on 
renal parenchymal abnormalities were reported.
One small study (Frey 1997) compared endoscopic subureteric injections of different 
concentrations of cross-linked collagen (GAX 65, GAX 35). VUR was five times and signifi-
cantly more likely to persist following GAX 35 than GAX 65 injections (Analysis 4.2.1 (1 study, 
28 children): RR 0.21, 95% CI 0.05 to 0.85). Recurrence of VUR was not significantly different 
between therapies (Analysis 4.2.2 (1 study, 28 children): RR 0.30, 95% CI 0.07 to 1.29). No 
data on UTIs or renal parenchymal abnormalities were reported.
Probiotic versus antibiotic prophylaxis 
Lee 2007 compared the potential benefits and harms of probiotic versus antibiotic 
prophylaxis in a single centre study including 120 children. There was no appreciable differ-
ence between the two interventions in symptomatic (Analysis 5.1.1 (1 study, 24 children): RR 
0.85, 95% CI 0.41 to 1.74) and febrile UTI (Analysis 5.1.2 (1 study, 24 children): RR 0.82, 95% 
CI 0.37 to 1.83) by one year. By the end of the one year follow-up period, 2/13 patients in the 
antibiotics group that had experienced a repeat UTI, had developed a new renal scar, versus 
1/11 in the probiotics group. In the probiotics group, seven symptomatic UTI recurrences 
(64%) had Escherichia coli identified as the causative organism, versus nine (69%) in the an-
tibiotics group. Whereas three of these were resistant to trimethoprim-sulphamethoxazole 
in the probiotic group, all of them were resistant in the antibiotic group (Analysis 5.2 (1 
study, 16 children): RR 0.46, 95% CI 0.21 to 1.02).
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Discussion 
Summary of main results 
The benefits and harms of interventions for primary VUR were assessed in 20 studies 
involving 2324 children.
Antibiotic prophylaxis versus surveillance/no treatment 
Overall, low-dose long-term antibiotic prophylaxis tended to reduce the number of re-
current symptomatic and febrile UTIs, but the result was not statistically significant. Only 
one of the included studies was adequately blinded. Its point estimate favoured antibiotic 
prophylaxis, but the result was not significant and patient numbers too small to adequately 
power this analysis. Long-term low-dose antibiotic prophylaxis reduced the number of chil-
dren developing new or progressive renal damage by 60% compared with no treatment. 
Assuming a baseline risk of 8% (Analysis 1.4.3; baseline risk 17/220), 33 children would need 
prophylaxis to prevent one extra child developing a new or progressive renal scar over the 
course of two to three years. Side effects of the preventive treatment were minor and infre-
quent but poorly reported. Little data were provided as to how side-effects had affected ad-
herence. Reported compliance rates varied between 70% and 100%, but they were incon-
sistently measured. Since previous studies have shown poor compliance for daily antibiotic 
regimens for VUR (Cohen 2005; Greenfield 1997), it raises the question whether antibiotics 
were inherently not very effective or not being used as prescribed. Treating VUR patients 
with long-term low-dose antibiotics was associated with a threefold increased risk of micro-
bial resistance against the prophylactic drug in breakthrough infection. This estimate how-
ever was based on the pooled data of only three studies, with high levels of heterogeneity 
and imprecision due to small numbers.
VUR correction with surgery plus antibiotics (1-24 months) versus antibiotics alone 
Only the European arm of the IRS study evaluated the differential risk of symptomatic 
UTI between medical and surgical management. Both strategies included prescription of 
antibiotics, for five years or until VUR resolution in medically treated children as opposed 
to six months in the surgically treated children. By four to five years there was no difference 
in symptomatic UTI. Both the European and the American arms of the IRS study however, 
investigated the risk of febrile UTI and found a significant benefit for those children who 
underwent surgical VUR correction. Assuming a baseline risk of 22% of developing febrile 
UTI when on antibiotics alone (Analysis 2.1.6; baseline risk 48/218), the estimated RR of 0.43 
would translate into a RD of 13% and eight patients needing surgery to prevent one extra 
febrile UTI over the course of five years. Further analysis at 10 years confirmed these re-
sults. It supports the idea that although surgery might not provide an added benefit over 
antibiotic prophylaxis in preventing symptomatic lower UTI, it might keep the infection 
from spreading to the upper tract, and ultimately prevent subsequent renal damage. No 
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evidence was found to corroborate this theory however, since the risk of developing new 
or progressive areas of renal damage at five and 10 years was no different between the 
treatment groups. You could argue that if VUR were an important modifiable risk factor for 
the development of UTI and renal damage, we would expect significant reduction in these 
outcomes for the group of surgically treated patients. It may be that delayed treatment of 
acute pyelonephritis is the more important risk factor, hence explaining why adverse out-
comes of renal damage are currently seen less frequently than they used to (Wennerstrom 
2000a; Wennerstrom 2000b). In addition, no differences between treatment groups were 
demonstrated for hypertension or CKD, but small numbers resulted in large imprecision 
and follow-up time was too short.
Potential benefits of surgery need to be weighed against its potential adverse effects. 
Whereas the Birmingham Reflux Study stated that no cases of postoperative obstruction 
were found after five years, they occurred in 7% of children (10/151) in the European arm 
of the International Reflux Study, corresponding to one every 14 to 15 patients undergoing 
the procedure.
Endoscopic treatment for VUR correction 
When compared with long-term low-dose antibiotic prophylaxis alone, endoscopic cor-
rection combined with antibiotics did not significantly reduce either symptomatic or febrile 
UTI by two years. There was also no significant difference in new or progressive renal dam-
age. Results however were derived from only two small studies with contradicting point 
estimates. When endoscopic correction was compared with no treatment in the Swedish 
Reflux Trial 2010, 45% fewer children developed symptomatic UTI by two years. A similar 
risk reduction was seen for febrile UTI, but the result was not significant. Children that un-
derwent endoscopic VUR correction also received antibiotic prophylaxis for a minimum 
of three months. Given that in the comparison of endoscopic treatment versus antibiotic 
prophylaxis, the point estimate favoured the prophylactic treatment alone, it seems unlikely 
that the endoscopic treatment was responsible for the reduced risk of febrile UTI in the 
comparison with no treatment.
Assuming correction were beneficial, endoscopic subureteric injection of various materi-
als could offer an alternative method of correcting VUR. It is currently widely used in North 
America and Europe since it is known to be associated with less pain and postoperative 
recovery time compared with open surgery. Four studies included in this review have dem-
onstrated acceptable rates of VUR correction with three different materials. In a systematic 
review of 63 studies involving 5527 patients, the success rates for correction of VUR grades 
I and II, III, IV and V were 78.5%, 72%, 63% and 51% after one treatment; second treatments 
had an overall success rate of 68% (Elder 2006). Therefore rates of correction appeared to 
be lower than those reported with surgical reimplantation techniques particularly for high 
grade VUR.
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Overall completeness and applicability of evidence 
For the primary outcome of symptomatic UTI and febrile UTI, study participants had 
mostly lower grades of VUR. Only five participants in the PRIVENT Study 2009 had VUR grade 
V. These patients are generally viewed as having the highest risk of developing renal scars 
after pyelonephritis. Hence we should be careful with extrapolating the results from this 
review to children with VUR grade V. Similarly, the studies that compared surgery and an-
tibiotics with antibiotics alone only included participants with higher degrees of VUR. This 
reflected the view that chances of spontaneous resolution would be slimmer and risks of 
renal scarring greater. VUR grade V however was also excluded from the International Reflux 
Study, since it was regarded to be part of a widespread malformation of the urinary tract 
instead of an isolated problem of the vesicoureteric junction and thought to experience a 
greater benefit from surgery.
A randomised comparison between antibiotic treatment and surgery alone has not been 
performed since in all studies, antibiotics were also given for a variable length of time. Only 
studies designed to assess the incremental benefit of surgery over antibiotics alone have 
been conducted.
Quality of the evidence 
The quality of conduct and reporting of these studies was variable, with many studies 
omitting crucial methodological information used to assess the risk of bias.
This review update has mainly added new studies that compared antibiotics to no treat-
ment. Although in general both methodological quality and standard of reporting were 
good, only the PRIVENT Study 2009 was optimally designed, providing placebo and ensur-
ing blinding of all participants, caregivers, outcome assessors and data analysts.
The effect estimate of incremental benefit of surgery was based on only one study that 
included 429 patients in the analysis. Given the nature of the intervention, it was not pos-
sible to blind participants or healthcare providers. Since this tends to result in overestima-
tion of the treatment effect (Schulz 1995), bias might have played a part in producing the 
statistically significant difference in febrile UTI in favour of surgical management.
Agreements and disagreements with other studies or reviews 
For over five decades, scientific published work has suggested the existence of a link 
between recurrent UTI, VUR and renal scarring (Olbing 2003; Smellie 1975; Smellie 1994; 
Smellie 1998). VUR has been thought to facilitate the involvement of the upper urinary tract 
during UTI by allowing retrograde passage of infected urine to the ureter. Subsequently all 
interventions have been targeted at preventing UTI-induced damage to the kidney. Earlier 
versions of this review (Hodson 2007; Wheeler 2004) were not been able to provide evi-
dence as to whether the common practice of diagnosing and treating children with VUR 
conferred important health benefits, since no adequately powered studies had included a 
no treatment arm. Five new studies have since been published that compare the adminis-
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tration of antibiotics with placebo or no treatment. Although the addition of these studies 
produced a risk estimate in favour of long-term low-dose antibiotics, the result was not sta-
tistically significant. Only one of studies was optimally designed with adequate blinding of 
all participants and personnel involved in the study (PRIVENT Study 2009). When analysed 
by itself it produced a RR of 0.70. The result was not significant (95% CI 0.35 to 1.24), but 
patient numbers too small to adequately power the analysis. In the original study, the inves-
tigators had included 576 children both with and without VUR. They found a 6% absolute 
risk reduction (95% CI 1 to 13) for the group treated with antibiotics versus those treated 
with placebo and the effect of preventive antibiotic treatment did not differ according to 
the VUR status.
In comparison to the previous review, we have highlighted symptomatic and febrile UTI 
as more relevant primary end points rather than positive urine cultures.
Authors’ conclusions 
Implications for practice
Compared with no treatment, use of long-term low-dose antibiotics tended to reduce 
the number of repeat symptomatic and febrile UTIs in children with VUR, but the result was 
not statistically significant. A large amount of unexplained heterogeneity in the analysis and 
inclusion of only one adequately blinded study, makes drawing firm conclusions challeng-
ing. Prophylaxis modestly reduced the risk of new or progressive renal damage, produced 
few side effects but was associated with a threefold increase in prophylactic drug resistance 
in subsequent UTIs.
The added benefit of surgery over long-term low-dose antibiotic use remains uncertain. 
Although there was a significant reduction in repeat episodes of febrile UTI, there were no 
differences in either symptomatic UTI or renal damage. Informed decision making should 
consider the risk of adverse events associated with surgery. Correcting VUR using endo-
scopic approaches would theoretically reduce these risks it but was not associated with a 
reduced number of symptomatic or febrile UTIs or a reduction in new or progressive renal 
damage.
Implications for research
We still need a well-designed, blinded and adequately powered study in children with 
VUR to resolve the remaining uncertainty surrounding the benefit of antibiotic prophylaxis 
in preventing UTI and renal damage. Hence we await with interest the results of the ongo-
ing, placebo-controlled ‘randomised Intervention for children with VesicoUreteral Reflux’ 
study (RIVUR Study), which examines the effect of low-dose antibiotic treatment on symp-
tomatic UTI and renal parenchymal injury assessed by DMSA scan. The role of surgery in the 
management of VUR needs further exploration. Of specific interest would be the impact of 
VUR correction by endoscopic subureteric injection without antibiotics versus no treatment 
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on the incidence of febrile UTI and renal parenchymal injury assessed by DMSA scan. 
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Abstract
Background. The prevalence of major depression in stage 5 chronic kidney disease (CKD) var-
ies between 14 and 30%. Patients with CKD who are depressed have a worse quality of life, 
are hospitalized more often and die sooner than those who are not depressed. Antidepres-
sant drugs are effective in the general population, but whether they improve outcomes in 
CKD is uncertain. Drug pharmacokinetics are altered in CKD, which may necessitate dose 
adjustment. We aimed to systematically review available evidence of the pharmacokinet-
ics, efﬁcacy and safety of antidepressant drugs when used in patients with CKD3 to CKD5 
(CKD3-5). 
Methods. This is a systematic review of randomized clinical trials and observational studies 
examining antidepressants in patients with CKD3-5, regardless of whether or not patients 
are on dialysis. Through comprehensive searches of seven databases, we identiﬁed all stud-
ies examining pharmacokinetic properties or clinical outcomes in patients with CKD3-5. 
One author assessed studies for eligibility and quality and extracted all data. Antidepres-
sant drugs were the studied intervention. The main outcomes were pharmacokinetic pa-
rameters, clinical outcomes such as response to treatment, reduction in depression severity 
and adverse events. 
Results. We identiﬁed 28 studies evaluating pharmacokinetic parameters in CKD for 24 antide-
pressants. Sparse and heterogeneous data precluded informative meta-analysis. Drug clear-
ance in CKD3-5 was markedly reduced for selegiline, amitriptylinoxide, venlafaxine, desven-
lafaxine, milnacipran, bupropion, reboxetine and tianeptine. We identiﬁed one randomized 
controlled trial (RCT) in 14 patients on haemodialysis for ﬂuoxetine versus placebo which 
showed no difference for efﬁcacy and safety measures. One other RCT of escitalopram ver-
sus placebo in 62 patients on haemodialysis provided no efﬁcacy data. There were nine 
non-randomized trials, all suggesting beneﬁt for the antidepressant under investigation. 
Side-effects were common, but mild in most patients. The limitations of this review include 
the scarcity of randomized trial data, the small size of the observational studies and possi-
bility of publication bias. In addition, study selection and data extraction were done by one 
reviewer only, increasing the risk for errors made in handling of the data. 
Conclusions. Dose reduction in CKD3-5 is necessary for selegiline, amitriptylinoxide, venlafax-
ine, desvenlafaxine, milnacipran, bupropion, reboxetine and tianeptine. The evidence on ef-
fectiveness of antidepressants versus placebo in patients with CKD3-5, and with the fourth 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)-deﬁned de-
pression is insufﬁcient, and in view of the high prevalence, a well-designed RCT is greatly 
needed.
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ERBP Recommendations 
1.1  We suggest that in patients with CKD3 to CKD5 (CKD3-5) who meet DSM-IV criteria for mod-
erate major depression, active treatment is started (2D). 
1.2  We suggest a trial with antidepressant drug therapy can be started. After 8–12 weeks, the 
treatment effect should be re-evaluated to avoid prolonging ineffective medication (2D). 
1.3  We suggest using a selective serotonin re-uptake inhibitor as a ﬁrst-line agent, if treatment 
with an antidepressant drug is considered (2C).
Rationale 
A recent Cochrane review on antidepressant drug therapy in the physically ill showed antidepressants to be signiﬁcantly more effective than placebo (odds ratio 2.33, 95% conﬁdence interval 1.8–3, number needed to treat = 6) [1]. For patients 
with CKD3-5, we identiﬁed only one published randomized trial in 14 patients, which did 
not suggest a beneﬁcial effect of antidepressant drugs. Nine reports of prospective non-
controlled studies that evaluated the effect of antidepressant drugs in CKD [2–10] found 
a beneﬁt for the antidepressant under investigation, yet effect estimates were of similar 
magnitude for the placebo effect found in the one randomized controlled trial (RCT). As 
such, there is insufﬁcient evidence for a general recommendation to routinely use an an-
tidepressant agent in patients with CKD3-5 and a DSM-IV-deﬁned depression. However in 
line with the current treatment guidelines, the high prevalence of depression in patients 
with CKD3-5 and its negative inﬂuence on survival and quality of life, active intervention 
seems justiﬁed. Given the very mild side effects of the studied antidepressants in CKD 3-5, 
an 8–12-week trial with these drugs can be considered in patients suffering from moderate 
depression according to DSM-IV [11]. However, the overall poor reporting of side-effects 
in trials in addition to observational data suggesting an association with increased risk of 
falls in elderly patients [12], means one should be careful when balancing the potential 
beneﬁts against their potential harms. In any case, the effectiveness of the treatment should 
be evaluated after the initial 8–12-week treatment phase and the drug should be withheld 
when no beneﬁts observed. 
Non-pharmacological treatments might provide equal beneﬁt, without the potential 
harms and can represent valuable alternatives to antidepressant drug therapy. As they were 
not studied in this review, we refrained from making any statements. Of all the clinically 
studied compounds in patients with (CKD3-5), all but one belong to the class of selective 
serotonin reuptake inhibitors. Hence, from an evidence-based viewpoint, it seems reason-
able to advocate the use of these agents as the ﬁrst-line treatment of choice.
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Introduction 
Major depression is diagnosed when symptoms of persistent unreactive mood and loss 
of all interest or pleasure are accompanied by insomnia, fatigue, lethargy, loss of energy or 
appetite, poor concentration, restlessness, inappropriate guilt and/or morbid thoughts of 
death [13]. With an estimated prevalence of 14–30%, major depression is the most common 
psychological problem in patients with stage 5 chronic kidney disease (CKD5) [14–16]. 
Aside from having a worse quality of life, depressed patients with CKD are hospitalized 
more often and die sooner than those who are not depressed [16–18]. Proposed causal 
mechanisms to explain these poor outcomes include inﬂammation as well as non-adher-
ence to therapy, an unhealthy lifestyle and poor nutrition [16]. It is reasonable to assume 
that successfully treating depression would improve overall wellbeing in these patients, but 
whether it will lead to better survival is uncertain. 
Antidepressants are effective in treating depression in the general population [19, 20]. 
Around 50–65% of patients have reduced symptoms when treated with antidepressants 
compared with 25–30% when treated with placebo [20]. Improvement is usually observed 
within the ﬁrst 3 weeks of starting therapy, but can take up to 6 weeks to become apparent. 
Antidepressant drugs act by increasing the activity of one or more of the neurotransmit-
ters serotonin, nor-adrenaline and/or dopamine in the central nervous synapses, by either 
preventing their enzymatic breakdown in the synaptic cleft, inhibiting re-uptake across the 
presynaptic cellular membrane, stimulating release from the pre-synaptic cells or stimulat-
ing effects on the postsynaptic receptor. 
CKD may affect antidepressant pharmacokinetics unpredictably for several reasons. 
Impaired kidney function decreases drug excretion, but may also lead to reduced intes-
tinal availability by slowed gastric emptying. Drug accumulation may result from altered 
absorption or hepatic metabolism and protein binding may differ according to the acidity 
of the drug [21]. Finally, dialysis may remove a drug to such extent that a substitution dose 
is needed to preserve the desired effect [22]. As a result, dose adjustments based on data 
from the general population and the expected inﬂuence of renal impairment may be highly 
inaccurate. 
In a recently updated Cochrane review on the use of antidepressants in the physically ill, 
Rayner et al. [23] identiﬁed only two small randomized, placebo controlled trials, conducted 
in, respectively, 14 and 62 patients with CKD5 [24, 25]. We are not aware of any previous at-
tempts to systematically summarize the pharmacokinetic data. 
Given these uncertainties, we aimed to identify antidepressant compounds that might 
need dose adjustments in CKD3-5 and to identify both the beneﬁts and harms of antide-
pressant medications in the management of CKD3-5 patients with depression.
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Materials and methods 
Criteria for considering studies for this review 
We considered all study types in which an antidepressant drug was studied prospec-
tively in humans. Neither randomized allocation nor a non-randomized control group was 
considered an absolute prerequisite, and we imposed no restrictions based on the number 
of participants in each trial. Because rare but potentially life-threatening side-effects are not 
necessarily captured by trials, we included all reports of serious adverse events, regardless 
of study design. 
We included studies enrolling adults or children with CKD stage 3 (CKD3), 4 (CKD4) or 
5 (CKD5) as deﬁned by the KDOQI guidelines [26]. That is, we included all patients with an 
estimated glomerular ﬁltration rate (eGFR) below 60 mL/min/1.73 m2 of body-surface area, 
calculated using the Modiﬁcation of Diet in Renal Disease formula or any other glomerular 
ﬁltration rate estimation equation. For trials evaluating the efﬁcacy of an antidepressant, 
we required participants to have a diagnosis of depression, although we did not specify the 
diagnostic tools used to make the diagnosis. We excluded trials in which antidepressants 
were prescribed primarily to treat symptoms other than depression. 
All drug compounds listed as antidepressants according to the British National For-
mulary [27], the American Hospital Formulary Service Drug Information [28] or the Dutch 
Farmacotherapeutisch Kompas [29] were eligible for this review (Table 4.1). We excluded 
mood-stabilising drugs such as lithium, even if they had been used to treat depression. 
The ﬁrst outcome category consisted of basic pharmacokinetic parameters reﬂecting 
the different aspects of absorption, bioavailability, drug distribution, metabolism and ex-
cretion (Table 4.2). The second category comprised measures of efﬁcacy and harm. Here, 
the main outcomes were response to treatment, improvement upon treatment and change 
in depression severity as deﬁned by the investigators and according to whatever scale they 
used. We also looked at hospitalization rate, all-cause mortality, suicide or suicide attempts, 
withdrawal from dialysis, adherence to treatment for CKD, quality of life and effect on nu-
tritional parameters. An attempt was made to report on adverse events attributable to the 
antidepressant intervention as a measure of tolerability and the number of dropouts from 
the antidepressant therapy as a proxy of acceptability. 
Search methods for identiﬁcation of studies 
The search strategies we used to retrieve studies from the bibliographic databases com-
bined medical subject headings and text words for CKD, end-stage renal disease, depres-
sion and antidepressants, limiting to studies conducted in humans. We did not apply a 
methodological ﬁlter nor did we impose any restriction on language. The search strategies 
are detailed in Supplementary Appendix 1. 
To identify studies for inclusion in this review, in December 2011, we searched The 
Cochrane Renal Group Specialized Register, CENTRAL in the Cochrane Library, MEDLINE 
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from 1950, EMBASE from 1980, PsychINFO from 1967, International Pharmaceutical Ab-
stracts from 1950, Clinical trial registries endorsed by the International Committee of Medi-
cal Journal Editors, reference lists of nephrology textbooks, pharmaceutical reference works, 
review articles and relevant studies. 
Data collection, extraction, analysis and assessment of risk of bias 
Both initial screening of all titles and abstracts, subsequent full-paper assessment of po-
tentially eligible studies and extraction of the data from included studies was done by E.V.N. 
All studies reported in a language other than English were translated before assessment. 
Additional data were requested from authors for the randomized controlled trials (RCTs) 
only.
The quality of the included studies was assessed by E.V.N., without blinding to author-
ship or journal. We did not formally evaluate the risk of bias in the pharmacokinetic stud-
ies, as no validated tool exists. Instead, we described the process for participant selection, 
participant characteristics, completeness of outcome reporting, addressing of all active 
metabolites, reporting of analytic procedures and mathematical model building. For rand-
omized trials describing efﬁcacy, we used the risk of bias checklist as recommended by the 
Cochrane handbook for systematic reviews on interventions [30]. For non-randomized or 
uncontrolled trials and observational studies, we highlighted the design features that may 
introduce bias [31]. 
Data reporting 
We reported both pharmacokinetic and clinical results in tables (See Supplementary 
Appendix 2 and 3). Sparse and heterogeneous data precluded informative formal meta-
analysis. For many drugs, not all pharmacokinetic parameters were known for individuals 
with renal impairment. In such cases, drug disposition was predicted from knowledge of 
the drug’s pharmacokinetics in patients with normal kidney function. Hence, we provided 
data generated in the general population, retrieved from six reference works [27–29, 32–33] 
and supplemented this with data from studies conducted speciﬁcally in patients with CKD. 
For pharmacokinetic data, we presented ﬁndings as continuous data with measures of 
central tendency and distribution as reported by the original authors. We reported exact 
P-values where possible. 
For efﬁcacy measures, we reported categorical data in absolute numbers. For controlled 
trials, we had planned to supply the results in terms of relative risks and their 95% conﬁdence 
interval (95% CI). Both of the two identiﬁed controlled trials, however, reported results only 
on a continuous scale. We reported these results as a mean difference and 95% conﬁdence 
interval when possible. For uncontrolled trials, ﬁndings were reported as change from base-
line or as group means at beginning and end of the trial. Standard deviations were supplied 
where possible. If signiﬁcance tests had been conducted, mean change from baseline, 95% 
conﬁdence intervals and P-values were reported as in the original article. If standard errors 
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were not available, attempts were made to calculate the 95% conﬁdence interval from exact 
P-values if they were available.
Results 
Pharmacokinetics 
Characteristics of included studies
We identiﬁed 33 published reports [2, 3, 21, 35–64] of 28 studies investigating pharma-
cokinetic parameters for 24 antidepressant medications. (Figure 4.1) Twelve studies exclu-
sively included patients with CKD5 treated either with peritoneal dialysis [50, 60] or haemo-
dialysis [2, 3, 45, 47, 50, 51, 55, 57, 58, 61, 63]. One study included only patients with CKD5, 
who were not yet on dialysis [45]. Another study included patients with CKD4 and CKD5 
treated either conservatively or with haemodialysis [53, 54]. Thirteen studies also included 
patients with CKD3 [35, 38, 40–43, 46, 48, 49, 56, 59, 62, 64], and in three, it was not possible 
to distinguish between CKD3 and more advanced CKD [21, 35, 48]. Finally, we accepted one 
study that had included one patient with CKD2 as well as two with CKD3 and ﬁve with CKD4, 
where individual patient data could not be extracted [52]. 
Four trials only looked at drug removal through dialysis [3, 45, 55, 57]. Two were in vitro 
studies of plasma protein binding [21, 52]. The 21 others were full pharmacokinetic studies, 
but reported outcomes incompletely [2, 35–44, 46–50, 52–54, 56, 58–64].
Of the 21 pharmacokinetics studies, ﬁve reported six of the nine pre-speciﬁed outcome 
measures [21, 41, 48, 61, 64], ﬁve reported ﬁve [36, 49, 53, 54, 56, 58, 59, 63], six reported four 
[39, 44, 62] or three [35, 37, 38, 46], and three reported two [42, 43, 47] or one [60] (Table 4.2). 
Table 4.2. Types of pharmacological outcome measures.
Symbol Full Unit of measurement
M Molecular Mass d, g/mol
A Degree of absorption from gastro-intestinal tract Qualitatively, % of total oral dose
F Bioavailability % of intravenous dose reaching systemic circulation
Cmax Peak plasma concentration ng/ml
tmax Time to peak plasma concentration hours
Vd Apparent distribution volume L or L/kg
PPB Degree of plasma protein binding % of total plasma concentration
AUC Area under the curve unitless
t½ Elimination half-life Hours
CL/F Plasma clearance after oral administration as cal-
culated from the area under the curve in a plasma 
concentration time curve
L/h 
CLr Plasma clearance by the kidney L/h
Cld Plasma clearance by dialysis L/h
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Finally, three studies only reported serum concentrations of the drug under investigation 
[2, 40, 50]. 
On average, the number of participants with CKD in each trial was small. Only three stud-
ies included >20 patients [21, 51, 64], 12 included between 11 and 20 [36– 44, 46, 49, 50, 53, 
54, 56, 59], 11 included between 2 and 10 [2, 3, 35, 47, 48, 52, 57, 58, 60, 62, 63], and 2 only 
included 1 patient [45, 55]. 
Fourteen studies mentioned inclusion or exclusion criteria. Only seven stated them ex-
plicitly [2, 36, 39, 49, 56, 59, 61, 63, 64]. Of the 19 trials that included dialysis patients, nine 
detailed both the frequency and duration of the dialysis procedure and the type of dialyser 
or the dialysis solutions used [21, 42, 43, 47, 51, 57, 58, 60, 61, 63]. Two studies provided 
details about frequency and duration only [3, 50]. 
No study clearly described the selection process. Underlying renal disease was explicitly 
reported in nine trials [40, 42, 43, 47–50, 58–60, 63], but only three studies detailed other 
comorbidities [2, 51, 57], and only eight listed other medications patients were chronically 
taking [35, 42, 43, 45, 50, 51, 57, 60, 63]. 
Of 23 trials needing control groups (all but the four dialysis studies), only ﬁve trials pre-
sented inclusion and or exclusion criteria for controls [2, 48, 61, 62, 64]. Characteristics were 
generally poorly described. Age, sex and or body weight were provided by 16 studies [2, 
35–39, 42–44, 48–52, 58, 60, 62, 64]. 
Three trials studied both single and multiple dosing [40, 42, 43, 58]. In the 24 others, 
authors limited analyses to only single [21, 35, 38, 39, 41, 44, 46–48, 51–54, 56, 57, 59–64] or 
5272 Citations identified from electronic database search
5126 Citations excluded based on title or abstract
31 Duplicate citations excluded
115 Potentially relevant citations
identified for full-text review
0 Citations identified from reference lists
82 Citations excluded based on full-text review:
20 Were not conducted in patients with CKD
1 Did not allow separation of patients with CKD
1 Not possible to extract number of participants
11 Did not evaluate antidepressants
11 Did not report appropriate outcome parameters
38 Reviews
115 Citations reviewed
33 Publications of
28 studies included
in systematic review
Figure 4.1. Selection process for inclusion of studies in review of pharmacokinetics.
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multiple dosing [2, 3, 37, 45, 50]. 
Of the 21 studies that should have addressed the pharmacokinetics of the active me-
tabolite [2, 21, 35–37, 40–45, 47, 49, 51, 53–57, 59–63], only 15 did so [2, 35–37, 42–44, 47, 
49, 51, 53–56, 59, 61–63]. The others only discussed the parent drug. 
Analytic procedures used to measure drug concentrations were detailed in 21 trials [2, 
21, 35, 37–39, 41– 44, 48, 50–52, 56–64]. Only limited detail was given in seven trials [36, 40, 
46, 47, 49, 53–55]. One did not mention them at all [56]. 
Of the 21 full pharmacokinetic studies, 17 described mathematical model building. Two 
allowed for non-linear kinetics [49, 64], whereas all others assumed a one-compartment 
model or linear kinetics [35, 37–39, 42–44, 46, 52–54, 56, 58–62, 64]. 
Findings 
Drug elimination was studied in patients with CKD3-5 including haemodialysis patients 
on a non-dialysis day. Elimination half-life was importantly prolonged and/or drug clear-
ance markedly reduced after oral intake for amitriptylinoxide [44], venlafaxine [61], desven-
lafaxine [64], milnacipran [52], bupropion [62] and reboxetine [41]. For selegiline, the elimi-
nation half-life could not be reliably calculated but the area under the plasma concentration 
curve was signiﬁcantly increased [50]. Mirtazapine had a reduced plasma clearance after 
oral intake, but not a prolonged elimination half-life [55]. 
For tianeptine neither elimination half-life nor clearance after oral intake was different 
for the parent compound [53, 54]. However, the elimination half-life of its active metabolite 
was markedly increased [53, 54]. For imipramine [50], sertraline [57] and nefazodone [38], 
on average the half-life was importantly increased numerically, although in these small and 
underpowered studies none of the differences in half-life were signiﬁcant when compared 
with healthy controls. For amitriptyline [60], doxepine [47], citalopram [48, 58], ﬂuoxetine 
[36, 49], trazodone [40] and moclobemide [56, 59], the various pharmacokinetic parameters 
were similar between patients with advanced CKD and healthy controls. Interindividual 
variability of parameters was high in all trials. 
Removal by haemodialysis was directly tested for nine compounds during a 4-h session 
with a low-ﬂux dialyser. For ﬂuvoxamine, there was an average 21% reduction in its plasma 
concentration during the dialysis session in three patients under evaluation [3]. Only limited 
amounts of desipramine [50], nortriptyline [42], amitriptyline [60], doxepin [47], citalopram 
[58], ﬂuoxetine [49], venlafaxine [61], trazodone [45] and mirtazapine [55] were removed by 
dialysis. Drug removal was only assessed for patients undergoing standard haemodialysis. 
No information was identiﬁed for the more efﬁcient strategies such as high-ﬂux dialysis, 
haemodiaﬁltration and daily or long dialysis. There was no speciﬁc information on removal 
by peritoneal dialysis. 
The potential need for a dose increase in patients on haemodialysis was evaluated in two 
studies. For two patients treated with amitriptyline, the elimination half-life was similar to 
that in the general population [50]. For six patients taking ﬂuoxetine, the steady-state serum 
con¬centration was numerically higher but not signiﬁcantly different compared with six 
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participants with normal renal function [37]. 
Effectiveness and safety 
We identiﬁed only three RCTs of antidepressant medications (Figure 4.2). 
One trial is still ongoing (CAST-trial-NCT00946998) and aiming to include 200 partici-
pants to evaluate sertraline in a 12-week placebo-controlled randomized trial in patients 
with CKD3-5 who are diagnosed with major depressive disorder. 
The two trials that have been ﬁnalized were both conducted in individuals on haemodi-
alysis [24, 25], and required a diagnosis based on a clinical interview using criteria from the 
fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), the 
gold standard for psychiatric diagnosis [13]. 
In the ﬁrst trial, escitalopram was compared with placebo in 62 patients, but the report 
was only published as an abstract [25]. The investigators suggested an improvement in de-
pression scores but provided no end-point data. Participants had no serious adverse events. 
Methodology was insufﬁciently detailed to allow a clear judgement of the risk of bias. We 
tried to contact the authors for additional information but did not receive a response. A 
second study of ﬂuoxetine versus placebo, provided adequate outcome data, but includ-
ed only 14 patients [24]. On average, after 8 weeks, patients treated with ﬂuoxetine had a 
10-point reduction in depression severity on the 63¬point Beck Depression Inventory (BDI) 
scale and a 9-point reduction on the 53-point Hamilton Depression Scale (HAM-D). The 
results were similar for patients treated with placebo. Adherence was not measured. The 
number of adverse events was numerically higher in those receiving ﬂuoxetine (34 events 
Figure 4.2. Selection process for inclusion of studies in review of efficacy and safety.
3747 Citations identified from electronic database search
3606 Citations excluded based on title or abstract
35 Duplicate citations excluded
106 Potentially relevant citations
identified for full-text review
1 Citation identified from reference lists
88 Citations excluded based on full-text review:
19 Were not conducted in patients with CKD
5 Did not allow separation of patients with CKD
10 Not possible to extract number of participants
18 Did not evaluate antidepressants
33 Did not report appropriate outcome parameters
3 Reviews
107 Citations reviewed
19 Publications of
17 studies included
in systematic review
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in six patients) than in those receiving placebo (22 events in seven patients). Hypotension 
was reported in four patients in the ﬂuoxetine group versus one in the placebo group. The 
severity of these events was not speciﬁed. Overall, we judged the risk of bias to be low, with 
adequate sequence generation, allocation concealment, blinding of all participant health-
carers, outcome assessors and data analysts, complete reporting of all outcomes and ad-
dressing missing data. 
We identiﬁed nine non-randomized uncontrolled trials, including 7–44 participants each 
[2–10]. In six studies, patients had to meet the criteria for major depressive disorder as out-
lined in the DSM-III [2, 4], or DSM-IV clinical psychiatric interview [5, 7, 9, 10, 65, 66]. The 
three others used various screening tools with a chosen cut-off as inclusion criterion [3, 
6, 8]. One evaluated the effects of a tricyclic antidepressant [4], whereas the eight others 
investigated one of the selective serotonin reuptake inhibitors. In three studies, response 
by the end of the 4–8-week trial, as deﬁned by a HAM-D score <18 or a reduction of 50% 
from baseline, varied between 39 and 80% [3, 4, 6]. After 8–12 weeks, depression severity 
decreased 7–9 points on the BDI scale in four studies [5, 8, 9, 10], and 2–12 points on the 
HAM-D scale after 8 weeks in two other studies [2, 7]. There were no data on hospitalization 
rate, all-cause mortality, suicide or suicide attempts and withdrawal from dialysis or for ad-
herence to treatment for CKD. 
Two groups investigated the effect of antidepressant treatment on nutritional parame-
ters [6, 7]. In an uncontrolled trial with paroxetine [7], a signiﬁcant increase in three measures 
of protein intake was observed. Plasma concentrations of albumin on average increased 
from 37.3 to 38.7 g/L and those of blood urea nitrogen from 24.3 to 30.2 mmol/L. Normal-
ized protein catabolic rate as a marker of protein intake, signiﬁcantly increased from 1.04 to 
1.17 g/kg/day [7]. The clinical relevance of this outcome might be questioned, given that 
both values are above the suggested lower limit for malnutrition in dialysis patients of 1 g/
kg/day [67]. Conversely, in a non-randomized uncontrolled study conducted in 39 patients 
on haemodialysis, Lee et al. [6] found no evidence that ﬂuoxetine signiﬁcantly changed 
body weight, fat-free mass or arm-muscle index. Adverse events were reported in ﬁve trials. 
The percentage of people suffering from side-effects in these trials varied between 9 and 
100%. Complaints were mainly minor and included dizziness, nausea, headache, sedation 
and somnolence. However, in up to 28% of those suffering side-effects, these caused the 
patient to discontinue treatment [2–4, 7, 65]. In the one study with a tricyclic agent [4], 
the investigators stated all patients reported side-effects, most frequently dizziness and dry 
mouth. However, there was no report of cardiotoxicity and most complaints caused only 
minor discomfort. 
We did identify three retrospective case-reports of serious adverse events associated 
with the use of a tricyclic compound in patients with severe CKD [68–70]. These included 
a cardiac arrest associated with the use of maprotiline [68], after exclusion of electrolyte 
disorders, a case of severe hyperventilation attributed to nortriptyline [70], after exclusion 
of organic causes of hyperventilation and the development of malignant neuroleptic syn-
drome in a patient started on amoxapine [69]. 
Nagler.indb   90 15/09/2015   16:14:38
Antidepressants in stage 3–5 chronic kidney disease
91
We also identiﬁed one case report of repeated deep venous thrombosis and subsequent 
pulmonary embolism in a patient treated with ﬂuoxetine [71], and one case in which a pa-
tient developed paranoid ideations while on venlafaxine [72].
Discussion 
Summary of main results
For patients with CKD, clearance of various antidepressants is altered. Elimination half-
life is prolonged and/or clearance after oral intake markedly reduced for selegiline [50], ami-
triptylinoxide [44], venlafaxine [61], desvenlafaxine [64], milnacipran [52], bupropion [62] 
and reboxetine [41]. For tianeptine, there is a marked increase in the elimination half-life of 
its active metabolite [53, 54]. There was large inter-individual variability in every trial and 
ﬁndings are based on single studies, all with methodological shortcomings. 
There is no high-quality evidence from randomized trials that suggests antidepressants 
are more effective than placebo in treating depression in patients with CKD3–5. In addition, 
there are even only a few reports of prospective observational studies that evaluate the ef-
fect of antidepressant drugs in CKD [2–9]. All these studies suggested treatment improved 
depression after 8–12 weeks but when compared with the only placebo-controlled trial, the 
magnitude of effect was similar to that of placebo. Side-effects were common, but seemed 
to be mild in most patients. 
Findings in the context of other published literature
A recent Cochrane review on antidepressant drug therapy in the physically ill showed an-
tidepressants to be signiﬁcantly more effective than placebo (odds ratio 2.33, 95% CI 1.8–3, 
number needed to treat = 6). At 6–8 weeks, there were more dropouts among patients 
treated with antidepressants than among patients treated with placebo (number needed 
to harm = 19) [23]. 
Of the common side-effects of antidepressant medications, dry mouth and sexual dys-
function were more frequently reported by patients treated with antidepressants. 
There was no signiﬁcant difference in response or adverse effects between tricyclic an-
tidepressants or selective serotonin re-uptake inhibitors. Unfortunately, this meta-analysis 
included only one trial conducted in patients with CKD. 
Strengths and limitations of this study
To our knowledge, this summary of the pharmacokinetics of antidepressants in CKD is 
the most extensive of its kind at present. It was based on six standard reference works in 
pharmacology and supplemented with original data from 41 primary studies. We identiﬁed 
these trials by systematically searching seven electronic databases and the reference lists 
of every obtained publication. However, for most compounds, parameter estimates were 
still based on single studies with few study subjects and, for all of the studies, we identiﬁed 
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methodological ﬂaws. 
Given our knowledge of the recent Cochrane review [23] and our expectation of sparse 
controlled trial data, we decided to include data from uncontrolled trials to help inform 
practice. 
All published non-controlled trials found a beneﬁt for the antidepressant under investi-
gation, yet effect estimates were similar for the placebo effect found by Blumenﬁeld et al. 
in their RCT [24]. Indeed, in depression, on average one-third of participants in clinical trials 
respond to placebo, making the estimation of any effect size without a placebo control arm 
problematic. In addition, as on average 21% discontinued the treatment, failure to include 
outcomes for these patients in the analysis, may have caused the effect size to be overly op-
timistic. Finally, selective outcome reporting and publication bias might have caused only 
positive results to have been published [30]. 
Diagnosis of major depression in patients with CKD is challenging since symptoms of 
uraemia might mimic those of clinical depression. Clearly, outcomes of interventional trials 
could be misleading if diagnostic tools fail to distinguish between uraemia and depressive 
symptoms. Both the randomized trials and six of the nine non-randomized studies required 
a diagnosis based on a clinical interview using DSM-III or -IV criteria, considered the gold 
standard to make the diagnosis of depression. Turk et al. used the BDI with a validated cut-
off of 15 [72], the other two used screening tools with cut-offs, that had been less validated 
in patients with CKD. 
The available study data point towards a different time lag needed for improvement after 
antidepressant therapy initiation for patients with CKD (up to 12 weeks) in comparison with 
the general population (3–6 weeks). Possibly, this is explained by inadequate dosing, drug 
availability or receptor-drug processing, non-adherence to treatment or somatic inﬂuences 
on treatment success, all of which is subject to further research. 
For the present systematic review, studies were selected and data extracted by one 
person only. Although the ﬁndings were carefully checked, failing to include independent 
study selection and data extraction by a second author increases the risk of errors made in 
handling of the data. 
Last but not least, the recommendations were generated by the authors, nephrologists 
with expertise in epidemiology. The omission of a multidisciplinary team, including psy-
chiatrists, general practitioners, renal nurses and patients may have caused the statements 
to insufficiently reflect the views of important stakeholders.
Implications for further research
High-quality efﬁcacy and safety data on the use of antidepressants in advanced CKD 
are lacking and a well-designed RCT to clarify the balance between beneﬁts and harms 
is long overdue. We know of only one ongoing randomized trial, comparing sertraline to 
placebo with a 12-week follow-up, aiming to include 200 patients. Longer follow-up would 
be needed to demonstrate a sustained beneﬁt of pharmacologic treatment and evaluate 
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whether hard end-points such as hospitalization and mortality are affected without too 
many side-effects. Given the lack of adherence and the variability of pharmacokinetic and 
dynamic effects, larger sample sizes will probably be necessary to reliably show a beneﬁcial 
treatment effect. 
Supplementary data 
Supplementary data are available online at http://ndt. oxfordjournals.org. 
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Abstract
Background. Hyponatraemia is a common electrolyte disorder. Multiple organisations have 
published guidance documents to assist clinicians in managing hyponatraemia. We aimed 
to explore scope, content and consistency of these documents.
Methods. We searched MEDLINE, EMBASE, and websites of guideline organisations and pro-
fessional societies to 09/2014 without language restriction for Clinical Practice Guidelines 
(defined as any document providing guidance informed by systematic literature review) 
and Consensus Statements (any other guidance document) developed specifically to guide 
differential diagnosis or treatment of hyponatraemia. Four reviewers appraised guideline 
quality using the 23-item AGREE II instrument, which rates reporting of the guidance devel-
opment process across six domains: scope and purpose, stakeholder involvement, rigour of 
development, clarity of presentation, applicability and editorial independence. Total scores 
were calculated as standardised averages by domain. 
Results. We found ten guidance documents; five clinical practice guidelines and five consen-
sus statements. Overall, quality was mixed: two clinical practice guidelines attained an av-
erage score of >50% for all of the domains. Three rated the evidence in a systematic way 
and two graded strength of the recommendations. All five consensus statements received 
AGREE scores below 60% for each of the specific domains.
 The guidance documents varied widely in scope. All dealt with therapy, and seven included 
recommendations on diagnosis, using serum osmolality to confirm hypotonic hyponatrae-
mia, and volume status, urinary sodium concentration and urinary osmolality for further 
classification of the hyponatraemia. They differed however in classification thresholds, what 
additional tests to consider and when to initiate diagnostic work-up. Eight guidance docu-
ments advocated hypertonic NaCl in severely symptomatic, acute onset (<48h) hyponatrae-
mia. In chronic (>48h) or asymptomatic cases, recommended treatments were NaCl 0.9%, 
fluid restriction and cause-specific therapy for hypovolaemic, euvolaemic and hypervolae-
mic hyponatraemia respectively. Eight guidance documents recommended limits for speed 
of increase of sodium concentration, but these varied between 8 and 12 mmol/L per 24h. 
Inconsistencies also existed in the recommended dose of NaCl, its initial infusion speed, and 
which second line interventions to consider.
Conclusions. Current guidance documents on the assessment and treatment of hyponatrae-
mia vary in methodological rigour and recommendations are not always consistent. 
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Background
Hyponatraemia is the most common electrolyte disorder in clinical medicine. It represents an excess of water relative to total body solute [1]. Hyponatraemia usually results from the intake and subsequent retention of electrolyte-free wa-
ter in response to true hypovolaemia due to gastro-intestinal solute loss or malnutrition; 
decreased effective circulating volume due to heart failure or liver cirrhosis; or non-osmotic 
vasopressin activity due to malignancies, infections, medications, pain or stress [2]. When 
defined as a serum sodium concentration below 135 mmol/L, hyponatraemia occurs in up 
to 8% of the general population and in up to 60% of hospitalised patients [2, 3].  Acute 
profound hyponatraemia can cause brain oedema, but also chronic mild hyponatraemia 
is associated with poor health outcomes. Even when comorbid conditions are taken into 
account, people with a mildly decreased serum sodium concentration have a 30% higher 
risk of death and are hospitalised 14% longer relative to those without hyponatraemia [2, 4]. 
Despite the frequency and severity of some of the associated complications, research 
suggests hyponatraemia is often neglected by clinicians [5]. If acquired in hospital, it may 
take days before the electrolyte disorder is investigated, potentially allowing a further de-
crease in serum sodium concentration and exposing patients to the dangers of profound 
hyponatraemia. When efforts are made to explore the underlying cause, clinicians use wide-
ly different strategies for differential diagnosis, testing is often inadequate and misclassifica-
tion of the hyponatraemia frequently occurs [6, 7]. 
Hyponatraemia may be managed clinically by different specialists, such as endocrinolo-
gists, nephrologists, geriatricians or intensivists, and accordingly, management strategies 
often vary [5]. Although probably related to variation in awareness, differences in expert 
opinion on whom and how to treat only add to the confusion over optimal management. 
For instance, although experts agree that acute symptomatic hyponatraemia should be 
treated with hypertonic saline, optimal concentrations and methods for determining initial 
infusion speeds are debated [1]. In addition, the risk of osmotic demyelination syndrome 
after rapid correction of hyponatraemia has fuelled intense debate among experts on 
whether complications of untreated hyponatraemia or complications of treatment pose the 
greatest risk [8]. As different specialist physicians deal with hyponatraemia, consultation of 
different information and guidance sources may add to the variability in treatment, seen in 
clinical practice today.
Clinical practice guidelines and consensus statements provide recommendations to 
help evidence based practice, by suggesting the most appropriate diagnostic tests and 
the most appropriate treatments. Over the years, multiple organisations have developed 
recommendations to assist clinicians in the management of hyponatraemia. To be reliable, 
these recommendations must be based on a systematic review of the evidence, and have 
a transparent and multidisciplinary development process [9]. Inconsistencies between rec-
ommendations may arise from failing to meet development standards and can only add 
to unwarranted variability in management. In this study, we aimed to explore the scope, 
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content and consistency of the existing guidance documents on the diagnosis and man-
agement of hyponatraemia in adults and children. 
Methods
Criteria for selection of studies
We included evidence-based clinical practice guidelines and consensus statements on 
the diagnosis and treatment of hyponatraemia. We defined clinical practice guidelines as 
statements that included recommendations intended to optimize patient care informed by 
a systematic review of evidence and an assessment of the benefits and harms of alternative 
care options [9].  We defined consensus statements as documents containing clinically rel-
evant suggestions or recommendations based on the collective opinion of an expert panel 
[9].  We included all publications independent of language. We excluded guidelines related 
to the prevention of hyponatraemia. We excluded guidelines relevant to conditions associ-
ated with hyponatraemia if they were not specifically designed to address hyponatraemia. 
Hence, we excluded guidelines targeting treatment of heart failure, cirrhosis and cancer un-
less they were developed with a focus on hyponatraemia as a complication. Finally, we also 
excluded draft unpublished guidelines, conference or discussion papers, personal opinions 
and obsolete guidelines replaced by updated recommendations from the same organisa-
tion. 
Search methods for guidelines and consensus statements
We searched MEDLINE (1946 to September Week 1, 2014) and EMBASE (1980 to Sep-
tember 2014), combining vocabulary terms and text words for hyponatraemia with terms 
related to clinical practice guidelines and consensus statements. We also searched guide-
line databases and websites of organisations, as well as of selected professional specialist 
societies in Nephrology, Endocrinology and Intensive Care Medicine. A list of the databases 
and websites along with the full search strategies are outlined in Supplement 1. EN and JV 
independently screened the titles and abstracts and discarded those that did not meet the 
inclusion criteria. Full texts for potentially relevant guidelines or consensus statements were 
retrieved and examined for eligibility. Both the initial screening and subsequent full-paper 
assessment stage were completed using Early Review Organizing Software (EROS) [10].
Data collection process and data items
We developed a draft data extraction form, which was piloted, and modified as neces-
sary. The extracted data included document characteristics (e.g. year of publication, coun-
try/region, development team, funding organisation), recommendations related to the di-
agnosis and assessment of hyponatraemia, and recommendations related to the treatment 
of hyponatraemia. EN and JV extracted all data using the standardised data extraction form 
(Supplement 2) and resolved discrepancies by consensus.
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Appraisal of guidelines and consensus statements
Four reviewers independently assessed methodological quality using the Appraisal of 
Guidelines for Research and Evaluation (AGREE II) instrument [11]. AGREE II is an internation-
ally validated, rigorously developed 23-item tool used to evaluate six domains of guideline 
development: scope and purpose, stakeholder involvement, rigour of development, clarity 
of presentation, applicability, and editorial independence [12] (Supplement 3). The AGREE 
tool has also been used to assess consensus statements [13, 14]. The reviewers rated each 
item on a Likert scale from 1 (‘Strongly Disagree’) to 7 (‘Strongly Agree’).  We calculated a 
total score for each domain by summing up all the scores of the individual items in a domain 
for each reviewer and then standardizing this total as a percentage of the maximum pos-
sible score for that domain, calculated as follows [12]: 
Obtained score – Minimum possible score 
*100%
Maximum possible score – Minimum possible score
The minimum possible score for each domain equalled the number of questions multi-
plied by the number of reviewers, multiplied by 1 (strongly disagree). The maximum score 
for a domain equalled the number of questions multiplied by the number of reviewers, mul-
tiplied by 7 (strongly agree). To ensure standardisation of each reviewer’s approach, all com-
pleted the online training tutorial (http://www.agreetrust.org/) before starting the project.
In a consensus meeting among the reviewers, we discussed every item for which scores 
differed by more than one point (e.g. 1 versus 3) on the original seven-point scale. Reviewers 
in turn explained the rationale for their score and had the opportunity to revise their score 
when they considered this appropriate. We audiotaped the consensus meeting to reliably 
record the underlying reasons for changing scores. 
Synthesis of guideline recommendations
We conducted a textual descriptive synthesis to analyse the scope, content and consist-
ency of the included recommendations. EN inductively coded the text manually to identify 
domains covered by the guidelines. These were cross-tabulated with the guidelines and rec-
ommendations were inserted into the corresponding cell. For each domain, we compared 
guideline recommendations to identify similarities and discrepancies.  Consistent with the 
scope of this review, we only tabulated the information on diagnosis and treatment of hy-
ponatraemia. 
Results
Search results
We identified 1402 citations, of which we excluded 1367 after screening titles and ab-
stracts, because they did not meet our eligibility criteria (Figure 5.1). We assessed the full 
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text of the remaining 39 citations and excluded 29 because they were not related to the 
diagnosis or treatment of hyponatraemia, were not clinical practice guidelines or consensus 
statements or were guidelines replaced by an updated version (Supplement 4). Ultimately, 
we included five clinical practice guidelines [15-19] and five consensus statements [20-24]. 
Six of these documents were retrieved through searching the medical databases [17-19, 
22-24], the other four through the search of guideline databases and professional society 
websites [15, 16, 20, 21].  
Table 5.1 shows the general characteristics of the included clinical practice guidelines 
and consensus statements. Eight national or regional organisations from the Netherlands 
[15], United Kingdom [16], Northern Ireland [21], Spain [22, 24], United States [17, 18] and 
Australia [20] and two international groups [19, 23] published these guidance documents 
between 2004 and 2014. One document specifically covered children [20], the others pri-
marily targeted adults.  Six groups reported undertaking a systematic review and appraisal 
of the evidence [15-19, 23]. Only three were explicit about the level of evidence that un-
derpinned their recommendations [15, 17, 19], and only two graded the strength of the 
guidance recommendations themselves [17, 19].  Five guidance documents covered hy-
ponatraemia broadly; one specifically covered it in the setting of primary care, one in liver 
cirrhosis, one in neurosurgery and one in exercise-associated hyponatraemia. Three includ-
Figure 5.1. Flow diagram of the identification process for clinical practice guidelines and con-
sensus statements on hyponatraemia.
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ed treatment only [22-24], the seven others covered diagnosis as well [15-21]. Two groups 
reported funding by a governmental institution [15, 21], one by the professional societies 
they represented [19]; the others did not report their funding sources [16-18, 20, 22-24]. 
Appraisal of guidelines and consensus statements
Figure 5.2 shows the standardised domain scores for each guideline for each of the 
six quality domains assessed with the Appraisal of Guidelines for Research and Education 
(AGREE II) tool (See Supplement 5 for mean individual scores per item across reviewers). The 
overall quality of reporting of the guideline development process as assessed by AGREE 
varied widely both between guidance documents across domains and within guidance 
documents between domains. Overall, guideline developers reported the details of the 
guideline development process only to a limited extent. Most had average scores below 
50% in four to six of the six AGREE II domains [16, 18, 20-24], only two received an average 
>50% on all six [15, 19]. 
Guidelines received the highest scores for scope and purpose (median 62%; range 28% 
to 92%) and clarity of presentation (median 47%; range 27% to 75%) and lowest scores for 
applicability (median 19%; range 10% to 68%) and editorial independence (median 19%; 
range 2% to 79%). 
Initial appraisal results differed more than one point on the Likert scale between two or 
more reviewers for 143/230 items (62%). The majority of discrepancies were found in the 
domain ‘Clarity of Presentation’, with 90% of items differing more than one point. Group 
discussion resulted in 287/920 (31%) of individual entries being changed. Finally, no scores 
differed more than two points and for 82% of items, scores were the same or within one 
point of each other. Major reasons for changing an entry were a change of own opinion 
after clarification of the opinion of other reviewers during the group discussion (180/920 
entries; 20% entries); aiming for consistency between entries given same available data 
(39/920; 4%); re-evaluation of the score in light of a noted comment during the appraisal 
process (30/920; 3%); correction for available data that were overlooked during the initial 
appraisal (22/920; 2%); misinterpretation of the question during the initial appraisal (6/920; 
0.7%); adjusting for arbitrary scoring of items that were felt to be inapplicable for some 
reason (3/920; 0.3%); adjusting for inconsistent approach to deal with the assumption that 
a criterion was fulfilled even if this was not clearly mentioned (4/920; 0.4%); data entry er-
ror (3/920, 0.3%). Overall this resulted in 29/60 (48%) of standardised domain scores being 
downgraded by a maximum of 10% and 10/60 (17%) of standardised domain scores being 
upgraded with a maximum of 10%; the remaining 35% remained unchanged.  
Synthesis of recommendations
The included guidance documents addressed three major themes: diagnosis, treatment 
and speed of correction.
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
Figure 5.2. Guideline assessment according to the appraisal of guideline for research and evaluation (AGREE 
II) instrument.
NIV – Nederlandse Internisten Vereniging[15]; NHS – National Health Service[16]; GAIN -  Guidelines and Audit Implementation 
Network[21]; AEEH – La Asociación Española para el Estudio del Hígado[22]; EHN - European Hyponatraemia Network[25]; ERBP – 
European Renal Best Practice, ESE – European Society of Endocrinology, ESICM – European Society of Intensive Care Medicine [REF]; UF 
– University of Florida[17]; HEP – Hyponatremia Expert Panel[18]; RCH Melbourne – the Royal Children’s Hospital Melbourne[20]; EAH-ICD – 
International Exercise-Associated Hyponatremia Consensus Development Conference[29]; *Classified as consensus statement.
Note: items were originally scored on a Likert scale of 1 [Strongly Disagree] to 7 [Strongly Agree]. The numerical scores presented for each 
domain are a summary of individual item scores by each reviewer.
Approaches to diagnostic strategies for hyponatraemia
Seven guidance documents covered diagnosis and differential diagnosis of hyponatrae-
mia [15-21]. 
Table 5.2 shows the key recommendations. The key areas addressed included the 
threshold for initiating diagnostic workup, confirmation and classification of hypotonic hy-
ponatraemia, and identification of the underlying disorder.
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Table 5.2. Summary of recommendations for approaches to diagnosis of hyponatraemia by included gui-
dance documents.
Criteria/Categories Guideline Organisation/Society
NIV[15] NHS[16] GAIN[21] AEEH[22] EHN [24]
Threshold workup [Na] < 135 mmol/L <135 mmol/L <135 mmol/L <130 mmol/L <135 mmol/L
Confirming hypotonic hyponatrae-
mia
Serum osmolality 
<275 mOsm/kg
Plasma osmolality 
< 280 mOsm/kg
Serum osmolality 
<275 mOsm/kg
 Plasma osmolality 
<275 mOsm/kg
How to classify hypotonic hyponatraemia to aid identification of underlying cause
Volume status/hydration state/
Extracellular fluid status
Clinical evalu-
ation
Physical examina-
tion/Clinical signs 
of dehydration or 
oedema
Physical examina-
tion/Clinical signs 
of dehydration or 
oedema
 Physical examina-
tion/Clinical signs 
of low circulating 
volume
Urinary [Na] /Threshold 30 mmol/L Spot urine: 20-30 
mmol/L
15 mmol/L  40 mmol/L
Urinary osmolality/ Threshold 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg  100 mOsm/kg
How to identify the underlying disorder
History  Medications Medications  
  Fluid intake Recently pre-
scribed  intrave-
nous fluids
 
  Nocturnal 
polyuria
Vomiting /Diar-
rhoea
 
Lab tests
 Serum potassium concentration + +   
 Serum chloride concentration  +   
 Serum urea concentration +/- +   
 Serum creatinine concentration + +   
 Serum glucose concentration + + +/-  
 Urinary potassium concentration +    
 Renal tests   +  
 Liver tests   +  
 Urinary protein  +/-   
 Thyroid function tests +/- +/- +/-  
 Adrenal function tests +/- +/- +/-  
 Serum protein electrophoresis  +/-   
 Urine protein electrophoresis  +/-   
 Fractional sodium excretion +/-    
 Serum uric acid concentration +/- +/-   
 Fractional uric acid concentration +/-    
 Fractional excretion urea +/-    
 Urinary chloride concentration +/-    
 Molar weight urine +/-    
 Serum bicarbonate concentration     
 Haematocrit     
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Table 5.2. (continued).
Criteria/Categories Guideline Organisation/Society
ERBP/ESE/ 
ESICM[19]
  UF[17]   HEP[18]   RCHM[20] EAH-
ICD[23] 
Threshold workup [Na] <135 mmol/L <131 mmol/L <135 mmol/L <135 mmol/L  
Confirming hypotonic hyponatrae-
mia
Serum osmolality 
<275 mOsm/kg
Serum osmolality 
<285 mOsm/kg
Plasma osmolality 
<280 mOsm/kg
Serum osmolal-
ity threshold not 
stated
 
How to classify hypotonic hyponatraemia to aid identification of underlying cause
Volume status/hydration state/
Extracellular fluid status
Physical examina-
tion/Clinical signs 
of dehydration or 
oedema
Physical examina-
tion/Laboratory 
measurements
Physical examina-
tion/Laboratory 
measurements
To assess but 
method not 
stated
 
Urinary [Na] /Threshold 30 mmol/L 25 mmol/L Spot urine: 20-30 
mmol/L
No threshold 
stated
 
Urinary osmolality/ Threshold 100 mOsm/kg 100 mOsm/kg 100 mOsm/kg No threshold 
stated
 
How to identify the underlying disorder
History Diuretic use     
     
     
Lab tests
 Serum potassium concentration   +  
 Serum chloride concentration   +  
 Serum urea concentration +/- +/- +  
 Serum creatinine concentration +/- +/- +  
 Serum glucose concentration +   +  
 Urinary potassium concentration +    
 Renal tests     
 Liver tests +/-    
 Urinary protein     
 Thyroid function tests +/-    
 Adrenal function tests +/-    
 Serum protein electrophoresis     
 Urine protein electrophoresis     
 Fractional sodium excretion     
 Serum uric acid concentration + +/-   
 Fractional uric acid concentration     
 Fractional excretion urea     
 Urinary chloride concentration + +/-   
 Molar weight urine     
 Serum bicarbonate concentration +/-    
 Haematocrit +/-    
[Na]: Serum sodium concentration; + : always; +/- : If clinically indicated/sometimes useful
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Guidance documents differed somewhat in their recommended threshold for starting 
diagnostic assessment. Six recommended starting diagnostic assessment when the serum 
sodium concentration dropped below 135 mmol/L [16, 18-22] and to confirm hypotonic-
ity through a measured serum or plasma osmolality <275-285 mOsm/kg [15-19, 21].  Two 
others set lower thresholds of serum sodium concentration <131 mmol/L [17] and <130 
mmol/L [22]. Six guidance documents advised classifying hypotonic hyponatraemia into 
categories of hypovolaemia, euvolaemia and hypervolaemia to aid differential diagnosis 
and guide treatment [15-21]. Most guidance documents recommended a clinical assess-
ment of hydration status and a urinary sodium concentration as well as a urinary osmolality 
measurement, although specific criteria, thresholds and algorithms differed. 
Most guidance documents proposed additional laboratory tests that could be of value 
to identify the underlying disorder, but they varied substantially in which tests to use in 
what situation and which reference values to use. Only two explicitly recommended taking 
a history of drug intake and symptoms as part of the assessment [16, 21].  Four presented 
an algorithm to guide differential diagnosis [15, 17, 19, 21].
Approaches to treatment for hyponatraemia
Table 5.3 shows the recommendations for the medical management of hyponatraemia. 
Guidance documents distinguished treatment scenarios based on whether patients had 
severe symptoms [16-21, 23, 24] or whether the hyponatraemia was acute (48h) or chronic 
[15]. All but one discussed treatment in the setting of severe symptoms and recommended 
infusion of hypertonic saline, usually specified as having a concentration of 3% [16, 18-20, 
23, 24]. One suggested using a formula to guide the infusion speed of a continuous infusion 
[15],  five others recommended giving a fixed dose [18, 19, 21, 23, 24] or a dose adjusted to 
body weight [20, 24] with repeated serum sodium concentration measurements to check 
progression [15, 19-21, 24]. 
Patients without symptoms of hyponatraemia were assumed to have chronic onset 
hyponatraemia, and treatment suggestions were mostly dependent on the classification 
hypovolaemic, euvolaemic, hypervolaemic. Only three guidance documents specifically ad-
vised treating the underlying condition [18, 19, 21]. Seven suggested 0.9% saline in hypo-
volaemia [15-21], with infusion speeds calculated with Adrogué-Madias [21], until restora-
tion of blood pressure [16, 18] or until nasogastric rehydration could start [20]. 
For euvolaemic asymptomatic hyponatraemia, the majority recommended fluid restric-
tion as the first-line treatment [15-24]. Five guidance documents proposed a number of 
other interventions as second-line treatments including loop diuretics [15, 17, 19, 24], de-
meclocycline [15-18], urea [15, 18, 19, 24], vasopressin-receptor antagonists [15, 16, 24] or 
lithium [17]. One guideline specifically recommended against vasopressin receptor antago-
nists in case of a serum sodium concentration <125 mmol/L [19].
For hypervolaemic asymptomatic hyponatraemia, seven guidance documents recom-
mended fluid restriction as the first-line treatment [15, 16, 18-22] (Table 5.3). Three guidance 
documents advocated concomitant salt restriction, without clear dose recommendations 
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[16, 18, 21], and one to avoid hypotonic infusion solution [20]. Three additionally proposed 
loop diuretics [15, 16, 18], three others generally stated to treat the underlying disease [16, 
19, 21], whereas one advised to consider stopping diuretics [22]. One guideline additionally 
proposed demeclocycline and two proposed vasopressin receptor antagonists as a second-
line treatment for refractory hyponatraemia [16, 18], whereas one guideline specifically rec-
ommended against both demeclocycline and vasopressin receptor antagonists [19].
Targets and limits of speed of correction
Table 5.4 shows the key recommendations. The key areas include targets and limits for 
increase in serum sodium concentration. 
Seven guidance documents provided targets or aims for the increase in serum sodium 
concentration in case of symptomatic and/or acute hyponatraemia [15, 16, 18-21, 24]. Sev-
en guidance documents provided limits for the increase in serum sodium concentration 
that should not be surpassed [15-21, 24].  Five did so independent of symptoms [15, 17, 
19, 21, 24]. Limits usually varied between 8 to 12 mmol/L during the first 24 hours [15-21, 
24] and 18 mmol/L during the first 48 hours [15, 16, 18, 19, 24], irrespective of whether hy-
ponatraemia was acute or chronic [15, 16, 19, 24]. Three guidance documents set a stricter 
limit of <8 mmol/L during the first 24 hours in case the patient was felt to be high risk for 
developing osmotic demyelination syndrome [15, 18, 24]. Four discussed what to do in case 
of overcorrection, i.e. to stop current treatment, and to consider re-lowering serum sodium 
concentration by starting hypotonic infusion and administering 1-4 μg desmopressin every 
six to eight hours [15, 18, 19, 24]. 
Discussion
We found five clinical practice guidelines and five consensus statements covering the 
diagnostic approach to and treatment of hyponatraemia. Although most used serum os-
molality, volume status, urinary sodium and urinary osmolality to guide differential diag-
nosis, they differed in classification thresholds, what additional tests to consider and when 
to initiate diagnostic work-up. Most advocated hypertonic NaCl in severely symptomatic, 
acute onset hyponatraemia and NaCl 0.9%, fluid restriction and cause-specific therapy for 
hypovolaemic, euvolaemic and hypervolaemic hyponatraemia respectively. However, they 
somewhat differed in the limits for speed of increase in serum sodium concentration and 
which specific medications to use. The reasons for offering different recommendations are 
undoubtedly multifactorial. They may in part be explained by the fact that recommenda-
tions were issued by organisations differing in context and scope. It is also very likely that 
some variability in guidance arose through limitations in the evidence available for guide-
line developers to base their recommendations on [8]. In the most recent guideline on diag-
nosis and treatment of hyponatraemia 98% of the graded recommendations were based on 
very low and low level of evidence, while none were based on a high level of evidence. The 
lack of high quality evidence may have increased the part opinion had to play in framing the 
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recommendations. In addition, the evidence that was available may have been interpreted 
differently dependent on the importance for decision making given to certain outcomes 
(e.g. serum sodium concentration). Finally, differences in personal experience due to dif-
fering availability of medications may partly explain possible differences in perception of 
uncertainties around drug safety. 
However, it is also possible that discrepancies between guidance documents may in part 
be explained by differences in underlying methods of development. Quality, as assessed 
by AGREE II was suboptimal at best, with only two documents obtaining a score > 50% for 
each of the six quality domains [15, 19]. The findings suggest that several aspects related to 
methodological rigour of development, stakeholder involvement, applicability and editori-
al independence could be improved, possibly improving consistency in provided guidance. 
This is in line with the findings of a recent overview of 42 appraisal studies including a total 
of 626 clinical practice guidelines across several clinical disciplines [25].
For guidelines to be trustworthy, they must be 1) founded on high quality systematic 
reviews, 2) include the relevant stakeholders and 3) be applicable in clinical practice [9]. 
Only half of the guidance groups stated they had conducted a systematic review of the 
evidence. Save one, the reviews would not have met the Institute of Medicine’s criteria for 
reporting high-quality systematic reviews [19, 26],  because key methods for finding and as-
sessing individual studies as well as synthesizing the body of evidence were not described. 
Conducting high-quality systematic reviews requires specific methodological expertise and 
support which may not be available to most groups [26].  One solution might be to harmo-
nise effort across organisations, thus focussing resources, allowing higher quality reviews, 
reducing duplication and possibly inconsistency between guidelines. 
Six groups included healthcare professionals from different specialties [15, 17, 19, 21, 23, 
24]. Multidisciplinary contribution serves to broaden the approach to healthcare problems, 
increase the completeness of evidence finding strategies and help to identify hurdles to im-
plementation. When reflecting on approaches to hyponatraemia, bringing together several 
disciplines mirrors the clinical reality of multiple specialty areas dealing with the same prob-
lem but looking at it from a different angle. Only one of the development groups reported 
considering patients’ views and experiences, but even then did so to a limited extent [19]. 
Decisions on clinical care should factor in patient values and preferences. Interventions for 
chronic hyponatraemia, such as fluid restriction, may affect quality of life and patient prefer-
ence should influence the ultimate recommendations. 
Low scores for applicability mostly reflect the absence of describing barriers to guideline 
implementation and failure to provide tools for putting the recommendations into practice. 
In part, guidelines are designed to deal with the challenges of increasing knowledge and 
time-pressure. They are designed to help make decisions at the point of care. However, be-
ing often lengthy publications without layered presentation of information, the majority 
of the guidance documents may not be likely to reach their target audience or stimulate 
implementation. Four guidance documents provided algorithms for diagnosis or treatment 
[15, 17, 19, 24]. Although these are likely to increase the utility of a guideline, it is unclear 
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to what extent they truly improve implementation of the recommendations. How to best 
communicate evidence-based recommendations to the relevant stakeholders is a recent 
but active area of research lead by the DECIDE consortium [27]. With results of their research 
expected, guideline developers will have additional targets for improving the applicability 
in the future.
To our knowledge, this is the first attempt to systematically synthesize and appraise clini-
cal guidelines on the diagnosis and treatment of hyponatraemia. We conducted a compre-
hensive search and searched an additional 337 websites of specialist societies and guide-
line organisations. We used AGREE II, a validated and reliable instrument, and an adequate 
number of reviewers to individually appraise the guidance documents [28]. On top of the 
individual appraisals, we included an attempt to resolve major discrepancies and increase 
consistency by introducing an audiotaped group consensus meeting. During this meeting, 
reviewers could explain and motivate their scores and adapt them if they wanted to. This 
mostly resulted only in modest downgrading of domain scores by 1% to 10%. Most of the 
changes happened because reviewers felt they had scored inconsistently for a same ration-
ale, or because they missed information during the initial appraisal that was in fact available 
in the document. Although the scores did not change substantially, the group felt the dis-
cussion further highlighted the qualitative differences between the guidance documents. 
In addition, even the reviewers with large deviations from the mean in their initial scores felt 
they agreed with the conclusion. It means that final average scores were truly a product of 
consensus rather than a mathematical calculation, as proposed in the original AGREE proto-
col. We believe that a consensus meeting is valuable in any guideline appraisal process, and 
particularly useful if reviewer groups have the intention to select a guideline for local use.
This study has its limitations. We based our assessment on what guideline organisations 
actually reported. Reporting by guideline developers may not wholly reflect what occurred 
in practice with respect to the AGREE criteria, and we did not seek additional clarification. 
However, contacting guideline developers is not standard practice when using AGREE as 
the instrument specifically aims to provide a framework for assessing the quality of report-
ing of recommendations. We aimed to summarize the existing recommendations on di-
agnosis and treatment of hyponatraemia as formulated by other guideline development 
groups and to evaluate the quality of the guideline development process. We did not aim 
to summarize or critically appraise the evidence base itself.  Consequently, it is difficult to 
assess to what extent differences between guidance documents stem from differences in 
development procedures rather than important limitations in the evidence base that un-
derpin individual recommendations. Secondly, the purpose of using the AGREE instrument 
was not to accuse guideline development groups of being biased, but rather to highlight 
both strengths and weaknesses of existing guidance to suggest on how we could make 
improvements in the future. 
Calculation of summary scores for each domain across reviewers required summing up 
all the scores of the individual items in a domain for each reviewer and then standardizing 
this total as a percentage of the maximum possible score for that domain. In doing so, the 
Nagler.indb   119 15/09/2015   16:14:41
Chapter 5
120
originally semi-qualitative Likert scale was converted to a quantitative score. This may have 
introduced numeric differences between the guidance documents that were beyond the 
discriminatory ability of the tool and possibly negligible in practice. Finally, we acknowl-
edge that four of the authors of this paper also authored one of the guidelines included in 
this review. Although we aimed to judge all guidance documents fairly against the criteria 
outlined by the AGREE instrument, we cannot rule out that a subconscious intellectual com-
peting interest unduly influenced the scoring. 
Conclusions
Current guidelines on the assessment and treatment of hyponatraemia often fail to meet 
methodological criteria for development and reporting as described by AGREE II. Despite 
many similarities, recommendations are sometimes inconsistent, but to what extent this is 
attributable to the underlying development process remains unclear. 
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Abstract  
Background. Chronic (present >48 hours) non-hypovolaemic hypotonic hyponatraemia oc-
curs frequently and is associated with increased mortality. Whether correction of the hy-
ponatraemia by itself can improve outcomes is less certain.
Objectives. We aimed to evaluate the benefits (reductions in all-cause mortality, health-related 
quality of life and specifically symptoms attributed to hyponatraemia) and harms (osmotic 
demyelination syndrome, rapid increase in serum sodium concentration, treatment-specific 
side-effects) of any intervention versus placebo, no treatment, standard care, or another 
active intervention in children and adults with chronic non-hypovolaemic hypotonic hy-
ponatraemia.
Search methods. We searched the Cochrane Renal Group’s Specialised Register to 22 April 
2015 through contact with the Trials Search Co-ordinator using search terms relevant to 
this review.
Selection criteria. We included randomised controlled trials (RCTs) and quasi-RCTs that com-
pared the effects of any intervention with placebo, no treatment, standard care, or any other 
intervention in patients with chronic non-hypovolaemic hypotonic hyponatraemia. We also 
included subgroups with hyponatraemia from studies with broader inclusion criteria (e.g. 
people with chronic heart failure or people with cirrhosis with or without hyponatraemia), 
provided we could obtain outcomes for participants with hyponatraemia from the report 
or the study authors.
Data collection and analysis. Two authors independently extracted data and assessed risk 
of bias. We expressed treatment effects as mean difference (MD) for continuous outcomes 
(health-related quality of life, length of hospital stay, change from baseline in serum sodium 
concentration, cognitive function), and relative risk (RR) for dichotomous outcomes (death, 
response and rapid increase in serum sodium concentration, hypernatraemia, polyuria, hy-
potension, acute kidney injury, liver function abnormalities) together with 95% confidence 
intervals (CI).
Main results. 28 studies (3189 participants) compared a vasopressin receptor antagonist ver-
sus placebo, usual care, no treatment or fluid restriction. In adults with chronic, non-hypo-
volaemic hypotonic hyponatraemia, vasopressin receptor antagonists modestly increased 
the serum sodium concentration (MD 4.17, 95% CI 3.18 to 5.16) and slightly reduces hospital 
stay (MD -1.63 days, 95% CI -2.96 to -0.30), but had unclear effects on all-cause mortality (RR 
1.11, 95% CI 0.92 to 1.33), was associated with an increased risk of rapid serum sodium cor-
rection (RR 1.67, 95% CI 1.16 to 2.40) and commonly caused side-effects such as thirst (OR 
OR 2.77, 95% CI 1.80 to 4.27) and polyuria (RR 4.69, 95% CI 1.59 to 13.85). Effects were gener-
ally consistent across the different agents, suggesting class effect.The evidence on patient-
important outcomes such as health-related quality of life, cognitive and general functional 
Nagler.indb   125 15/09/2015   16:14:41
Chapter 6
126
status was limited and generally showed no important beneficial treatment effect. Overall, 
based on GRADE criteria, evidence for vasopressin receptor antagonists in people with hy-
ponatraemia (mortality, change and rapid increase in serum sodium concentration) was of 
low quality and suggested that additional studies may change our confidence in the esti-
mates of effect or our confidence in these results.
 Data for other interventions such as fluid restriction, urea, mannitol, loop diuretics, corticos-
teroids, demeclocycline, lithium and phenytoin were largely absent.
Authors’ conclusions. In people with chronic hyponatraemia, vasopressin receptor antago-
nists modestly raise serum sodium concentration at the cost of a 3% increased risk of it 
being rapid, and a subsequent small but unknown increased risk of osmotic demyelination 
syndrome. To date there is little evidence from RCTs for a beneficial effect on mortality, qual-
ity of life or any other truly important health outcome of these agents or in fact any other 
treatment for chronic hyponatraemia. It makes any recommendation problematic.
 Further studies assessing standard treatments such as fluid restriction or urea against pla-
cebo and one-another would inform practice and are warranted given limited evidence 
that in chronic hyponatraemia aside from affecting the surrogate (increase in serum sodium 
concentration) any treatment results in improved patient-centred outcomes.
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Background  
Description of the condition  
Hypotonic hyponatraemia is a common condition, occurring in up to 60% of peo-ple admitted to hospitals, depending on the definition of hyponatraemia, the types of patients who are studied and the healthcare facility to which these pa-
tients are admitted (Upadhyay 2009). Hypotonic hyponatraemia is usually defined as a se-
rum sodium concentration < 135 mmol/L with an osmolality < 285 mOsm/kg (Reynolds 
2006). It develops when the body retains an excess of water relative to the amount of so-
dium. It can be caused by intrinsic kidney disease but usually results from incomplete sup-
pression of vasopressin activity despite decreased tonicity of the plasma. In situations of de-
creased circulating blood volume, vasopressin release is increased in a physiologic response 
to maintain haemodynamic homeostasis. This occurs either with true volume depletion or 
with reduced effective arterial circulating volume, as seen in heart failure, liver cirrhosis or 
nephrotic syndrome. In the syndrome of inappropriate antidiuretic hormone secretion, the 
increased release of vasopressin is non-haemodynamic and can have multiple causes in-
cluding ectopic production of vasopressin by a variety of tumours (Verbalis 2013).
When plasma tonicity is low, water tends to enter the cells and causes them to swell. If 
blood sodium concentrations drop rapidly (within a 48 hour period), the swelling of brain 
cells may lead to brain oedema, brain stem herniation and eventually even death. Fortu-
nately, when blood sodium concentrations drop more gradually, brain cells adapt to their 
hypo-osmolar surroundings and prevent swelling by the transport of solutes from the in-
tracellular to the extracellular compartments. As a consequence, immediate symptoms at-
tributable to chronic hyponatraemia are usually less severe than for acute hyponatraemia 
(Reynolds 2006). Nevertheless, people with chronic hyponatraemia have reduced attention 
and less stable gait than those without hyponatraemia (Renneboog 2006). They fall more 
often and have increased risk of osteoporosis and bone fractures (Arampatzis 2013; Hoorn 
2011; Kinsella 2010; Renneboog 2006; Verbalis 2010). Finally, they stay in hospital longer 
and have an increased risk of death, even when sodium concentrations are only mildly de-
creased and underlying or comorbid conditions are adjusted for (Wald 2010).
Description of the intervention  
It is accepted that acute hypotonic hyponatraemia requires an immediate increase in 
serum sodium concentration to prevent severe neurologic complications (Ellison 2007). 
What to do with chronic hypotonic hyponatraemia is less clear. Firstly, chronic non-hypo-
volaemic hypotonic hyponatraemia has been treated under the assumption that increasing 
the sodium concentration improves important health outcomes; that patients live longer, 
feel better and are hospitalised less frequently. Although several observational studies have 
indicated an association between hyponatraemia and undesirable outcomes, it is still un-
clear whether correcting the hyponatraemia improves them (Upadhyay 2009; Wald 2010). 
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Secondly, once brain cells have adapted to their hypo-osmolar environment, they become 
vulnerable to osmotic demyelination in case the environment is restored. Although rare, os-
motic demyelination is a devastating neurologic complication that may occur when the my-
elin sheath around pontine and extrapontine neurons breaks down after rapid rises in se-
rum sodium concentration. It very rarely does if the increases stay below 8 to 12 mmol/L/24 
h and 18 mmol/L/48 h (Adrogue 2012; Ellison 2007; Reynolds 2006). Treatment for chronic 
hypotonic hyponatraemia must balance the uncertain benefit of increasing the sodium 
concentration against the risk of complications due to overly rapid correction.
How the intervention might work  
Whatever the underlying cause, chronic non-hypovolaemic hypotonic hyponatraemia 
usually results from urine being insufficiently dilute to maintain serum osmolality within the 
normal range (Adrogue 2000). Several treatment strategies can be used to try overcoming 
this (Adrogue 2012; Ellison 2007; Verbalis 2013).
Restriction of fluid intake aims to decrease the amount of free water needing excretion.
Urea and mannitol improve electrolyte-free water clearance by increasing urine osmolal-
ity and creating osmotic diuresis (Lindner 2012). Loop diuretics, such as furosemide, bu-
metanide and ethacrynic acid, impair free-water absorption in the collecting duct by reduc-
ing the hypertonicity of the renal medulla. Corticosteroids with a mineralocorticoid effect 
increase renal sodium retention by active reabsorption of sodium in the principal cells of 
the cortical collecting tubule. Demeclocycline, lithium, phenytoin and vasopressin recep-
tor antagonists act by pharmacologically inhibiting the effect of antidiuretic hormone on 
the principal cells of the collecting duct, thereby limiting insertion of water channels in the 
luminal membrane and thus preventing free water reabsorption. 
As hyponatraemia with true volume depletion (chronic hypovolaemic hypotonic hy-
ponatraemia) is treated by restoring volume with water and salt, we do not cover it in this 
review.
Why it is important to do this review  
The benefits and harms of treatments for chronic non-hypovolaemic hypotonic hy-
ponatraemia have not been formally evaluated in a systematic review. Two systematic 
reviews have explored the efficacy and safety of vasopressin receptor antagonists (e.g. 
conivaptan, lixivaptan, satavaptan, tolvaptan) versus placebo, no treatment or fluid restric-
tion (Jaber 2011; Rozen-Zvi 2010), but to our knowledge there has been no attempt to com-
pare them with any other intervention or to compare any of the other interventions versus 
placebo or against one another.
Both systematic reviews have found an early increase in serum sodium concentration, 
but no improvement in outcomes important to patients. Indeed, most randomised con-
trolled trials (RCTs) have evaluated short-term and surrogate outcomes only, making it 
difficult to adequately asses any expected benefit in the long-term. Since the most recent 
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systematic review was published, 12 additional RCTs comparing vasopressin receptor an-
tagonists versus control have been completed, increasing the total sample size by at least 
50%. Although outcomes are still mostly surrogate and short-term, the largest study was 
terminated early due to a numeric imbalance in the number of early deaths in the experi-
mental group (FDA 2012). We believe it justifies reanalysis including in-depth investigation 
of possible heterogeneity at this point.
Objectives 
This review aimed to look at the benefits and harms of interventions for chronic non-
hypovolaemic hypotonic hyponatraemia when compared with placebo, no treatment or 
head-to-head.
The review aimed to determine if benefits and harms vary in absolute or relative terms 
dependent on the specific compound within a drug class, on the dosage used, or the under-
lying disorder causing the hyponatraemia.
Methods 
Criteria for considering studies for this review  
Types of studies  
All RCTs and quasi-RCTs (RCTs in which allocation to treatment was obtained by alterna-
tion, use of alternate medical records, date of birth or other predictable methods) looking at 
interventions for chronic, non-hypovolaemic hypotonic hyponatraemia.
We also included data for hyponatraemia subgroups within studies with broader inclu-
sion criteria (e.g. people with chronic heart failure or people with cirrhosis with or without 
hyponatraemia) which report outcomes for participants with hyponatraemia, or where we 
could obtain these subgroup data from the study authors.
Types of participants  
Inclusion criteria
• Adults and children beyond the neonatal period (the interval from birth to 28 days of age
• Chronic, hypotonic hyponatraemia: presence of hyponatraemia > 48 hours, serum osmo-
lality < 285 mOsm/kg and serum sodium concentration < 135 mmol/L, or as defined by 
authors); not requiring immediate treatment and due to:
• decreased effective circulating volume in the setting of heart failure, liver cirrhosis or 
nephrotic syndrome
• inappropriate antidiuresis, associated with any underlying condition (includes syn-
drome of inappropriate antidiuretic hormone secretion and nephrogenic syndrome of 
inappropriate antidiuresis) 
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• impaired renal dilutional capacity due to kidney disease.
Sodium concentrations can be measured in any type of blood sample (e.g. serum, plas-
ma, whole blood, venous, arterial, capillary) using any measurement method (e.g. flame 
emission spectrophotometry, direct or indirect reading potentiometry by an ion-selective 
electrode) in any setting (e.g. central laboratory, local laboratory, point of care device).
Exclusion criteria
• Children in the neonatal period (the interval from birth to 28 days of age)
• Isotonic or hypertonic hyponatraemia (osmolality ≥ 285 mOsm/kg)
• Hyponatraemia due to true (extracellular) volume depletion, such as from third spacing 
(type of fluid leakage into interstitial spaces seen in pancreatitis, bowel obstruction, sep-
sis,.. ), and gastrointestinal, or renal sodium loss
• Hyponatraemia due to secondary adrenal insufficiency or hypothyroidismHyponatrae-
mia due to primary psychogenic polydipsia
• Patients treated with any form of dialysis or extracorporeal ultrafiltration.
Types of interventions  
We included studies of any degree of fluid restriction or any drug treatment that has 
the aim of increasing the sodium concentration. Any dose or route of administration was 
permitted, and interventions could be compared with placebo, no treatment, a different 
dose of the same or different interventions, different administration routes of the same or 
different interventions, or different combinations of interventions.
Treatments included (but were not limited to):
• vasopressin receptor antagonists (conivaptan, mozavaptan, lixivaptan, satavaptan, 
tolvaptan)
• fluid restriction
• urea
• mannitol
• loop diuretics (furosemide, bumetanide, ethacrynic acid)
• corticosteroids (hydrocortisone or equivalent, fludrocortisone)
• demeclocycline
• lithium
• phenytoin.
We excluded studies in which any form of dialysis treatment was given to correct serum 
sodium concentration.
Types of outcome measures  
We assessed outcomes up to one week, up to one, two and six months, and up to one 
and five years.
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Primary outcomes  
• Death (all-cause mortality)
• Health-related quality of life and specifically symptoms attributed to hyponatraemia by 
trialists.
Secondary outcomes  
• Length of hospital stay
• Serum sodium concentration (mmol/L) at end of treatment or change from beginning 
to end of treatment
• Response defined as increase of ≥ 5 mmol/L or normalisation of serum sodium concen-
tration (≥ 135 to 145 mmol/L, or as defined by the authors)
• Outcomes related to over-correction of serum sodium concentration
• Incidence of hypernatraemia (serum sodium concentration > 145 mmol/L, or as de-
fined by the authors)
• Rapid increase in serum sodium concentration (increase in serum sodium concentra-
tion > 8-12 mmol/L in 24 h or > 18 mmol/L in 48h, or as defined by the authors)
• Incidence of osmotic demyelination syndrome, previously known as central pontine 
and extrapontine myelinolysis (diagnosed clinically, by MRI, or post mortem)
• Any treatment-specific side effects as defined by authors
• Acute kidney injury (demeclocycline, mannitol, loop diuretics)
• Chronic kidney disease (lithium)
• Hypotension (mannitol, loop diuretics, vasopressin receptor antagonists)
• Thirst (mannitol, loop diuretics, fluid restriction, vasopressin receptor antagonists)
• Central nervous system symptoms (phenytoin)
• Polyuria (mannitol, loop diuretics, vasopressin receptor antagonists)
• Any other adverse event as reported by trialists
• Treatment discontinuation or switch
Search methods for identification of studies  
Electronic searches  
We searched the Cochrane Renal Group’s Specialised Register to 22 April 2015 through 
contact with the Trials’ Search Co-ordinator using search terms relevant to this review.
The Cochrane Renal Group’s Specialised Register contains studies identified from the fol-
lowing sources:
• Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)
• Weekly searches of MEDLINE OVID SP
• Handsearching of renal-related journals and the proceedings of major renal conferences
• Searching of the current year of EMBASE OVID SP
• Weekly current awareness alerts for selected renal journals
• Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTri-
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als.gov.
Studies in the Specialised Register are identified through search strategies for CENTRAL, 
MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these 
strategies, as well as a list of handsearched journals, conference proceedings and current 
awareness alerts, are available in the specialised register section of information about the 
Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources  
• Reference lists of clinical practice guidelines, review articles and relevant studies.
• Letters seeking information about unpublished or incomplete studies to investigators 
known to be involved in previous studies.
• Point-of-care sources such as Dynamed and UpToDate as well as US Food and Drug Ad-
ministration (FDA) and European Medicines Agency (EMA) applications.
Data collection and analysis  
Selection of studies  
The search strategy described was used to obtain titles and abstracts of studies possi-
bly relevant to the review. The titles and abstracts were screened independently by two 
authors (EVN and MCH), who discarded studies that were not applicable; however studies 
and reviews that possibly included relevant data or information on studies of interest for 
our analysis were retained initially. Two authors independently assessed retrieved abstracts 
and, if necessary the full text, of these studies to determine which studies satisfied the inclu-
sion criteria.
Data extraction and management  
Data extraction was carried out independently by two authors using standard data ex-
traction forms. Studies reported in non-English language journals were translated before 
assessment. Where more than one publication of one study existed, reports were grouped 
together and the publication with the most complete data was used in the analyses. Where 
relevant outcomes were only published in earlier versions these data were used.
Assessment of risk of bias in included studies  
The following items were independently assessed by two authors using the risk of bias 
assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately prevented during the study 
(detection bias)?
• Participants and personnel
• Outcome assessors
• Were incomplete outcome data adequately addressed (attrition bias)?
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• Are reports of the study free of suggestion of selective outcome reporting (reporting 
bias)?
• Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect  
For dichotomous outcomes (e.g. death, number of patients with serum sodium concen-
tration increase of ≥ 5 mmol/L, number of patients that develop hypernatraemia, number 
of patients with rapid increase in serum sodium concentration, number of patients that de-
velop osmotic demyelination syndrome), individual study results were expressed as risk ra-
tios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were 
used to assess the effects of treatment (e.g. length of hospital stay, serum sodium concen-
tration at the end of the study or its change from beginning to the end of treatment), results 
were expressed as the mean difference (MD). For outcomes reported both as dichotomous 
and continuous data (thirst), we presented individual study results as odds ratios (OR), by 
converting standardized mean differences to the natural logarithm of the odds ratios as 
suggested by Chinn (Higgins 2011).
Unit of analysis issues  
If studies had multiple treatment groups, we tried to collapse these into one where ap-
propriate to enable single pair wise comparison (e.g. collapsing three groups of different 
doses of vasopressin receptor antagonists into one group and including them in single pair 
wise comparison versus placebo) (Higgins 2011).
Dealing with missing data  
Any further information required from the original authors was requested by email-
ing the corresponding author. If no response or insufficient information was retrieved, 
we subsequently emailed the sponsor. Any relevant information obtained in this manner 
was included in the review. Evaluation of important numerical data such as screened, ran-
domised patients as well as intention-to-treat, as-treated and per-protocol population was 
performed. Attrition rates, for example drop-outs, losses to follow-up and withdrawals were 
investigated. Issues of missing data and imputation methods (for example, last-observa-
tion-carried-forward) were critically appraised (Higgins 2011).
Assessment of heterogeneity  
Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha 
of 0.05 used for statistical significance and with I² calculated to measure the proportion of 
total variation in the estimates of treatment effect that was due to heterogeneity beyond 
chance (Higgins 2003). I² values of 25%, 50% and 75% correspond to low, medium and high 
levels of heterogeneity.
Assessment of reporting biases  
Funnel plots were used to assess for the potential existence of small study bias. If we 
suspected asymmetry on visual inspection and the analysis included >10 studies, we con-
ducted formal hypothesis testing, using Egger’s test for continuous outcomes and Peter’s 
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regression test for dichotomous outcomes (Higgins 2011).
Data synthesis  
Where feasible and appropriate, data were pooled using the random-effects model. 
Dichotomous outcome results were expressed as risk ratio (RR) and continuous outcome 
results were expressed as mean difference (MD), both with 95% confidence intervals. For 
outcomes reported both as dichotomous and continuous data (thirst), we converted stand-
ardized mean differences to log-transformed odds ratios, combined them using the generic 
inverse-variance method and expressed the overall effect estimate as an odds ratio with its 
95% confidence interval (Higgins 2011). Although the underlying conditions causing hy-
ponatraemia are very different, the mechanism by which hyponatraemia develops is similar 
in that vasopressin activity plays a role in most forms of the disorder. We believe it justified 
pooled analysis across subgroups of participants with different underlying conditions.
We summarised the quality of the evidence together with absolute treatment effects 
based on estimated baseline risks by using the Grading of Recommendations Assessment, 
Development, and Evaluation guidelines (Guyatt 2008). To estimate the absolute number 
of people with hyponatraemia who avoided death or incurred a rapid increase in serum 
sodium concentration with vasopressin receptor antagonists, the risk estimate and 95% CI 
were obtained from the control arm of the corresponding meta-analyses.
Subgroup analysis and investigation of heterogeneity  
We analysed data for death, length of hospital stay, change from baseline and response 
in serum sodium concentration, cognitive function and outcomes related to overcorrec-
tion of serum sodium concentration within subgroups of participants dependent on the 
type of vasopressin receptor antagonist they were treated with. Additional prespecified 
subgroup analyses and univariate random effects meta-regression were conducted to ex-
plore potential sources of heterogeneity in effects of vasopressin receptor antagonists on 
death, change in serum sodium concentration and rapid increase in serum sodium con-
centration. The potential sources of heterogeneity included type of vasopressin receptor 
antagonist under evaluation, the underlying condition causing the hyponatraemia (with 
as non-prespecified categories studies only including participants with inappropriate an-
tidiuresis; studies only including participants with heart failure or liver cirrhosis or studies 
including both), mean baseline serum sodium concentration, treatment duration and risk 
of selection bias. Meta-regression was undertaken on the log RR scale using Comprehensive 
Meta Analysis® software, each study weighting equal to the inverse of the variance of the 
estimate for that study, with between study variance estimated using the method of mo-
ments. Results were expressed as the ratio of the RR within each subgroup for categorical 
explanatory variables and per one unit increase for continuous variables.
Sensitivity analysis  
In addition to estimating treatment effects using random effects models, we also esti-
mated fixed effects models to ensure robustness of the model chosen and susceptibility to 
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outliers. Finally we also assessed whether including the number of deaths during follow-up 
(in contrast to only including those occurring during treatment) affected the estimate of the 
effect of treatment on all-cause mortality.
Results  
Description of studies  
Results of the search  
We identified 1531 citations through electronic searches conducted in April 2015. We 
found 10 additional reports by screening the reference lists, contacting authors and con-
Figure 6.1. Study flow diagram.
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ducting online searches for full reports of included abstracts. We reviewed in detail 112 re-
ports, which led to the inclusion of 78 reports of 33 unique studies including 3389 partici-
pants (Figure 6.1).
Included studies  
Twenty-eight studies (providing data for 3189 participants) compared a vasopressin re-
ceptor antagonist versus placebo, usual care or no treatment (ACTIV in CHF Study 2004; 
Annane 2009; BALANCE Study 2010; Decaux 2006; DILIPO Study 2011; EVEREST Study 2007; 
Ghali 2006; Gheorghiade 2003; Gines 2008; Gross 1999; HARMONY Study 2012; HYPOCAT 
Study 2008; INSIGHT Study 2007; Koren 2011; LIBRA Study 2012; Naidech 2010; Nevens 2009; 
Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c; Salahudeen 2014; SALT-1 
Study 2006; SALT-2 Study 2006; Soupart 2006; Wong 2003; Yang 2013; Zeltser 2007), or ver-
sus fluid restriction (Gheorghiade 2006). Studied vasopressin receptor antagonists included 
conivaptan (Annane 2009; Ghali 2006; Koren 2011; Naidech 2010; Zeltser 2007), lixivaptan 
(BALANCE Study 2010; Gross 1999; HARMONY Study 2012; LIBRA Study 2012; Wong 2003), 
satavaptan (Decaux 2006; DILIPO Study 2011; Gines 2008; HYPOCAT Study 2008; Soupart 
2006), tolvaptan (ACTIV in CHF Study 2004; EVEREST Study 2007; Gheorghiade 2003; Gheo-
rghiade 2006; INSIGHT Study 2007; Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 
2011c; Salahudeen 2014; SALT-1 Study 2006; SALT-2 Study 2006; Yang 2013) and M0002 - 
also termed SPD556 or RWJ 351647 (Nevens 2009). One study assessed different doses of 
conivaptan (Kalra 2011).
One study (50 participants) compared fluid restriction with normal maintenance fluid in 
children with bacterial meningitis and reported data for the subgroup with hyponatraemia 
(26 participants) (Singhi 1995). One study (14 participants) compared captopril + furosem-
ide versus furosemide alone (Dzau 1984) in adults with decompensated heart failure. One 
study (24 participants) compared infusion of human salt poor albumin in combination with 
fluid and sodium restriction versus fluid and sodium restriction alone in patients with liver 
cirrhosis and ascites (Jalan 2007). A final study (19 participants ) compared a change in pre-
scribed medications versus standard care in elderly patients admitted to the internal medi-
cine ward or residents of the nursing home of the same institution (Peyro Saint Paul 2013).
Twenty-seven studies were conducted specifically in participants with hyponatraemia 
(LIBRA Study 2012; HARMONY Study 2012; Salahudeen 2014; Annane 2009; BALANCE Study 
2010; Decaux 2006; Dzau 1984; Ghali 2006; Gheorghiade 2006; HYPOCAT Study 2008; Gines 
2008; Gross 1999; INSIGHT Study 2007; Jalan 2007; Otsuka Study 2011c; Kalra 2011; Koren 
2011; Otsuka Study 2011b; Naidech 2010; Nevens 2009; Peyro Saint Paul 2013; SALT-1 Study 
2006; SALT-2 Study 2006; Soupart 2006; Wong 2003; Yang 2013; Zeltser 2007). For five stud-
ies, participants with hyponatraemia formed a subgroup of a larger study including both 
participants with and without hyponatraemia (DILIPO Study 2011; Gheorghiade 2003; AC-
TIV in CHF Study 2004; EVEREST Study 2007; Singhi 1995).
Studies included on average mostly older adults (median 65 years, interquartile range 
5) with moderate hyponatraemia (median 129 mmol/L; range 124-133). Participants had 
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as primary cause of hyponatraemia a syndrome of inappropriate antidiuresis in nine stud-
ies (Decaux 2006; HARMONY Study 2012; LIBRA Study 2012; Naidech 2010; Otsuka Study 
2011a; Peyro Saint Paul 2013; Salahudeen 2014; Singhi 1995; Soupart 2006), heart failure in 
seven studies (ACTIV in CHF Study 2004; BALANCE Study 2010; Dzau 1984; EVEREST Study 
2007; Gheorghiade 2003; Otsuka Study 2011b; Yang 2013) and liver cirrhosis in five stud-
ies (Gines 2008; HYPOCAT Study 2008; Jalan 2007; Nevens 2009; Otsuka Study 2011c). The 
others included a mixed group of patients. Sample sizes varied and were generally small 
(median 69 participants; range 6 to 652). Treatment was mostly short-term (median 8 days; 
range 1 to 365). Data for at least one outcome of interest were available from 31 studies and 
3365 participants, two studies reported no numeric data (Jalan 2007; Otsuka Study 2011c).
Excluded studies  
We excluded 13 studies: three were not randomised trials but rather observational stud-
ies (Bichet 1999; Maji 2013; Zellweger 2001); eight did not include the appropriate popu-
lation, with participants either not having hyponatraemia at randomisation (Albert 2013; 
De Vita 2012; Galton 2011; Mori 1999; Ramsay 1988; Zamboli 2011), or having hyponatrae-
mia but caused by psychogenic polydipsia (Alexander 1991) or prolonged exercise (Rogers 
2011); one randomised trial studied two different salt-restricted diets in combination with 
step-wise increase of diuretic treatment for reducing weight and ascites in patients with de-
compensated liver cirrhosis (Bernardi 1993); and finally one study (Gines 2007) would have 
led to double counting of participants as it represented a second randomised trial built on 
top of a first included study (HYPOCAT Study 2008) using the same study medication.
Risk of bias in included studies  
The risk of bias is described in Figure 6.2 and Figure 6.3.
Low risk of bias         Unclear risk of bias         High risk of bias?
0% 25% 50% 75% 100%
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Blinding of outcome assessment (detection bias)
?
?
?
?
?
?
Figure 6.2. Risk of bias graph: 
review authors’ judgements about each risk of bias item presented as percentages across all included studies. 
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Figure 6.3. Risk of bias summary: 
review authors’ judgements about each risk of bias item for each included study. 
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Allocation (selection bias)  
The allocation sequence was adequately generated in 14 studies (BALANCE Study 2010; 
DILIPO Study 2011; EVEREST Study 2007; Gross 1999; HYPOCAT Study 2008; Naidech 2010; 
Otsuka Study 2011a; Otsuka Study 2011b; Peyro Saint Paul 2013; Salahudeen 2014; SALT-1 
Study 2006; SALT-2 Study 2006; Singhi 1995; Wong 2003), and adequately concealed in 12 
studies (ACTIV in CHF Study 2004; BALANCE Study 2010; EVEREST Study 2007; Gheorghiade 
2003; Gross 1999; HYPOCAT Study 2008; Naidech 2010; Peyro Saint Paul 2013; Salahudeen 
2014; SALT-1 Study 2006; SALT-2 Study 2006; Wong 2003). For the remaining studies the 
authors provided insufficient information about the procedures to permit a judgement of 
the risk of bias.
Blinding (performance bias and detection bias)  
In 26 studies, all assessing a vasopressin receptor antagonist, the investigators attempted 
to blind participants and personnel by providing a matching placebo (ACTIV in CHF Study 
2004; Annane 2009; BALANCE Study 2010; Decaux 2006; DILIPO Study 2011; EVEREST Study 
2007; Ghali 2006; Gheorghiade 2003; Gines 2008; Gross 1999; HARMONY Study 2012; HY-
POCAT Study 2008; INSIGHT Study 2007; Kalra 2011; Koren 2011; LIBRA Study 2012; Nevens 
2009; Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c; Salahudeen 2014; 
SALT-1 Study 2006; SALT-2 Study 2006; Soupart 2006; Wong 2003; Zeltser 2007). Although 
it was probably unlikely for participants and personnel to be fully blinded due to important 
increases in urine output when treated with a vasopressin receptor antagonist, co-interven-
tions of fluid restriction or salt-intake were reported and similar in 12 studies (Annane 2009; 
DILIPO Study 2011; Ghali 2006; Gross 1999; HARMONY Study 2012; HYPOCAT Study 2008; 
Kalra 2011; Koren 2011; LIBRA Study 2012; Salahudeen 2014; Soupart 2006; Zeltser 2007). 
For two studies, fluid restriction could be adapted by both participant and treating physi-
cian - e.g. based on urine output. We judged this would not have introduced important risk 
of bias for death and objective outcomes related to serum sodium concentration, but may 
have biased health-related quality of life measures and resulted in biased estimates of risk 
of rapid increase in serum sodium concentration (SALT-1 Study 2006; SALT-2 Study 2006).
Three studies explicitly reported blinding of outcomes assessors (BALANCE Study 2010; 
SALT-1 Study 2006; SALT-2 Study 2006 ). In 28 others we judged blinding of outcome asses-
sors would likely have occurred or measured outcomes were objective enough so that the 
risk of bias was probably low (ACTIV in CHF Study 2004; Annane 2009; Decaux 2006; DILIPO 
Study 2011; Dzau 1984; EVEREST Study 2007; Ghali 2006; Gheorghiade 2003; Gheorghiade 
2006; Gross 1999; HARMONY Study 2012; HYPOCAT Study 2008; INSIGHT Study 2007; Jalan 
2007; Kalra 2011; Koren 2011; LIBRA Study 2012; Naidech 2010; Nevens 2009; Otsuka Study 
2011a; Otsuka Study 2011b; Otsuka Study 2011c; Peyro Saint Paul 2013; Salahudeen 2014; 
Singhi 1995; Soupart 2006; Wong 2003; Zeltser 2007).
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Incomplete outcome data (attrition bias)  
In 17 studies, attrition stayed below 20% with either well documented reasons and/or 
limited opportunity for important bias (ACTIV in CHF Study 2004; Annane 2009; BALANCE 
Study 2010; DILIPO Study 2011; Dzau 1984; Ghali 2006; Gheorghiade 2006; HYPOCAT Study 
2008; INSIGHT Study 2007; Kalra 2011; Koren 2011; Naidech 2010; Otsuka Study 2011a; Ot-
suka Study 2011b; Salahudeen 2014; Singhi 1995; Soupart 2006). Eight studies had attrition 
rates >25% and either did not attempt to reinclude participants in the analysis (EVEREST 
Study 2007; Gheorghiade 2003 Peyro Saint Paul 2013) or used imputation methods to deal 
with missing serum sodium concentration values that may have caused overestimation of 
the effect of the study medication - e.g. last observation carried forward, thus ignoring re-
bound hyponatraemia on cessation of treatment (HARMONY Study 2012; LIBRA Study 2012; 
SALT-1 Study 2006; SALT-2 Study 2006; Wong 2003; Zeltser 2007). The others provided insuf-
ficient information to allow judgement of high or low risk of bias (Decaux 2006; Gheorghia-
de 2003; Gines 2008; Gross 1999; Jalan 2007; Nevens 2009; Otsuka Study 2011c; Yang 2013).
Selective reporting (reporting bias)  
For 15 studies, we found a registered protocol in a trial registry (ACTIV in CHF Study 2004; 
BALANCE Study 2010; DILIPO Study 2011; EVEREST Study 2007; HARMONY Study 2012; HY-
POCAT Study 2008; INSIGHT Study 2007; LIBRA Study 2012; Naidech 2010; Otsuka Study 
2011a; Otsuka Study 2011b; Otsuka Study 2011c; Peyro Saint Paul 2013; SALT-1 Study 2006; 
SALT-2 Study 2006). The Otsuka Study was registered as a single study but reported as three 
separate ones (Otsuka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c). Investiga-
tors fully reported all expected pre-registered outcomes at pre-registered time-points in 
two of those (INSIGHT Study 2007; Naidech 2010). Whether a protocol was provided or not, 
for 12 studies investigators reported all expected outcomes related to benefit and harms at 
reasonable time-points (Annane 2009; Decaux 2006; DILIPO Study 2011; Ghali 2006; HAR-
MONY Study 2012; Kalra 2011; Koren 2011; LIBRA Study 2012; Peyro Saint Paul 2013; Singhi 
1995; Soupart 2006; Zeltser 2007). In seven studies with treatment duration >1 week, au-
thors did not report the primary outcomes all-cause mortality or health-related quality of 
life or any outcome related to rapid increases in serum sodium concentration (ACTIV in CHF 
Study 2004; Gheorghiade 2003; HYPOCAT Study 2008; Gines 2008; Nevens 2009; Salahu-
deen 2014; Yang 2013). In eight studies with treatment duration ≤1 week, authors did not 
report any secondary outcome related to serum sodium concentration or rapid increases 
thereof (Dzau 1984; Gheorghiade 2006; Gross 1999; Jalan 2007; Otsuka Study 2011a; Otsuka 
Study 2011b; Otsuka Study 2011c; Wong 2003).
Other potential sources of bias  
Bias through possible financial conflict of interest of the authors and/or sponsorship 
bias
Industry funded 27 studies (ACTIV in CHF Study 2004; Annane 2009; BALANCE Study 
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2010; Decaux 2006; DILIPO Study 2011; EVEREST Study 2007; Ghali 2006; Gheorghiade 2003; 
Gheorghiade 2006; Gross 1999; HARMONY Study 2012; HYPOCAT Study 2008; INSIGHT 
Study 2007; Kalra 2011; LIBRA Study 2012; Koren 2011; Naidech 2010; Nevens 2009; Ot-
suka Study 2011a; Otsuka Study 2011b; Otsuka Study 2011c; Salahudeen 2014; Salahudeen 
2014; SALT-1 Study 2006; SALT-2 Study 2006; Soupart 2006; Wong 2003; Zeltser 2007). The 
funding source was unclear for six studies (Dzau 1984; Gines 2008; Jalan 2007; Peyro Saint 
Paul 2013; Singhi 1995; Yang 2013). For 17 studies we retrieved a declaration of interest 
for the authors featuring on the reports (ACTIV in CHF Study 2004; Annane 2009; DILIPO 
Study 2011; EVEREST Study 2007; Ghali 2006; Gheorghiade 2003; Gines 2008; Gross 1999; 
HARMONY Study 2012; HYPOCAT Study 2008; Kalra 2011; Koren 2011; LIBRA Study 2012; 
Naidech 2010; SALT-1 Study 2006; SALT-2 Study 2006; Zeltser 2007). All save one (Naidech 
2010) had author lists who featured people who had received money for presentations or 
consultancy, or were employed by the sponsor.
Effects of interventions  
Vasopressin receptor antagonists versus placebo or no treatment
Primary outcomes
Vasopressin receptor antagonists had uncertain effects on mortality (Analysis 1.1, 15 
studies, 2330 participants: RR 1.11, 95% CI 0.92 to 1.33; I²=0%). Vasopressin receptor an-
tagonists slightly increased scores for the mental component summary of the Short Form 
Health Survey (SF-12) (Analysis 1.2, 2 studies, 297 participants: MD 4.76, 95% CI 0.11 to 9.41, 
I²=63%) and shortened hospital stay (Analysis 1.3, 3 studies, 610 participants: MD -1.63 days, 
95% CI -2.96 to -0.30, I²=0%). Using GRADE criteria, we judged this evidence of low quality 
because study results possibly suffered from high risk of performance bias, attrition bias, se-
lective outcome reporting bias, sponsorship bias or bias through possible financial conflict 
of interest of the authors.
Secondary outcomes
Vasopressin receptor antagonists caused a modest increase in serum sodium concentra-
tion. At the end of treatment, participants treated with placebo had an average increase in 
serum sodium concentration ranging from 0.5 to 4.7 mmol/L. In comparison, people treated 
with a vasopressin receptor antagonist had an average increase that was approximately 4 
mmol/L higher (Analysis 1.4, 21 studies, 2641 participants: MD 4.15 mmol/L, 95% CI 3.13 to 
5.17; I²=98%). These results were generally consistent for studies with shorter and longer 
follow-up. Although there was substantial heterogeneity among included studies as de-
scribed by the I², individual point estimates all favoured vasopressin receptor antagonists. 
Investigators often also analysed serum sodium concentration as a dichotomous outcome, 
defining response as an increase of 5 to 6 mmol/L or normalisation of the absolute value. 
Defined as such, the previous data translated into more than twice as many people having 
a response with vasopressin receptor antagonists compared with placebo (Analysis 1.5, 18 
studies, 2104 participants: RR 2.58, 95% CI 2.00 to 3.33 I²=56%). On average 23% of partici-
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pants treated with placebo had a response versus 60% treated with a vasopressin receptor 
antagonist. Overall, in absolute terms this implies treating 3 adults with hyponatraemia with 
a vasopressin receptor antagonist could result in one more individual attaining an increase 
in serum sodium concentration of 5 mmol/L. We judged the evidence to be of moderate 
quality due to risks of performance, attrition, selective reporting and sponsorship bias or 
bias through possible financial conflicts of interest of the study investigators.
Three studies evaluated cognitive function (BALANCE Study 2010; INSIGHT Study 2007; 
Salahudeen 2014). In a first study, using the trail making test part B, a neuropsychologi-
cal test of visual attention and task switching, the investigators found lixivaptan did not 
shorten the time to complete the test (1 study, 652 participants: MD 13.60, 95% CI 12.82 to 
14.38). A second study tested reaction time, psychomotor and processing speeds and found 
no difference in change between the groups (1 study, 56 participants, 0.20, 95% CI -0.10 to 
0.50). The third study, assessing the change in mini mental state exam with tolvaptan, found 
no change from baseline (1 study, 30 participants, MD -0.70, 95% CI -2.23, 0.83).
Treatment with a vasopressin receptor antagonist raised the risk of rapid increases in 
serum sodium concentration by 67%, resulting in three additional people with a rapid 
increase per 100 treated with a vasopressin receptor antagonist versus placebo (Analysis 
1.6, 14 studies, 2058 participants: RR 1.67, 95% CI 1.16 to 2.40; I²=0%). The analysis showed 
no significant heterogeneity. The effects for hypernatraemia were unclear (Analysis 1.7, 10 
studies, 1595 participants: RR 1.37, 95% CI 0.63 to 3.01; I²=1%). None of the included studies 
reported participants developing osmotic demyelination syndrome.
Overall, treatment with vasopressin receptor antagonists increased the odds for thirst 
nearly three times compared versus treatment with placebo (Analysis 1.8, 13 studies, 1666 
participants: OR 2.77, 95% CI 1.80 to 4.27; I²=66%). Other side-effects were generally less 
extensively reported. Nevertheless there was some evidence vasopressin receptor antago-
nists substantially increased the risk of polyuria (Analysis 1.9.1, 6 studies, 1272 participants: 
RR 4.69, 95% CI 1.59 to 13.85, I²=0%). The risks remained uncertain for hypotension (Analysis 
1.9.2, 14 studies, 1748 participants: RR 1.11, 95% CI 0.75 to 1.63; I²=0%), acute kidney injury 
(Analysis 1.9.3, 8 studies, 1920 participants: RR 0.89, 95% CI 0.67 to 1.18; I²=0%) and liver 
function abnormalities (Analysis 1.9.4, 3 studies, 811 participants: RR 2.43, 95% CI 0.88 to 
6.70). Half of the studies in which the vasopressin receptor antagonist was administered in-
travenously evaluated important adverse events related to the infusion itself. Overall there 
were almost three times as many patients developing infusion-site phlebitis (Analysis 1.10, 
3 studies, 250 participants: RR 2.72, 95% CI 1.17 to 6.31; I²=0%); the effects for infusion-site 
thrombosis were less clear (Analysis 1.10, 3 studies, 250 participants: RR 1.45, 95% CI 0.25 
to 8.55; i²=0%). There were slightly fewer people who discontinued treatment when given 
placebo than when given a vasopressin receptor antagonist (Analysis 1.11, 14 studies, 2429 
participants: RR 0.93, 95% CI 0.85 to 1.00; I²=0%).
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Analysis of heterogeneity
Using univariate metaregression and subgroup analyses, we explored possible sources 
of heterogeneity in the effect of vasopressin receptor antagonists on the change in serum 
sodium concentration. Our prespecified potential sources were: the specific vasopres-
sin receptor antagonist compound, the underlying condition causing the hyponatraemia 
(with as non-prespecified categories studies only including participants with inappropriate 
antidiuresis; studies only including participants with heart failure or liver cirrhosis or stud-
ies including both), mean baseline serum sodium concentration, treatment duration and 
risk of selection bias as sources of heterogeneity. A higher serum sodium concentration at 
baseline resulted in smaller increases in serum sodium with treatment (Figure 6.4). Per 1 
mmol/L increase in baseline serum sodium concentration between 124 and 133 mmol/L, 
the mean difference on average decreased from 5.7 by 0.33 mmol/L (95% CI -0.89 to -0.60) 
to 2.7 mmol/L. There was no evidence that the compound, the cause of hyponatraemia, 
the treatment duration or risk of selection bias modified the effect of vasopressin receptor 
antagonists on change from baseline in serum sodium concentration (Table 6.1).
We observed asymmetry in the funnel plot for the outcomes of response (Peters’ regres-
sion test, p=0.002), suggesting the presence of small-study effects or publication bias, such 
Figure 6.4.  Effect of baseline serum sodium concentration on change in natraemia: metaregression.
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that studies with small or null effects are not in the public domain and were not uncovered 
by our sensitive searching. Sensitivity analysis for this outcome excluding four studies with 
the largest effect estimates and largest estimate of variance reduced the relative risk with 
30% (RR 2.07, 95%CI 1.67 to 2.56). However, the funnel plots for other related outcomes 
were more symmetrical. No asymmetry was observed in funnel plots for change and rapid 
increase in serum sodium concentration, thirst, treatment discontinuation, and data for 
death, length of hospital stay, cognitive function, hypernatraemia or other adverse events 
were insufficient to allow for detection of small-study effects.
Sensitivity analysis
Including the number of deaths occurring during follow-up rather than during treat-
ment had little effect on the estimate of the treatment effect (Analysis 1.12, 16 studies, 2404 
participants: RR 1.11, 95% CI 0.87 to 1.41).
For the serum sodium concentration analysis, when we excluded seven studies judged 
at high or unclear risk of performance bias, the summary treatment estimate remained un-
changed (14 studies, 1458 participants: MD 4.89 mmol/L, 95% CI 4.02 to 5.76). When we 
excluded eight studies judged at high or unclear risk of attrition bias, we found similar treat-
ment effect estimates (13 studies, 1342 participants: MD 4.71 mmol/L, 95% CI 3.34 to 6.08).
Conivaptan versus conivaptan
Kalra 2011 (117 participants) compared four regimens with or without a loading dose 
with one another and found no significant difference in any of the measured outcomes 
(death, change from baseline serum sodium concentration, response in serum sodium con-
centration, thirst, injection-site phlebitis, injection-site thrombosis, treatment discontinua-
tion (data not shown).
Table 6.1. Metaregression.
Covariate N Scale
Proportional change in risk ratio or 
absolute change in mean difference P value
Baseline serum sodium concentration 21 Per 1 mmol/L increase -0.33 (-0.65 to -0.02) 0.04
Compound 21 Relative to conivaptan  0.17
Conivaptan 5  -  
Lixivaptan 4  -2.79 (-5.47 to -0.10)  
Satavaptan 3  -0,23 (-3.34 to 2.87)  
Tolvaptan 9  -0.82 (-3.13 to 1.50)  
Cause of hyponatraemia 21 Relative to SIAD  0.18
SIAD 5  -  
Combined SIAD - heart failure, cirrhosis 10  0.67 (-1.77 to 3.13)  
Heart failure 6  -1.19 (-3.84 to 1.47)  
Treatment duration 21 Per day increase -0.02 (-0,04 to 0.00) 0.10
Risk of selection bias 21 Relative to low risk  0.86
Low risk 8  -  
High risk 13  0.18 (-1.90 to 2.27)  
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Fluid restriction versus normal maintenance fluid treatment
Singhi 1995 (26 participants) compared fluid restriction (calculated as 65% of normal) 
versus normal maintenance intravenous fluid administration in children with bacterial men-
ingitis. At two days, administration of restricted volumes significantly increased the serum 
sodium concentration (Table 6.2, 1 study, 26 participants: MD 4.40 mmol/L, 95% CI 1.79 to 
7.01), but had uncertain effects on the risk of death (Table 6.1, 1 study, 26 participants: RR 
7.80, 95% CI 0.46 to 131.62).
Captopril and furosemide versus captopril
Dzau 1984 (14 participants) found after five days of treatment, the combination of capto-
pril and furosemide resulted in a 10 mmol/L higher serum sodium concentration compared 
with captopril alone (Table 6.2, 1 study, 14 participants, MD 10.00 mmol/L, 95% CI 8.60 
to 11.40). The report did not include outcomes related to death, quality of life or adverse 
events due to rapid increases in serum sodium concentration caused by treatment.
Albumin versus no treatment
Jalan 2007 (24 participants) compared infusion of human salt poor albumin in combina-
tion with fluid and sodium restriction versus fluid and sodium restriction alone in patients 
with refractory ascites caused by liver cirrhosis. We only identified an abstract and it did not 
include comparative data.
Medication change versus standard care
Peyro Saint Paul 2013 (19 participants) compared a change in medication regimen to 
standard care in older adults suspected of having drug-induced hyponatraemia. Compared 
Table 6.2.  Single study results. 
Comparison
Outcome Studies Participants Effect size, 95% CI
Fluid restriction versus normal maintenance fluid treatment
Death 1 26 RR 7.80, 95% CI 0.46 to 131.62
Change from baseline serum sodium concentration 1 26 MD 4.40, 95% CI 1.79 to 7.01 mmol/L
Captopril + furosemide versus furosemide
Serum sodium concentration 1 14 MD 10.00, 95% CI 8.60 to 11.40
Medication change versus standard care
Death at 1 month 1 19 RR 0.37, 95% CI 0.02 to 8.01
Death at 3 months 1 14 RR 0.75, 95% CI 0.06 to 9.72
Change from baseline serum sodium concentration at 1 
month 1 14 MD 1.70, 95% CI -1.39 to 4.79 mmol/L
Response in serum sodium concentration at 1 month 1 14 RR 10.11, 95% CI 0.68 to 150.68
Hypernatraemia at 1 month 1 14 Not estimable
Osmotic demyelinating syndrome 1 14 Not estimable
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with standard care, changing the medication regimen had uncertain effects on risk of death 
(Analysis 5.1; 1 study, 19 participants: RR 0.37, 95% CI 0.02 to 8.01), response in serum sodi-
um concentration (Analysis 5.3; 1 study 14 participants: RR 10.11, 95% CI 0.68 to 150.68) and 
change from baseline in serum sodium concentration at one month (Analysis 5.4, 1 study, 
14 participants: MD 1.70, 95% CI -1.39 to 4.79). No participant in either group developed 
hypernatraemia or osmotic demyelination syndrome.
No studies evaluated the effects of urea, mannitol, corticosteroids, demeclocycline, lithi-
um or phenytoin with regard to correction of hyponatraemia.
Discussion  
Summary of main results (Table 6.3)
In low quality evidence from 21 randomised controlled trials involving 2641 participants, 
treatment of hyponatraemia with a vasopressin receptor antagonist modestly increased the 
serum sodium concentration (4 mmol/L) and slightly reduced hospital stay (-1.6 days), but 
had unclear effects on all-cause mortality, was associated with an increased risk of rapid 
serum sodium correction and commonly caused adverse effects such as thirst and polyuria. 
On average, treating 1,000 people would cause 290 additional people to have an increase 
in serum sodium concentration of at least 5 mmol/L, but it would come at a cost of an ad-
ditional 29 people having an increase exceeding 10-12 mmol/L/day, generally considered 
as the threshold from which on there is an increased risk for osmotic demyelination. Effects 
were generally consistent across the different drugs in this class.The evidence on patient-
important outcomes such as quality of life, cognitive and general functional status were 
limited and generally showed no important beneficial treatment effects. Despite the large 
patient population included, no cases of osmotic demyelination syndrome were reported. 
Randomized trial data for other interventions such as fluid restriction, urea, mannitol, loop 
diuretics, corticosteroids, demeclocycline, lithium and phenytoin were largely absent. As 
such, it remains unclear whether interventions aiming to raise serum sodium result in im-
portant health outcomes.
Overall completeness and applicability of evidence  
Although the United States Food and Drug Administration (FDA) and the European Med-
icines Agency (EMA) have approved certain vasopressin receptor antagonists for treating 
people with hyponatraemia, regulatory approval was largely based on surrogate outcomes 
in short-term studies. To date, clinically important outcomes (e.g. reduction in all-cause 
mortality or improvement in quality of life, cognitive and general functional status) remain 
insufficiently investigated. The limited data we did have, suggested vasopressin receptor 
antagonists have little or no benefit on these outcomes for people with hyponatraemia. In 
the context of intervention studies, a surrogate is a measurable outcome such as a labora-
tory test, which responds to an intervention (e.g. lowering of cholesterol with statins) and is 
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Outcomes Anticipated absolute effects* (95% CI) Relative 
effect 
(95% CI) 
ʋ of 
participants 
(Studies)  
Quality of the 
evidence 
(GRADE)  
Comments
Risk with placebo or no 
treatment 
Risk with Vasopressin receptor 
antagonists 
Death (Death) 
follow up: range 2 to 
180 days  
Study population  RR 1.11
(0.92 to 
1.33)  
2330 
(15 RCTs)  
۩۩۵۵ 
LOW  1 2 
 
143 per 1000  159 per 1000(132 to 190)  
Health-related quality 
of life (HRDOL) 
assessed with: Mental 
component score SF12 
follow up: mean 30 
days  
The mean health-related 
quality of life in the control 
group was 0  
The mean health-related 
quality of life in the 
intervention group was 4.76 
higher (0.11 higher to 9.41 
higher)  
-  297 
(2 RCTs)  
۩۩۵۵ 
LOW  3 
Scale 0 to 
100 (worst to 
best)  
Length of hospital 
stay (Hospital stay) 
follow up: range 1 to 2 
years  
The mean length of 
hospital stay in the control 
group was 6 to 11 days  
The mean length of hospital 
stay in the intervention group 
was 1.58 lower (2.92 lower to 
0.24 lower)  
-  580 
(2 RCTs)  
۩۩۵۵ 
LOW  3 
 
Serum sodium 
concentration - 
continuous (Sodium - 
continuous) 
follow up: range 1 to 
180 days  
The mean serum sodium 
concentration - continuous 
in the control group was 
0.3 to 4.8 mmol/L  
The mean serum sodium 
concentration - continuous in 
the intervention group was 
4.17 higher (3.18 higher to 
5.16 higher)  
-  2641 
(21 RCTs)  
۩۩۩۵ 
MODERATE  4 
 
Serum sodium 
concentration - 
dichotomous 
follow up: range 4 to 
180 days  
Study population  RR 2.25
(1.96 to 
2.58)  
2104 
(18 RCTs)  
۩۩۩۵ 
MODERATE  4 
 
231 per 1000  
521 per 1000
(454 to 597)  
Rapid sodium 
increase (Rapid 
sodium increase) 
follow up: range 1 to 5 
days  
Study population  RR 1.67
(1.16 to 
2.40)  
2058 
(14 RCTs)  
۩۩۩۵ 
MODERATE  1 
 
44 per 1000  
73 per 1000
(51 to 105)  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; 
GRADE Working Group grades of evidence; 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the 
effect, but there is a possibility that it is substantially different; 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the 
effect; 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect.
Table 6.3. Summary of findings. Vasopressin receptor antagonists compared to placebo or no treatment for 
chronic non-hypovolaemic hypotonic hyponatraemia.
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causally associated a clinically important outcome (e.g. reduction in mortality with statins) 
(Ballinger 2014). Investigators often use surrogates instead of important health outcomes 
because surrogates can substantially reduce the cost, sample size and duration of a ran-
domised trial. However, not all are valid proxies of clinically important outcomes. It is true 
that in acute and profound hyponatraemia, the evidence from observational studies is so 
overwhelming that we readily accept that increasing the serum sodium concentration is 
life-saving. It is also true that a chronically low serum sodium concentration is strongly and 
consistently associated with increased mortality and risk of bone fractures (Wald 2010). 
However, there is currently insufficient evidence that aside from affecting the surrogate (e.g. 
increase in serum sodium concentration with a vasopressin receptor antagonist) treatment 
in case of chronic hyponatraemia also changes the patient-centred outcomes downstream 
of the surrogate in the same causal pathway (e.g. reduction in mortality as a consequence of 
raising serum sodium concentration with a vasopressin receptor antagonist).
Studies contributing to this review included mostly participants with mild to moderate 
hyponatraemia (mean serum sodium concentration at study level ≥123 mmol/L). Meta-re-
gression revealed a modifying effect of the serum sodium concentration at baseline, with 
lower values associated with larger increasesin natraemia. Extrapolation of meta-regression 
data would suggest higher increases, but possibly higher risks of rapid correction as the 
baseline serum sodium decreases. Although no study reported osmotic demyelination, it is 
unclear what would happen if vasopressin receptor antagonists were used on a larger scale 
and in people with sodium concentrations below those included in the RCTs that contrib-
uted to this review.
Finally, studies evaluating the effectiveness of alternative interventions for increasing se-
rum sodium concentration in people with chronic, non-hypovolaemic hyponatraemia are 
largely absent. 
Quality of the evidence  
Overall, according to GRADE criteria, data evaluating the effects of vasopressin recep-
tor antagonists for people with chronic, non-hypovolaemic, hypotonic hyponatraemia on 
mortality, change and rapid increase in serum sodium concentration were of low quality. 
Low quality evidence suggests that additional studies are likely to change our confidence in 
the effects (Guyatt 2008). Although results were consistent among studies and we believed 
them to be generalizable to patients with hyponatraemia outside the RCT context, they 
were based on indirect and sometimes imprecise information obtained from surrogate out-
comes. In addition, the estimates of treatment effect were derived from studies at generally 
high risk of bias. The quality of conduct and reporting of studies included in this review in-
deed was variable, with many studies omitting crucial methodological information used to 
assess the risk of bias. Importantly, all studies assessing benefits and harms of vasopressin 
receptor antagonists were likely instigated and sponsored by the pharmaceutical company 
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developing or seeking to commercialise the compound. For the studies that provided a 
declaration of interest for the authors of study reports, all save one had author lists who fea-
tured people who had received money for presentations or consultancy, or were employed 
by the sponsor. Empiric evidence shows that pharmaceutical industry-sponsored studies 
are more likely to have favourable efficacy results (risk ratio 1.32, 95% confidence interval 
1.21 to 1.44) and harm results (risk ratio 1.87, 95% confidence interval 1.54 to 2.27) than 
studies not sponsored by industry (Lundh 2012). Data for other interventions such as fluid 
restriction, change in medical regimens, captopril or albumin were sparse and inconclusive.
Potential biases in the review process  
Although this review was conducted by two or more independent authors, used a com-
prehensive search of the published and unpublished research designed by a specialist li-
brarian, and examined all potentially relevant clinical outcomes, potential biases exist in 
the review process. The major weakness of this review is the paucity of data for treatments 
other than vasopressin receptor antagonists. First, summary of existing evidence therefore 
focusses the discourse on new, and expensive, treatments, rather than focusing on exist-
ing, and cheaper alternatives. Randomized trials are extraordinarily expensive and conse-
quently often conducted by the pharmaceutical industry. This results in a catch-22 situation 
of evidence being mostly created, and thus only available, for newer interventions in gen-
eral. Many other interventions are or have been used in clinical practice, but were driven to 
the background because randomised trial data were largely absent. Notably, also for fluid 
restriction, despite it being the currently accepted first-line treatment for both hypervolae-
mic and euvolaemic hyponatraemia, there are no randomised trial data available. Current-
ly, there are limited opportunities for use of vasopressin receptor antagonists in practice. 
Only two vasopressin receptor antagonists have obtained large scale regulatory approval. 
Conivaptan is FDA approved for euvolaemic and hypervolaemic hyponatraemia in hospi-
talised patients. It is available only as an intravenous preparation and treatment duration 
is limited to a maximum duration of 4 days because of drug-interaction effects with other 
agents metabolized by the cytochrome P450 3A4 hepatic isoenzyme (FDA 2012). Tolvaptan, 
an oral agent, is also FDA approved for the treatment of euvolaemic and hypervolaemic 
hyponatraemia. In the European Union, tolvaptan is approved only for the treatment of eu-
volaemic hyponatraemia. Although theoretically available for long-term treatment, recent 
concerns around the potential for severe liver injury in patients with autosomal dominant 
polycystic kidney disease has caused the FDA to restrict the use of tolvaptan to 30 days and 
issue a contra-indication for patients with underlying liver disease (Samsca 2013) .
Agreements and disagreements with other studies or reviews  
This review largely agreed with the findings of two earlier systematic reviews. However, 
neither of these previous reviews sought to examine any other treatments beyond vaso-
pressin receptor antagonists for treating chronic non-hypovolaemic hypotonic hyponatrae-
Nagler.indb   149 15/09/2015   16:14:43
Chapter 6
150
mia. The first, including 15 RCTs and 1619 participants found vasopressin antagonists on av-
erage increased the serum sodium concentration by approximately 5 mmol/L at one week 
(13 studies, 1119 participants: MD 5.27 mmol/L, 95% CI 4.27 to 6.26), and approximately 3.5 
mmol/L beyond the first week (8 studies, 793 participants: MD 3.49 mmol/L, 95% CI 2.56 to 
4.41), but it came at a cost of increased risk of overly rapid correction of the serum sodium 
concentration (8 trials, 860 participants: RR, 2.52, 95% CI 1.26 to 5.08) (Rozen-Zvi 2010).The 
second review, including 11 RCTs and 1094 participants, found vasopressin antagonists on 
average increased the serum sodium concentration by approximately 5 mmol/L at day 4 (11 
studies, 1094 participants: MD 4.90 mmol/L, 95% CI 4.10 to 5.80), but was associated with a 
6% increased risk of overly rapid correction of the serum sodium concentration (9 studies, 
995 participants: RD 0.06, 95% CI 0.03 to 0.10) (Jaber 2011).
We also largely agreed with the interpretation of these data by the respective study 
authors as presented in their discussion. However, we disagreed with the conclusion pre-
sented by Rozen-Zvi. We did not believe these data justified the conclusion that ‘vasopres-
sin receptor antagonists were effective for the treatment of hypervolaemic and euvolaemic 
hyponatraemia.’ Although there is little doubt these agents increase the serum sodium con-
centration, this outcome needs to be weighed against the increased risk of an overly rapid 
correction and in itself is insufficient to conclude they will also improve the outcomes that 
matter to patients.
A recently published European guideline on the diagnosis and treatment of hyponatrae-
mia stated in moderate or profound hyponatraemia, restricting fluid intake was first-line 
treatment (2D). In moderate or profound hyponatraemia, equal second-line treatments 
were: increasing solute intake with 0.25–0.50 g/kg per day of urea or a combination of low-
dose loop diuretics and oral sodium chloride (2D). In moderate hyponatraemia, vasopressin 
receptor antagonists were not recommended (1C). In profound hyponatraemia, the guide-
line recommended against vasopressin receptor antagonists. In mild hyponatraemia the 
guideline suggested against treatment with the sole aim of increasing the serum sodium 
concentration (2C) (Spasovski 2014). In contrast to this, a largely American guideline pub-
lished in 2013 projected vasopressin receptor antagonists were likely to become a mainstay 
of treatment for euvolaemic hyponatraemia and probably represented the best approach 
to treating hyponatraemia in most oedema-forming states (Verbalis 2013).
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Authors’ conclusions
Implications for practice  
In people with chronic hyponatraemia, vasopressin receptor antagonists modestly raise 
serum sodium concentration at the cost of a 10% increased risk the increase being too rapid, 
and a subsequent small but unknown increased risk of osmotic demyelination syndrome. 
To date there is little evidence from RCTs for a beneficial effect on mortality, quality of life or 
any other truly important health outcome of these agents or in fact any other treatment for 
chronic hyponatraemia. It makes any recommendation problematic.
Implications for research  
Further studies assessing commonly used treatments such as fluid restriction would 
inform practice and are warranted given limited evidence that in chronic hyponatraemia 
aside from affecting the surrogate (e.g. increase in serum sodium concentration) any treat-
ment results in improved patient-centred outcomes and do not merely result in patients 
constantly feeling thirsty, thereby impairing their quality of life.
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Differences between protocol and review  
Liver function abnormalities were not anticipated as an adverse effect attributable to 
vasopressin receptor antagonists. A communication issued by Otsuka, indicating concerns 
around possibility for liver failure - be it in patients with autosomal polycystic kidney disease 
and at doses higher than those given for hyponatraemia - highlighted the outcome for in-
clusion in our review. 
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Appendix 1. Electronic search strategies
Database Search terms
CENTRAL
hyponatr*emi*:ti,ab,kw
“inappropriate ADH syndrome”:ti,ab,kw
“inappropriate vasopressin secretion”:ti,ab,kw
{or #1-#3}
MEDLINE
Hyponatremia/
Inappropriate ADH Syndrome/
hyponatr?emi*.tw.
inappropriate ADH syndrome.tw.
inappropriate vasopressin secretion.tw.
or/1-5
EMBASE
hyponatremia/
inappropriate vasopressin secretion/
hyponatr?emi*.tw.
inappropriate ADH syndrome.tw.
inappropriate vasopressin secretion.tw.
or/1-5
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Abstract
 Hyponatraemia, defined as a serum sodium concentration <135 mmol/l, is the most com-
mon disorder of body fluid and electrolyte balance encountered in clinical practice. It can 
lead to a wide spectrum of clinical symptoms, from subtle to severe or even life threatening, 
and is associated with increased mortality, morbidity and length of hospital stay in patients 
presenting with a range of conditions. Despite this, the management of patients remains 
problematic. The prevalence of hyponatraemia in widely different conditions and the fact 
that hyponatraemia is managed by clinicians with a broad variety of backgrounds have 
fostered diverse institution- and speciality-based approaches to diagnosis and treatment. 
To obtain a common and holistic view, the European Society of Intensive Care Medicine 
(ESICM), the European Society of Endocrinology (ESE) and the European Renal Association – 
European Dialysis and Transplant Association (ERA–EDTA), represented by European Renal 
Best Practice (ERBP), have developed the Clinical Practice Guideline on the diagnostic ap-
proach and treatment of hyponatraemia as a joint venture of three societies representing 
specialists with a natural interest in hyponatraemia. In addition to a rigorous approach to 
methodology and evaluation, we were keen to ensure that the document focused on pa-
tient-important outcomes and included utility for clinicians involved in everyday practice.
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Foreword
Hyponatraemia is a clinical feature in 15–20% of emergency admissions to hospi-tal. It is associated with increased mortality, morbidity and length of hospital stay in patients presenting with a range of conditions. Hyponatraemia is therefore 
both common and important.
Despite this, the management of patients remains problematic. The prevalence of hy-
ponatraemia under widely different conditions and the fact that hyponatraemia is man-
aged by clinicians with a broad variety of backgrounds have fostered diverse institution- and 
speciality-based approaches to diagnosis and treatment. However, the paucity of well-de-
signed, prospective studies in the field has limited the evidence-base to these approaches. 
Previous guidance has often been based on experience or practice, without a systematic 
approach to evaluation and lacking a clear, patient-centred focus. Clinicians using previous 
guidance may have noted a number of problems:
It has been difficult to follow the guidance in day-to-day clinical practice, especially by 
doctors in training who are managing patients in the ‘front line’. Here, the requirement is for 
clear, concise and practical advice on what has to be done, including during the critical ‘out-
of-office hours’ period. Complex diagnostic algorithms and time-consuming investigations 
are real barriers to implementation in this context.
The guidance has been over-simplistic and does not reflect the range of clinical prob-
lems encountered in day-to-day practice.
The guidance has been limited by a diagnosis-, mechanism- or duration-based approach 
to treatment, failing to recognise that establishing the diagnosis, mechanism or duration of 
hyponatraemia may be difficult. Previous guidance has mostly used duration of hyponatrae-
mia as a key point on which to base management. Yet, duration can be hard to establish, 
especially in emergency settings. Decisions often have to be made on limited information.
The guidance has demonstrated an institutional or specialty-specific bias, limiting imple-
mentation across sites and clinical disciplines. This is best demonstrated in institution- or 
speciality-specific approaches to investigations.
The guidance has used a biochemical focus, failing to prioritise clinical status in decisions 
on treatment options. Clinicians know that the degree of biochemical hyponatraemia does 
not always match the clinical state of the patient. Guidance that bases management advice 
simply on the serum sodium concentration may be counter to clinical experience, risking 
credibility and engagement.
Together, these factors have limited the utility of previous advice. Two emerging themes 
require that we revisit the area:
• The clear recognition of the importance of evidence-based approaches to patient care 
to enhance quality, improve safety and establish a clear and transparent framework for 
service development and healthcare provision.
• The advent of new diagnostics and therapeutics, highlighting the need for a valid, reli-
able and transparent process of evaluation to support key decisions.
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To obtain a common and holistic view, the European Society of Intensive Care Medicine 
(ESICM), the European Society of Endocrinology (ESE) and the European Renal Association–
European Dialysis and Transplant Association (ERA–EDTA), represented by European Renal 
Best Practice (ERBP), have developed new guidance on the diagnostic approach and treat-
ment of hyponatraemia. In addition to a rigorous approach to methodology and evaluation, 
we were keen to ensure that the document focused on patient-important outcomes and 
included utility for clinicians involved in everyday practice.
Composition of the guideline development group
A steering committee with representatives of all the three societies convened in October 
2010 and decided on the composition of the Guideline Development Group, taking into ac-
count the clinical and research expertise of each proposed candidate.
Guideline development group co-chairs
• Goce Spasovski
Consultant Nephrologist, State University Hospital Skopje, Skopje, Macedonia.
• Raymond Vanholder
Consultant Nephrologist, Ghent University Hospital, Ghent, Belgium.
Work Group
• Bruno Allolio
Consultant Endocrinologist, Würzburg University Hospital, Würzburg, Germany.
• Djillali Annane
Consultant Intensivist, Raymond Poincaré Hospital, University of Versailles Saint Quentin, 
Paris, France.
• Steve Ball
Consultant Endocrinologist, Newcastle Hospitals and Newcastle University, Newcastle, 
UK.
• Daniel Bichet
Consultant Nephrologist, Hospital, Montreal, Canada.
• Guy Decaux
Consultant Internal Medicine, Erasmus University Hospital, Brussels, Belgium.
• Wiebke Fenske
Consultant Endocrinologist, Würzburg University Hospital, Würzburg, Germany.
• Ewout Hoorn
Consultant Nephrologist, Erasmus Medical Centre, Rotterdam, The Netherlands.
• Carole Ichai
Consultant Intensivist, Nice University Hospital, Nice, France.
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• Michael Joannidis
Consultant Intensivist, Innsbruck University Hospital, Innsbruck, Austria.
• Alain Soupart
Consultant Internal Medicine, Erasmus University Hospital, Brussels, Belgium.
• Robert Zietse
Consultant Nephrologist, Erasmus Medical Centre, Rotterdam, The Netherlands.
ERBP methods support team
• Maria Haller
Specialist Registrar Nephrology, KH Elisabethinen Linz, Linz, Austria.
• Evi Nagler
Specialist Registrar Nephrology, Ghent University Hospital, Ghent, Belgium.
• Wim Van Biesen
Consultant Nephrologist, Chair of ERBP, Ghent University Hospital, Belgium.
• Sabine van der Veer
Implementation Specialist, Amsterdam Medical Centre, Amsterdam, The Netherlands.
Purpose and scope of this guideline
Why was this guideline produced?
The purpose of this Clinical Practice Guideline was to provide guidance on the diagnosis 
and treatment of adult individuals with hypotonic hyponatraemia. It was designed to pro-
vide information and assist in decision-making related to this topic. It was not intended to 
define a standard of care and should not be construed as one. It should not be interpreted 
as prescribing an exclusive course of management.
This guideline was developed as a joint venture of three societies representing special-
ists with a natural interest in hyponatraemia: the ESICM, the ESE and the ERA–EDTA, repre-
sented by ERBP.
All three societies agreed that there was a need for guidance on diagnostic assessment 
and therapeutic management of hyponatraemia. A recent systematic review, which includ-
ed three clinical practice guidelines and five consensus statements, confirmed the lack of 
high-quality guidelines in this field [1]. The guidance documents scored low to moderate in 
the six domains of the AGREEII tool – scope and purpose, stakeholder involvement, rigour 
of development, clarity of presentation, applicability and editorial independence – and the 
management strategies proposed in the different guidance documents were sometimes 
contradictory [2].
Who is this guideline for?
This guideline was meant to support clinical decision-making for any healthcare profes-
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sional dealing with hyponatraemia, i.e. general practitioners, internists, surgeons and other 
physicians dealing with hyponatraemia in both an outpatient and an in-hospital setting. 
The guideline was also developed for policymakers for informing standards of care and for 
supporting the decision-making process.
What is this guideline about?
This section defines what this guideline intended to cover and what the guideline devel-
opers considered. The scope was determined at a first meeting held in Barcelona in October 
2010 with representatives of ESICM, ESE and ERBP present.
Population
The guideline covers hyponatraemia in adults through the biochemical analysis of a 
blood sample. It does not cover hyponatraemia detected in children because the guideline 
development group judged that hyponatraemia in children represented a specific area of 
expertise. The guideline also does not cover screening for hyponatraemia.
Conditions
The guideline specifically covers diagnosis and management of true hypotonic hy-
ponatraemia. It covers the differentiation of hypotonic hyponatraemia from non-hypotonic 
hyponatraemia but does not deal with the specific diagnostic and therapeutic peculiarities 
in the setting of pseudo-hyponatraemia, isotonic or hypertonic hyponatraemia. These situ-
ations are not associated with the hypotonic state responsible for the majority of symptoms 
attributable to true hypotonic hyponatraemia. The guideline covers diagnosis and manage-
ment of both acute and chronic hypotonic hyponatraemia in case of reduced, normal and 
increased extracellular fluid volume. It does not cover the diagnosis or treatment of the 
underlying conditions that can be associated with hypotonic hyponatraemia.
Healthcare setting
This guideline targets primary, secondary and tertiary settings dealing with diagnostic 
testing and the management of hyponatraemia in adults.
Clinical management
This guideline deals with diagnostic tools for improving accuracy of the differential diag-
nosis of hypotonic hyponatraemia, allowing more specific treatment strategies tailored to 
the underlying cause and/or pathophysiological mechanism.
This guideline covers the treatment for adults with acute or chronic, symptomatic or 
asymptomatic hypotonic hyponatraemia, regardless of the underlying condition.
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Methods for guideline development
Establishment of the guideline development group
The councils of the three participating societies, ESICM, ESE and ERBP, selected the co-
chairs of the guideline development group. The co-chairs then assembled the steering com-
mittee with representatives of the three societies involved in this joint venture. This steering 
committee convened in October 2010 and decided on the composition of the guideline 
development group, taking into account the clinical and research expertise of the proposed 
candidates. The guideline development group consisted of content experts, which includ-
ed individuals with expertise in hyponatraemia, endocrinology, general internal medicine, 
intensive care medicine and clinical nephrology as well as an expert in systematic review 
methodology. The ERBP methods support team provided methodological input and practi-
cal assistance throughout the guideline development process.
Developing clinical questions
From the final scope of the guideline, specific research questions, for which a systematic 
review would be conducted, were identified.
Diagnosis and differential diagnosis of hypotonic hyponatraemia
• In patients with hypotonic hyponatraemia, how accurate are various ‘diagnostic strate-
gies’ in comparison with a reference test of infusing 2 l 0.9% sodium chloride solution for 
differentiating hypovolaemic from euvolaemic hyponatraemia?
• In patients with hypotonic hyponatraemia, how accurate are various ‘diagnostic strat-
egies’ in comparison with a reference test of expert panel diagnosis in differentiating 
hypovolaemic from euvolaemic hyponatraemia?
Acute and chronic treatment of hypotonic hyponatraemia
• In patients with hypotonic hyponatraemia, which treatments are effective in improving 
outcomes?
• In patients with hypotonic hyponatraemia, does the change in serum sodium concentra-
tion per unit time influence outcomes?
Development of review questions
The methods support team assisted in developing review questions, i.e. framing the 
clinical questions into a searchable format. This required careful specification of the patient 
group (P), the intervention (I), the comparator (C) and the outcomes (O) for intervention 
questions and the patient group, index tests, reference standard and target condition for 
questions of diagnostic test accuracy [3]. For each question, the guideline development 
group agreed on explicit review question criteria including study design features (See Ap-
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pendices 1 and 2 for Detailed Review Questions and PICO tables. See section on Appen-
dix given at the end of this article).
Assessment of the relative importance of the outcomes
For each intervention question, the guideline development group compiled a list of 
outcomes, reflecting both benefits and harms of alternative management strategies. The 
guideline development group ranked the outcomes as critically, highly or moderately im-
portant according to their relative importance in the decision-making process. As such, 
patient-important health outcomes related to hyponatraemia and the treatment for hy-
ponatraemia were considered critical. Owing to its surrogate nature, the outcomes ‘change 
in serum sodium concentration’ and ‘correction of serum sodium concentration’ were con-
sidered less important than the critically and highly important clinical outcomes (Table 7.1).
 Table 7.1. Hierarchy of outcomes.
Hiera rchy Outcomes
Critically important Patient survival
Coma
Brain damage/brain oedema
Epileptic seizures
Osmotic demyelinating syndrome
Respiratory arrest
Quality of life
Cognitive function
Highly important Bone fractures
Falls
Length of hospital stay
Moderately important Serum sodium concentration
Target population perspectives
An effort was taken to capture the target population’s perspectives by adopting two 
strategies. First, ERBP has a permanent patient representative in its board. Although he was 
not included in the guideline development group or in the evidence review process, drafts 
of the guideline document were sent for his review and his comments were taken into ac-
count in revising and drafting the final document.
Secondly, the guideline underwent public review before publication. The guideline was 
sent to the council of two different societies for each specialty involved: for ESICM, the Aus-
tralian and New Zealand Intensive Care Society (ANZICS) and American Society of Critical 
Care Medicine (SSCM); for ESE, the Endocrine Society of Australia (ESA) and the Endocrine 
Society (USA); and for ERBP, the Kidney Health Australia–Caring for Australasians with Renal 
Impairment (KHA–CARI) and the American Society of Nephrology (ASN). Each of these soci-
eties was specifically asked to indicate two to three reviewers. Reviewers could use free text 
to suggest amendments and/or fill in a matrix questionnaire in Microsoft Excel. All members 
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of the ERA–EDTA received an online questionnaire with a standardised answer form in Mi-
crosoft Excel. ERA–EDTA members were asked to express to what extent they judged the 
individual statements were clear and implementable and to what extent they agreed with 
the content. In addition, a free text field was provided to allow for additional comments.
Searching for evidence
Sources
The ERBP methods support team searched The Cochrane Database of Systematic Re-
views (May 2011), DARE (May 2011), CENTRAL (May 2011) and MEDLINE (1946 to May, week 
4, 2011) for questions on both diagnosis and treatment. To identify the limits for the in-
crease in serum sodium concentration above which the risk of osmotic demyelination starts 
to rise, we searched MEDLINE database from 1997 onwards under the assumption that ear-
lier reports would describe more dramatic increases and would not contribute to helping 
us set an upper limit. All searches were updated on 10th December 2012. The search strate-
gies combined subject headings and text words for the patient population, index test and 
target condition for the diagnostic questions and subject headings and text words for the 
population and intervention for the intervention questions. The detailed search strategies 
are available in Appendix 3, see section titled Appendix given at the end of this article.
Reference lists from included publications were screened to identify additional papers. 
The methods support team also searched guideline databases and organisations including 
the National Guideline Clearinghouse, Guidelines International Network, Guidelines Finder, 
Centre for Reviews and Dissemination, National Institute for Clinical Excellence, and profes-
sional societies of Nephrology, Endocrinology and Intensive Care Medicine for guidelines to 
screen the reference lists.
Selection
For diagnostic questions, we included every study that compared any of the predefined 
clinical or biochemical tests with infusion of 2 l 0.9% saline as a reference test or with an ex-
pert panel for differentiating hypovolaemic from euvolaemic hyponatraemia. For questions 
on treatment strategies, we included every study in which one of the predefined medi-
cations was evaluated in humans. We excluded case series that reported on benefit if the 
number of participants was ≤5 but included even individual case reports if they reported 
an adverse event. No restriction was made based on language. For identifying the limits for 
the increase in serum sodium concentration above which the risk of osmotic demyelination 
starts to rise, we included all observational studies reporting cases of osmotic demyelinat-
ing syndrome and corresponding serum sodium concentration correction speeds.
A member of the ERBP methods support team screened all titles and abstracts to discard 
the clearly irrelevant ones. All members of the guideline development group completed a 
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second screening. All abstracts that did not meet the inclusion criteria were discarded. Any 
discrepancies at this stage were resolved by group consensus.
The methods support team retrieved full texts of potentially relevant studies and two 
reviewers examined them for eligibility independently of each other. The reviewer duos 
always consisted of one content specialist and one methodologist from the ERBP meth-
ods support team. Any discrepancies were resolved by consensus. If no consensus could be 
reached, the disagreement was settled by group arbitrage.
Data extraction and critical appraisal of individual studies
For each included study, we collected relevant information on design, conduct and rel-
evant results through standardised data extraction forms in Microsoft Excel (2010). As part 
of an ongoing process of introducing software to facilitate the guideline development pro-
cess, the ERBP methods support team used two formats for data extraction and collation. 
For detailed methods, see Appendices 4 and 5, see section titled Appendix given at the end 
of this article. Briefly, we used both a simple spreadsheet format and a more sophisticated 
version, which incorporated user forms programmed in Visual Basic. For each question, two 
reviewers extracted all data independently of each other. We produced tables displaying 
the data extraction of both reviewers. Both reviewers checked all data independently of 
each other. Any discrepancies were resolved by consensus and if no consensus could be 
reached, disagreements were resolved by an independent referee. From these tables, we 
produced merged consensus evidence tables for informing the recommendations. The evi-
dence tables are available in Appendices 6 and 7, see section titled Appendix given at the 
end of this article.
Risk of bias of the included studies was evaluated using various validated checklists, as 
recommended by the Cochrane Collaboration. These were AMSTAR for Systematic Reviews 
[4], the Cochrane Risk of Bias tool for randomised controlled trials [5], the Newcastle Ottawa 
scale for cohort and case–control studies [6] and QUADAS for diagnostic test accuracy stud-
ies [7]. Data were compiled centrally by the ERBP methods support team.
Evidence profiles
The evidence for outcomes on therapeutic interventions from included systematic re-
views and randomised controlled trials was presented using the ‘Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the 
international GRADE working group (http://www.gradeworkinggroup.org/). The evidence 
profiles include details of the quality assessment as well as summary – pooled or un-pooled 
– outcome data, an absolute measure of intervention effect when appropriate and the sum-
mary of quality of evidence for each outcome. Evidence profiles were constructed by the 
methods support team and reviewed and confirmed with the rest of the guideline devel-
opment group. Evidence profiles were constructed for research questions addressed by at 
least two randomised controlled trials. If the body of evidence for a particular comparison 
of interest consisted of only one randomised controlled trial or of solely observational data, 
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the summary tables provided the final level of synthesis.
Rating the quality of the evidence for each outcome across studies
In accordance with GRADE, the guideline development group initially categorised the 
quality of the evidence for each outcome as high if it originated predominantly from ran-
domised controlled trials and low if it originated from observational data. We subsequently 
downgraded the quality of the evidence one or two levels if results from individual studies 
were at serious or very serious risk of bias, there were serious inconsistencies in the results 
across studies, the evidence was indirect, the data were sparse or imprecise or publication 
bias thought to be likely. If evidence arose from observational data, but effect sizes were 
large, there was evidence of a dose–response gradient or all plausible confounding would 
either reduce a demonstrated effect or suggest a spurious effect when results showed no 
effect, we would upgrade the quality of the evidence (Table 7.2). Uncontrolled case series 
and case reports automatically received downgrading from low to very low level of evi-
dence for risk of bias, so that no other reasons for downgrading were marked. By repeating 
this procedure, we would obtain an overall quality of the evidence for each outcome and 
each intervention. For list of definitions, see Table 7.3.
 Table 7.2. Method of rating the quality of the evidence.
Step 1: Starting grade 
according to study design
Step 2: Lower if Step 3: Higher  if Step 4: determine final 
grade for quality of 
evidence
Randomized trials= High
Observational Studies= Low
Risk of Bias
-1 Serious   -2 Very Serious 
Inconsistency
-1 Serious  -2 Very Serious
Indirectness
-1 Serious  -2 Very Serious
Imprecision
-1 Serious  -2 Very Serious
Publication Bias
-1 Likely     -2 Very likely
Large effect
+1 Large
+2 Very Large
Dose response
+1 Evidence of a gradient
All plausible confounding
+1 Would reduce a 
demonstrated effect
+1 Would suggest a 
spurious effect when 
results show no effect
High (four plus: ++++)
Moderate (three plus: +++)
Low (two plus: ++)
Very Low (one plus: +)
Adapted from Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, et al. 
 Table 7.3. Grade for the overall quality of evidence.
Grade Quality Level Definition
A High We are confident that the true effects lies close to that of the estimates of the effect
B Moderate The true effects are likely to be close to the estimates of the effects, but there is a pos-
sibility that they are substantially different
C Low The true effects might be substantially different from the estimates of effects
D Very low The estimates are very uncertain, and often will be far from the truth.
 Adapted from Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ & GRADE Working Group. 
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 336 924–926.
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Formulating statements and grading recommendations
Recommendations
After the summary tables were produced and evidence profiles had been prepared, re-
vised and approved by the guideline development group, two full-weekend plenary meet-
ings were held in September 2012 and December 2012 to formulate and grade the recom-
mendations.
Recommendations can be for or against a certain strategy. The guideline development 
group drafted the recommendations based on their interpretation of the available evi-
dence. Judgements around four key factors determined the strength of a recommendation: 
the balance between desirable and undesirable consequences of alternative therapeutic or 
diagnostic strategies, the quality of the evidence, the variability in values and preferences. 
We did not conduct formal decision or cost analysis. In accordance to GRADE, we classified 
the strength of the recommendations as strong, coded ‘1’ or weak, coded ‘2’ (Table 7.4; Fig-
ure 7.1) [8]. Individual statements were made and discussed in an attempt to reach group 
consensus. If we could not reach consensus, we held a formal open vote by show of hands. 
 Table 7.4. Implications of strong and weak recommendations for stakeholders.
Implications
Grade Patients Clinicians Policy
1 - STRONG
‘We recommend’
Most people in your situation 
would want the  recommended 
course of action, only a small 
proportion would not
Most patients should receive the 
recommended course of action
The recommendation can 
be adopted a as policy in 
most situations
2 - WEAK
‘We suggest’
Most people in your situation 
would want the recommended 
course of action, but many would 
not
You should recognise that 
different choices will be 
appropriate for different patients
You must help each patient to 
arrive at a management decision 
consistent with her or his values 
and preferences. 
Policy making will require 
substantial debate and 
involvement of many 
stakeholders 
Adapted from Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati 
A, Schünemann HJ & GRADE Working Group. Going from evidence to 
recommendations. BMJ 2008 336 1049–1051. The additional category ‘Not 
Graded’ was used, typically, to provide guidance based on common sense 
or where the topic does not allow adequate application of evidence. The 
most common examples include recommendations regarding monitoring 
intervals, counselling and referral to other clinical specialists. The ungraded 
recommendations are generally written as simple declarative statements but are 
not meant to be interpreted as being stronger recommendations than level 1 or 
2 recommendations. 
Figure 7.1. Grade system for grading recommendations.
Adapted from Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello 
P, Schünemann HJ & GRADE Working Group. GRADE: an emerging consensus 
on rating quality of evidence and strength of recommendations. BMJ 2008 336 
924–926. [8] 
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An arbitrary 80% had to cast a positive vote for a statement to be accepted. Voting results 
and reasons for disagreement were specified in the rationale.
Ungraded statements and advice for clinical practice
We decided to use an additional category of ungraded statements for areas where formal 
evidence was not sought and statements were based on common sense or expert experi-
ence alone. They were termed ‘statement’ to differentiate them from graded recommenda-
tions and do not hold an indicator for the quality of the evidence. The ungraded statements 
were generally written as simple declarative statements but were not meant to be stronger 
than level 1 or 2 recommendations.
We also provided additional advice for clinical practice. The advice is not graded and 
is only for the purpose of improving practical implementation. It contains some elabora-
tion on one of the statements, clarifying how the statement can be implemented in clinical 
practice.
Optimizing implementation
Recommendations often fail to reach implementation in clinical practice partly because 
of their wording. As part of a research project to evaluate methods for improving guideline 
development processes, we integrated the GuideLine Implementability Appraisal (GLIA) in-
strument to optimise the wording of the recommendations [9]. The tool primarily enables 
structured evaluation of factors such as executability (is it clear from the statement exactly 
what to do) and decidability (exactly under what conditions) of preliminary recommenda-
tions. In addition, the tool is designed to highlight other problems possibly hindering im-
plementation, e.g. recommendations being inconsistent with clinicians’ existing beliefs or 
patients’ expectations. The appraisal was done by a panel of target guideline users external 
to the guideline development group. Comments and remarks were communicated to the 
guideline development group and used to help refine the recommendations.
Writing rationale
We collated recommendations and ungraded statements for each of the clinical ques-
tions in separate sections structured according to a specific format. Each question resulted 
in one or more specific boxed statements. Within each recommendation, the strength was 
indicated as level 1 or 2 and the quality of the supporting evidence as A, B, C or D as pre-
scribed by the GRADE methodology (Table 7.4).
These statements are followed by advice for clinical practice where relevant and the 
rationale. The rationale contains a brief section on ‘why this question’ with relevant back-
ground and justification of the topic, followed by a short narrative review of the evidence 
in ‘what did we find’ and finally a justification of how the evidence translated in the recom-
mendations made in ‘how did we translate the evidence into the statement’.
When areas of uncertainty were identified, the guideline development group considered 
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making suggestions for future research based on the importance to patients or the popula-
tion and on ethical and technical feasibility.
Internal and external review
Internal review
A first draft of the guideline was sent to a selected group of internal reviewers. Each 
society nominated experts in hyponatraemia and/or members of their governance body. 
Internal reviewers were asked to complete a grid-based evaluation of overall appreciation 
of each individual statement, using a score between 1 and 5. These scores were averaged 
and colour-coded between red [1] and green [5] to help visualise any problematic part. In 
addition, internal reviewers were asked to comment on the statements and the rationale 
within free text fields limited to 225 characters. All these comments and suggestions were 
discussed during an additional meeting of the guideline development group in June 2013. 
For each comment or suggestion, the guideline development group evaluated whether it 
was needed to adapt the statement, again taking into account the balance between desir-
able and undesirable consequences of the alternative management strategies, the quality 
of the evidence and the variability in values and preferences.
External review
The guideline was sent to the ESA and KHA–CARI for review. Reviewers could use free 
text to suggest amendments and/or fill in a matrix questionnaire in Microsoft Excel. In ad-
dition, all members of the ERA–EDTA received an online questionnaire with a standardised 
answer form in Microsoft Excel. ERA–EDTA members were asked to express to what extent 
they believed the individual statements were clear, implementable and to what extent they 
agreed with the content on a scale from 1 to 5. In addition, a free text field was provided to 
allow for additional comments. All these valid comments and suggestions were discussed 
with the guideline development group through e-mail and during a final meeting of the 
co-chairs of the guideline development group, the methods support team and the chair of 
ERBP.
Timeline and procedure for updating the guideline
It was decided to update the guideline at least every 5 years. New evidence requiring 
additional recommendations or changes to existing statements could instigate an earlier 
update.
At least every 5 years, the ERBP methods support team will update its literature searches. 
Relevant studies will be identified and their data will be extracted using the same procedure 
as for the initial guideline. During a 1-day meeting, the guideline development group will 
decide whether or not the original statements require updating. An updated version of the 
guideline will be published online accompanied by a position statement in the journals of 
the three societies describing the changes made.
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During the 5-year interval, the guideline development group co-chairs will notify the 
ERBP chair of new information that may justify changes to the existing guideline. Together, 
they will consult at least one guideline development group member representing each of 
the collaborating societies. If they decide that an update is needed, an updated version of 
the guideline will be produced using the same procedures as for the initial guideline.
Pathophysiology of hyponatraemia
Introduction
Hyponatraemia, defined as a serum sodium concentration <135 mmol/l, is the most 
common disorder of body fluid and electrolyte balance encountered in clinical practice. 
It occurs in up to 30% of hospitalised patients and can lead to a wide spectrum of clinical 
symptoms, from subtle to severe or even life threatening [10, 11]. Because hyponatraemia 
can result from a varied spectrum of conditions, based on different mechanisms, we be-
lieved that it would be useful to include an introductory section that outlines some of the 
pathophysiological principles encountered in hyponatraemia. It was not intended to be a 
detailed reference section. It was only meant to clarify some of the important concepts to 
enhance understanding of the rationale of the statements in the guideline.
Hyponatraemia is primarily a disorder of water balance, with a relative excess of body 
water compared to total body sodium and potassium content. It is usually associated with 
a disturbance in the hormone that governs water balance, vasopressin (also called antidiu-
retic hormone). Even in disorders associated with (renal) sodium loss, vasopressin activity is 
generally required for hyponatraemia to develop. Therefore, after describing common signs 
and symptoms, we detail the mechanisms involved in vasopressin release.
Changes in serum osmolality are primarily determined by changes in the serum concen-
tration of sodium and its associated anions. It is important to differentiate the concepts of 
total osmolality and effective osmolality or tonicity. Total osmolality is defined as the con-
centration of all solutes in a given weight of water (mOsm/kg), regardless of whether or not 
the osmoles can move across biological membranes. Effective osmolality or tonicity refers 
to the number of osmoles that contribute water movement between the intracellular and 
extracellular compartment. It is a function of the relative solute permeability properties of 
the membranes separating the intracellular and extracellular fluid compartments [12]. Only 
effective solutes create osmotic pressure gradients across cell membranes leading to os-
motic movement of water between the intracellular and extracellular fluid compartment. In 
most cases, hyponatraemia reflects low effective osmolality or hypotonicity, which causes 
symptoms of cellular oedema. However, hyponatraemia may also (rarely) occur with iso-
tonic or hypertonic serum if the serum contains many additional osmoles, such as glucose 
or mannitol. Therefore, we discuss not only how hypo-osmolar but also how isosmolar and 
hyperosmolar states develop.
Finally, we review the pathophysiology of distinct clinical disorders that can cause hy-
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ponatraemia. We have categorised the causes of hyponatraemia in those associated with a 
reduced, normal or increased extracellular fluid volume. Although the clinical assessment 
of volume status is often difficult in practice, the concept of volume status has proven use-
ful because it provides a simple framework to understand the diagnosis and treatment of 
hypo-osmolar disorders.
Clinical features
Symptoms can vary from mild, non-specific to severe and life-threatening (Table 7.5). 
Severe symptoms of hyponatraemia are caused by brain oedema and increased intracranial 
pressure. Brain cells start to swell when water moves from the extracellular to the intra-
cellular compartment because of a difference in effective osmolality between brain and 
plasma. This usually occurs when hyponatraemia develops rapidly, and the brain has had 
too little time to adapt to its hypotonic environment. Over time, the brain reduces the num-
ber of osmotically active particles within its cells (mostly potassium and organic solutes) 
in an attempt to restore the brain volume (Figure 7.2). This process takes ∼24–48 h, hence 
the reason for using the 48-h threshold to distinguish acute (<48 h) from chronic (≥48 h) 
hyponatraemia.
Although the more severe signs of acute hyponatraemia are well established, it is now 
increasingly clear that even patients with chronic hyponatraemia and no apparent symp-
toms can have subtle clinical abnormalities when analysed in more detail. Such abnormali-
ties include gait disturbances, falls, concentration and cognitive deficits [13]. In addition, 
patients with chronic hyponatraemia more often have osteoporosis and more frequently 
 Table 7.5. Classification of symptoms of hyponatraemia.
Severity Symptom
Moderately severe Nausea without vomiting
 Confusion
 Headache
Severe Vomiting
 Cardio-respiratory distress
 Abnormal and deep somnolence
 Seizures 
 Coma (Glasgow Coma Scale ≤ 8)
The guideline development group wants to underscore that these symptoms can also be induced by other 
conditions. Clinical and anamnestic data should be taken into account when assessing the causal relation 
between the hyponatraemia and a certain symptom (i.e. to assess whether the symptom has been caused by 
the hyponatraemia or the hyponatraemia by the underlying condition/symptom). The less pronounced (e.g. 
mild) the biochemical degree of hyponatraemia, the more caution should be taken when considering that the 
hyponatraemia is the cause of the symptoms. 
This list is not exhaustive, and all symptoms that can be signs of cerebral oedema should be considered as severe 
or moderate symptoms that can be caused by hyponatraemia. 
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sustain bone fractures than normonatraemic persons [14, 15, 16]. Finally, hyponatraemia is 
associated with an increased risk of death [17, 18]. Whether these are causal associations or 
merely symptoms of underlying problems such as heart or liver failure remains unclear [19].
Regulation of water intake and homeostasis
As the serum sodium concentration is determined by the amount of extracellular water 
relative to the amount of sodium, it can be regulated by changing intake or output of water. 
The major mechanisms responsible for regulating water metabolism are thirst and the pitui-
tary secretion and renal effects of vasopressin. Regulation of body water serves to minimise 
osmotically induced disruptions in cell volume with adverse effects on multiple cellular 
functions. Osmoreceptive neurons located in the anterior hypothalamus detect changes 
in cell stretch due to changes in systemic effective osmolality. A decrease in cell stretch 
increases the firing rate of osmoreceptive neurons, which leads to both increased thirst and 
increased release of vasopressin from the pituitary gland. Vasopressin in turn increases the 
re-absorption of water from the primitive urine in the distal tubules of the nephron, which 
leads to urine that is more concentrated. To prevent persistent thirst, the threshold for re-
Figure 7.2. Adaptation of the brain to hypotonicity.
Reproduced with permission from Massachusetts Medical Society, Copyright © 2000 Adrogue HJ & Madias NE. 
Hyponatremia. New England Journal of Medicine 2000 342 1581–1589. 
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leasing vasopressin is lower than that for triggering thirst (Figure 7.3) [12].
Osmoregulation and vasopressin release
Under normal circumstances, osmotic regulation of the release of vasopressin from the 
posterior pituitary primarily depends on the effective osmolality of the serum. Central os-
moreceptors, expressing transient receptor potential vanilloid 1 (TRPV1), and peripheral 
osmoreceptors, expressing TRPV4, relay the information on osmolality [20, 21]. The stretch-
inactivating cationic TRPV1 and TRPV4 channels transduce osmotically evoked changes in 
cell volume into functionally relevant changes in membrane potential. TRPV1 is an osmoti-
cally activated channel expressed in the vasopressin producing magnocellular cells and in 
the circumventricular organs [22, 23]. Recently, afferent neurons expressing the osmotically 
activated ion channel TRPV4 (able to detect physiological hypo-osmotic shifts in blood os-
molality) have been identified in the thoracic dorsal root ganglia, which innervate hepatic 
blood vessels [21].
Figure 7.3. Osmotic stimulation of vasopressin release.
Schematic representation of normal physiological relationships among plasma osmolality, plasma AVP concentrations, urine 
osmolality and urine volume in man. Note particularly the inverse nature of the relationship between urine osmolality and 
urine volume, resulting in disproportionate effects of small changes in plasma AVP concentrations on urine volume at lower 
AVP levels. Reproduced with permission from Elsevier Copyright © 2003 Verbalis JG. Disorders of body water homeostasis. 
Best Practice & Research. Clinical Endocrinology & Metabolism 2003 17 471–503.
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Baroregulation of vasopressin release
Stretch-sensitive receptors in the left atrium, carotid sinus and aortic arch sense circulat-
ing volume. When the circulating volume is increased, afferent neural impulses inhibit the 
secretion of vasopressin [12]. Conversely, when the volume is decreased, the discharge rate 
of the stretch receptors slows and vasopressin secretion increases [24]. Reductions in blood 
pressure as little as 5% increase the serum vasopressin concentration [25]. In addition, there 
seems to be an exponential association between the serum vasopressin concentration and 
the percentage decline in mean arterial blood pressure, with faster increases as blood pres-
sure progressively decreases.
Because osmoregulated and baroregulated vasopressin secretion are interdependent, 
renal water excretion can be maintained around a lower set point of osmolality under con-
ditions of moderately decreased circulating volume [26]. As the circulatory hypovolaemia 
worsens, the serum vasopressin concentration dramatically increases and baroregulation 
overrides the osmoregulatory system.
Osmosensitive neurons are located in the subfornical organ and the organum vasculo-
sum of the lamina terminalis. Because these neurons lie outside the blood–brain barrier, 
they integrate osmotic information with endocrine signals borne by circulating hormones, 
such as angiotensin II and atrial natriuretic peptide. The direct angiotensin II effect on os-
moregulatory neurons has been termed ‘osmoregulatory gain’ since Zhang et al. [27] have 
shown that in rats, angiotensin II amplifies osmosensory transduction by enhancing the 
proportional relationship between osmolality, receptor potential and action potential firing 
in supra-optic nucleus neurons. Modifications in osmoregulatory gain induced by angioten-
sin, together with changes in vasopressin secretion induced by baroregulation (see below), 
may explain why the changes in the slope and threshold of the relationship between serum 
osmolality and vasopressin secretion are potentiated by hypovolaemia or hypotension and 
are attenuated by hypervolaemia or hypertension (Figure 7.4) [28].
Figure 7.4. Effects of hypovolaemia on osmoreceptor gain.
Reproduced with permission from The Endocrine Society Copyright © 1976 Robertson GL & Athar S. The interaction 
of blood osmolality and blood volume in regulating plasma vasopressin in man. Journal of Clinical Endocrinology and 
Metabolism 1976 42 613–620.

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Unregulated vasopressin release
The posterior pituitary is the only organ in which regulated vasopressin release takes 
place. Under pathological conditions, both pituitary and other cells may also synthesise 
and secrete vasopressin independent of serum osmolality or circulating volume. Origi-
nally, Schwartz & Bartter [29] introduced the term syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) as an overarching term. We now know that both genetic and 
pharmacological factors can also increase water permeability in the collecting duct in the 
absence of vasopressin. Others have previously introduced the term syndrome of inappro-
priate antidiuresis (SIAD) to cover both situations. We will use it throughout this text.
Renal actions of vasopressin
In order to re-absorb water from the collecting duct, and to concentrate the urine, the 
collecting duct must become permeable to water. The basolateral membrane is always per-
meable to water because of aquaporin-3 and aquaporin-4 water channels. Vasopressin reg-
ulates the permeability of the apical membrane by insertion of aquaporin-2 water channels 
through vasopressin-2-receptor activation. The high osmolality of the medulla provides 
the driving force needed for re-absorption of water from the collecting duct. Thanks to the 
counter current configuration of the loops of Henle, the kidney is able to create solute gra-
dients from the cortex to the inner medulla. Because of the re-absorption of both sodium 
and urea from the lumen, the osmolality of the tip of the medulla may reach 1200 mOsm/l 
in case of water depletion. The medullary osmolality determines maximum urine osmolality 
and is influenced by vasopressin.
Pseudohyponatraemia
Pseudohyponatraemia is a laboratory artefact that occurs when abnormally high con-
centrations of lipids or proteins in the blood interfere with the accurate measurement of 
sodium. Pseudohyponatraemia was seen more frequently with flame photometric meas-
urement of serum sodium concentration than it is now with ion-selective electrodes, but 
despite common opinion to the contrary, it still occurs [30], because all venous blood sam-
ples are diluted and a constant distribution between water and the solid phase of serum is 
assumed when the serum sodium concentration is calculated [30] (Figure 7.5). Serum os-
molality is measured in an undiluted sample and the result will be within the normal range 
in case of pseudohyponatraemia. If the measurement of serum osmolality is not available, 
direct potentiometry using a blood gas analyser will yield the true sodium concentration, as 
this measures the sodium concentration in an undiluted sample too.
Reset osmostat
In reset osmostat, there is a change in the set point as well as in the slope of the osmoreg-
ulation curve [12]. The response to changes in osmolality remains intact. We see this phe-
nomenon, for example, in pregnancy where the serum sodium concentration may mildly 
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decrease 4–5 mmol/l.
Non-hypotonic hyponatraemia
Isotonic hyponatraemia
In the majority of patients that present with hyponatraemia, the serum is hypotonic, i.e. 
both the sodium concentration and the effective osmolality are low. Sometimes, the se-
rum contains additional osmoles that increase effective osmolality and reduce the serum 
sodium concentration by attracting water from the intracellular compartment. Examples 
of such osmoles include glucose (hyperglycaemia due to uncontrolled diabetes mellitus), 
mannitol and glycine (absorption of irrigation fluids during urological or gynaecological 
surgery) [31, 32, 33]. The resulting ‘translocational’ hyponatraemia is often wrongly consid-
ered a form of pseudohyponatraemia. However, as described earlier, in pseudohyponatrae-
mia, serum osmolality is normal and no shifts of water occur.
Hypertonic hyponatraemia
In hyperglycaemia-induced hyponatraemia, hyponatraemia is caused by dilution due to 
hyperosmolality. It is important to make the distinction between measured osmolality and 
effective osmolality [34].
Effective osmolality may be calculated with the following equations:
Figure 7.5. Pseudohyponatraemia.
Normally, serum contains 7% solids by volume. In order to reduce the volume of blood needed for analysis, serum is 
frequently diluted before the actual measurement is obtained. The same volume of diluent is always used; the degree 
of dilution is estimated under the assumption that the serum contains 7% solid-phase particles. When the fraction of 
solid-phase particles is increased, the same amount of diluent results in a greater dilution, unbeknownst to the laboratory 
personnel (right side of figure). Consequently, the calculation of an ion level with the use of a degree of dilution that is 
based on the incorrect fraction of solid-phase particles will lead to an underestimate. Reproduced with permission from 
Massachusetts Medical Society Copyright © 2003 Turchin A, Seifter JL & Seely EW. Clinical problem-solving. Mind the gap. 
New England Journal of Medicine 2003 349 1465–1469.
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• Effective osmolality (mmol/kg H2O) = 
2 × (serum Na (mmol/l) + serum K (mmol))+ serum glycaemia (mg/dl)/18
• Effective osmolality (mmol/kg H2O) = 
2 × (serum Na (mmol/l)+ serum K (mmol/l)) + serum glycaemia (mmol/l)
This includes only osmoles that are restricted to the extracellular fluid volume. As water 
returns to the intracellular space during treatment of hyperglycaemia, serum sodium con-
centration should increase, thus resulting in a constant effective osmolality. If it does not, 
brain oedema may ensue due to an overly rapid drop in effective osmolality [35].
Ineffective osmoles
High urea concentrations in kidney disease may also increase measured osmolality. How-
ever, urea is not an effective osmole because it readily passes across the cellular membrane. 
It does not change effective osmolality, does not attract water to the extracellular fluid com-
partment and does not cause hyponatraemia [36].
Hypotonic hyponatraemia with decreased extracellular fluid volume
Depletion of circulating volume, with or without deficit of total body sodium, can mark-
edly increase the secretion of vasopressin leading to water retention despite hypotonicity. 
Although the vasopressin release in this case is inappropriate from an osmoregulatory point 
of view, it happens in order to preserve intravascular volume and can be considered appro-
priate from a circulatory point of view.
Non-renal sodium loss
Gastrointestinal sodium loss
Volume depletion can occur if the body loses sodium through its gastrointestinal tract. In 
case of severe diarrhoea, the kidneys respond by preserving sodium and urine sodium con-
centrations are very low. In case of vomiting, metabolic alkalosis causes renal sodium loss as 
sodium accompanies bicarbonate in the urine despite activation of the renin–angiotensin 
system. By contrast, in patients with diarrhoea, chloride accompanies ammonium excreted 
by the kidneys in an effort to prevent metabolic acidosis.
Transdermal sodium loss
The body can lose substantial amounts of sodium transdermally due to heavy sweat-
ing. This may be caused by impaired re-absorption of sodium in the sweat duct as in cystic 
fibrosis or by an impaired natural barrier function due to extensive skin burns. It results in 
increased vulnerability to sodium depletion and volume depletion. The amount of sodium 
that is lost in sweat varies markedly between healthy individuals, but to date, no link has 
been found between the sodium concentration in sweat and cystic fibrosis-causing muta-
tions of the cystic fibrosis transmembrane conductance regulator gene [37].
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Renal sodium loss
Diuretics
Urinary sodium loss can cause volume depletion and, if sufficiently severe, trigger vaso-
pressin release. Diuretics and especially thiazides are frequently implicated as a cause of 
hyponatraemia. The traditional explanation is that renal sodium loss leads to volume con-
traction with subsequent release of vasopressin. However, this would require a substantial 
loss of sodium and body weight, while patients with thiazide-induced hyponatraemia often 
have increased body weight [38]. It might be reasonable to assume that thiazides directly 
induce the release of vasopressin or increase the response of the collecting duct to circula-
tory vasopressin. In any case, there appears to be an individual susceptibility to these ef-
fects, as hyponatraemia only occurs in certain patients and usually reoccurs if thiazides are 
reintroduced [38]. Despite the potential for causing more urinary sodium loss, loop diuretics 
only rarely cause hyponatraemia because they reduce osmolality in the renal medulla and 
thus limit the kidney’s ability to concentrate urine [39].
Primary adrenal insufficiency
In primary adrenal insufficiency, hypoaldosteronism causes renal sodium loss, contract-
ed extracellular fluid volume and hyponatraemia. Although primary adrenal insufficiency 
usually presents in combination with other clinical symptoms and biochemical abnormali-
ties, hyponatraemia can be its first and only sign [40].
Cerebral salt wasting
Renal sodium loss has been documented in patients with intracranial disorders such as 
subarachnoid bleeding. This renal salt wasting has been rather confusingly named ‘cerebral’ 
salt wasting, and increased levels of brain natriuretic peptide have been implicated in its 
pathogenesis [41]. Because diagnosis may be difficult, and both inappropriate antidiuresis 
and secondary adrenal insufficiency are actually more common in this clinical setting, cer-
ebral salt wasting may be over diagnosed [42]. Nevertheless, the recognition of cerebral salt 
wasting is important because its treatment requires volume resuscitation rather than water 
restriction.
Kidney disease
Renal salt wasting can also occur in kidney dysfunction. The so-called salt-losing ne-
phropathies, such as tubulopathy after chemotherapy or in analgesic nephropathy, medul-
lary cystic kidney disease and certain pharmacological compounds can inhibit the kidney’s 
ability to re-absorb appropriate amounts of sodium [43].
Third spacing
Bowel obstruction, pancreatitis, sepsis or muscle trauma may markedly reduce effective 
circulating blood volume through fluid leakage from blood vessels. This causes barorecep-
tor activation and vasopressin release, which may result in hyponatraemia. Infusion of hy-
potonic fluids in this case may worsen hyponatraemia.
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Hypotonic hyponatraemia with normal extracellular fluid volume
Euvolaemic hyponatraemia is caused by an absolute increase in body water, which re-
sults from an excessive fluid intake in the presence of an impaired free water excretion, 
either due to inappropriate release of vasopressin or due to a low intake of solutes.
Syndrome of inappropriate antidiuresis
The vasopressin secretion in SIADH is inappropriate because it occurs independently 
from effective serum osmolality or circulating volume. It may result from increased release 
by the pituitary gland or from ectopic production. Inappropriate antidiuresis may also result 
from increased activity of vasopressin in the collecting duct or from a gain-of-function mu-
tation in its type 2 receptor [44]. Throughout this text, we will use the terminology ‘SIAD’ as 
an overarching term because management principles are the same for both conditions and 
any distinction is merely academic and out of the scope of this document [45].
In SIAD, antidiuresis causes progressive hyponatraemia until the expression of vasopres-
sin V2 receptors and aquaporin-2 water channels is down-regulated, a process appropri-
ately called ‘vasopressin escape’ [46]. Because of the vasopressin activity, urine osmolality 
will be inappropriately high (usually >100 mOsm/l) and this is one of the criteria required 
for a diagnosis of SIAD. The criteria are largely the same as originally proposed by Bartter & 
Schwartz [29]. Importantly, SIAD remains a diagnosis of exclusion (Table 7. 6).
General anaesthesia, nausea, pain, stress and a variety of drugs are non-specific but po-
tent stimuli for the secretion of vasopressin and a frequent cause of SIAD in hospitalised 
patients. The use of prescribed or illicit drugs may result in either increased vasopressin re-
lease or increased effects of vasopressin in the collecting duct. The most frequent causes of 
increased inappropriate secretion of vasopressin include cancers (e.g. small cell carcinoma 
 Table 7.6. Diagnostic criteria for the syndrome of inappropriate antidiuresis.
Essential criteria
Effective serum osmolality < 275 mOsm/kg 
Urine osmolality > 100 mOsm/kg at some level of decreased effective osmolality
Clinical euvolaemia
Urine sodium concentration > 30 mmol/L  with normal dietary salt and water intake
Absence of adrenal, thyroid, pituitary or renal insufficiency 
No recent use of diuretic agents 
Supplemental criteria
Serum uric acid < 0.24 mmol/L (< 4 mg/dL)
Serum urea < 3.6 mmol/L (< 21.6 mg/dL)
Failure to correct hyponatraemia after 0.9% saline infusion
Fractional sodium excretion > 0.5%
Fractional urea excretion > 55%
Fractional uric acid excretion > 12%
Correction of hyponatraemia through fluid restriction
Adapted from Schwartz WB, Bennett W, Curelop S & Bartter FC. A syndrome of renal sodium loss and hyponatremia 
probably resulting from inappropriate secretion of antidiuretic hormone. American Journal of Medicine 1957 23 
529–542 [29] and Janicic N & Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. 
Endocrinology and Metabolism Clinics of North America 2003 32 459–481, vii. 
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of the lung) and diseases of the lung (e.g. pneumonia) or central nervous system (e.g. suba-
rachnoid haemorrhage) (Table 7. 7). Recently, several genetic disorders causing SIAD have 
Table 7.7. Causes of the syndrome of inappropriate antidiuresis.
Malignant 
diseases
Pulmonary 
disorders
Disorders of the 
nervous system
Drugs Other causes
Carcinoma
Lung 
Oropharynx
Gastro-intestinal  
tract  
stomach
duodenum
pancreas
 
Genitourinary tract  
ureter
bladder
prostate
endometrium
Endocrine thymoma
Lymphomas
Sarcomas
Ewing’s sarcoma
Olfactory neuroblas-
toma
Infections
Bacterial pneumonia
Viral pneumonia
Pulmonary abscess
Tuberculosis
Aspergillosis
Asthma
Cystic fibrosis
Respiratory failure 
associated with 
positive-pressure 
breathing 
Infection
Encephalitis
Meningitis
Brain abscess
Rocky Mountain spot-
ted fever
AIDS
Malaria
Vascular and masses
Subdural hematoma
Subarachnoid haem-
orrhage
Stroke
Brain tumours
Head trauma
Other
Hydrocephalus
Cavernous sinus 
thrombosis
Multiple sclerosis
Guillain-Barré syn-
drome
Shy-Drager syndrome
Delirium tremens
Acute intermittent  
porphyria
Vasopressin release or 
action stimulants
Antidepressants
- SSRIs
- Tricyclic  
- MAOI
- Venlafaxine
Anticonvulsants
- Carbamazepine
- Oxacarbamazepine
- Sodium valproate
- Lamotrigine
Antipsychotics
- Phenothiazides
- Butyrophenones
Anticancer drugs
- Vinca alkaloids
- Platinum compounds
- Ifosfamide
- Melphalan
- Cyclophosphamide
- Methotrexate
- Pentostatin
Antidiabetic drugs
- Chlorpropamide
- Tolbutamine
Miscellaneous
-Opiates
-MDMA (XTC)
-Levamisole
-Interferon
-NSAIDs
-Clofibrate
-Nicotine
-Amiodarone
-Proton pump inhibitors
-Monoclonal antibodies 
Vasopressin analogues
Desmopressin
Oxytocin
Terlipressin
Vasopressin
Hereditary
Gain-of-function 
mutation of the vaso-
pressin V2 receptor
Idiopathic
Transient
Exercise-associated 
hyponatraemia
General anesthesia
Nausea
Pain
Stress
Adapted from Liamis G al. Am J Kidney Dis 2008; 52: 144-153.
AIDS, acquired immunodeficiency syndrome; MOAI, monoamine oxidase inhibitors; MDMA, 3, 4-methylenedioxymethamphetamine; 
NSAIDs, non-steroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors.
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been identified. Among them are polymorphisms resulting in a loss-of-function of TRPV4, 
a gene that encodes for an osmosensitive calcium channel expressed in osmosensing neu-
rons [47]. Another is a gain-of-function mutation in the vasopressin 2 receptor, resulting 
in a constitutively activated receptor causing increased water re-absorption and chronic 
hyponatraemia [44].
Secondary adrenal insufficiency
The production of aldosterone is less impaired in secondary than in primary adrenal in-
sufficiency and renal sodium loss does not contribute to the development of hyponatrae-
mia. Secondary adrenal insufficiency is caused by reduced or absent secretion of adreno-
corticotrophic hormone, resulting in hypocortisolism. Under normal circumstances, cortisol 
suppresses both production of corticotrophin-releasing hormone and vasopressin in the 
hypothalamus. In secondary adrenal insufficiency, persistently low concentrations of corti-
sol fail to suppress vasopressin and hyponatraemia results from impaired free water excre-
tion, as it does in SIAD [48].
Hypothyroidism
Although included in many diagnostic algorithms, hypothyroidism very rarely causes 
hyponatraemia [49]. In 2006, Warner et al. [50] observed that serum sodium concentration 
decreased by 0.14 mmol/l for every 10 mU/l rise in thyroid-stimulating hormone, indicating 
that only severe cases of clinically manifest hypothyroidism resulted in clinically important 
hyponatraemia. Development of hyponatraemia may be related to myxoedema, resulting 
from a reduction in cardiac output and glomerular filtration rate [51].
High water and low solute intake
Under conditions of high water and low solute intake, the excess water intake is primarily 
responsible for hyponatraemia. Vasopressin activity is absent, which is reflected by an ap-
propriately low urine osmolality, usually <100 mOsm/kg. Patients with primary polydipsia 
drink more than what the kidneys can eliminate. Primary polydipsia may occur in combina-
tion with psychiatric disorders such as schizophrenia. Although excess water intake contrib-
utes most to hyponatraemia, renal loss of solutes and an acquired impairment in free water 
excretion may also occur [52].
The amount of water that the kidneys can remove on a daily basis depends on solute 
excretion and hence solute intake. Depending on the kidney’s ability to dilute urine, 50–100 
mmol of solutes, such as urea and salts, are required to remove 1 l of fluid. If solute intake is 
low relative to water intake, the number of available osmoles can be insufficient to remove 
the amount of water ingested. This is seen in patients with anorexia (nervosa), beer potoma-
nia and so-called ‘tea and toast’ hyponatraemia [53].
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Hypotonic hyponatraemia with increased extracellular fluid volume
Kidney disease
When glomerular filtration rate deteriorates, or when there is tubular injury or scarring, 
the ability to dilute urine and excrete free water decreases. In advanced kidney disease, 
urine osmolality is usually close to serum osmolality (isosthenuria). Free water removal is 
no longer regulated by vasopressin but is determined by the number of osmoles excreted 
in the urine (i.e. solute intake). Consequently, hyponatraemia can readily develop if patients 
do not adhere to fluid restriction. In addition, in patients treated with peritoneal dialysis, the 
use of icodextrin-based dialysis solutions can cause clinically relevant hyponatraemia [54].
Heart failure
Approximately 20–30% of patients with chronic heart failure New York Heart Association 
(NYHA) classes III and IV have hyponatraemia [55]. It is associated with more severe heart 
failure and an increased risk of death, independent of other comorbid conditions [55, 56]. 
Whether this reflects (unacknowledged) disease severity or has a causal effect remains 
unclear. Although renal sodium retention tends to increase the extracellular volume, the 
effective circulating blood volume is generally reduced due to impaired cardiac output. Ba-
roreceptor-mediated neurohumoral activation commonly results in increased secretion of 
vasopressin by the pituitary. Simultaneous activation of the renin–angiotensin system and 
increased release of vasopressin reduces urinary sodium excretion and increases urine os-
molality. Although simultaneous use of diuretics may contribute to the development of hy-
ponatraemia, loop diuretics have less potential for causing hyponatraemia than thiazides.
Liver failure
Also in liver failure, hyponatraemia is associated with poorer survival [57]. Whether this 
reflects disease severity or has a direct contributory effect remains unclear [58]. Systemic 
vasodilation and arteriovenous shunting of blood may reduce the effective arterial blood 
volume. As in heart failure, this reduction can lead to neurohumoral activation and water 
retention due to baroreceptor-mediated vasopressin release.
In addition, mineralocorticoid receptor blockers such as spironolactone, which either 
alone or in combination with loop diuretics, are frequently used to reduce sodium retention 
in liver failure, can contribute to hyponatraemia [59].
Nephrotic syndrome
In nephrotic syndrome, blood volume may be decreased due to the lower serum oncotic 
pressure (under-fill hypothesis). If this happens, stimulation of vasopressin secretion can 
cause patients to develop hyponatraemia. The tendency for water retention is generally 
balanced by intense sodium retention, but the increased renal re-absorption of sodium usu-
ally necessitates a considerable dose of diuretics. The combination of increased vasopressin 
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release and diuretic use may promote moderate hyponatraemia, especially in children with 
low blood pressure [60].
Diagnosis of hyponatraemia
Classification of hyponatraemia
Definition of hyponatraemia based on biochemical severity
• We define ‘mild’ hyponatraemia as a biochemical finding of a serum sodium 
concentration between 130 and 135 mmol/l as measured by ion-specific electrode.
• We define ‘moderate’ hyponatraemia as a biochemical finding of a serum sodium 
concentration between 125 and 129 mmol/l as measured by ion-specific electrode.
• We define ‘profound’ hyponatraemia as a biochemical finding of a serum sodium 
concentration <125 mmol/l as measured by ion-specific electrode.
Definition of hyponatraemia based on time of development
• We define ‘acute’ hyponatraemia as hyponatraemia that is documented to exist <48 h.
• We define ‘chronic’ hyponatraemia as hyponatraemia that is documented to exist for 
at least 48 h.
• If hyponatraemia cannot be classified, we consider it being chronic, unless there is 
clinical or anamnestic evidence of the contrary (Table 7. 8).
Definition of hyponatraemia based on symptoms
• We define ‘moderately symptomatic’ hyponatraemia as any biochemical degree of 
hyponatraemia in the presence of moderately severe symptoms of hyponatraemia 
(Table 7. 5).
Table 7.8. Drugs and conditions associated with acute hyponatraemia (< 48 hours)
Postoperative phase 
Post-resection of the prostate, post-resection of endoscopic uterine surgery 
Polydipsia 
Exercise 
Recent thiazides prescription 
3,4-methyleendioxymethamfetamine (MDMA, XTC)
Colonoscopy preparation 
Cyclophosphamide (intravenous)
Oxytocin
Recently started desmopressin therapy
Recently started terlipressin, vasopressin 
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• We define ‘severely symptomatic’ hyponatraemia as any biochemical degree of 
hyponatraemia in the presence of severe symptoms of hyponatraemia (Table 7. 5).
Rationale
Why did we choose to set definitions?
Hyponatraemia can be classified based on different parameters. These include serum so-
dium concentration, rate of development, symptom severity, serum osmolality and volume 
status. For this guideline, we wanted the classification to be consistent and clear so that 
all users would have a correct understanding of the terminology used. We also wanted to 
make the classification directly relevant for patient management. However, treatment strat-
egies cannot be adequately classified with reference to a single criterion. Hence, treatment 
strategies have been classified according to combinations of these criteria.
What are these definitions based on?
Classification based on serum sodium concentration
Authors mostly use the terms ‘mild’, ‘moderate’ and ‘severe’ [61, 62,63]. We have chosen 
to replace ‘severe’ by ‘profound’ to avoid confusion with the classification based on symp-
toms, for which we have reserved the term ‘severe’. The definitions of mild, moderate and 
profound hyponatraemia in published research are variable, especially the threshold used 
to define profound hyponatraemia for which values have ranged from 110 to 125 mmol/l 
[64,  65]. Several studies report that when serum sodium concentrations drop below 125 
mmol/l, symptoms become more common [61, 66, 67, 68, 69, 70, 71], and the correction to 
normonatraemia necessitates careful monitoring to avoid overly rapid correction [72].
Classification based on duration and speed of development
Published research suggests using a threshold of 48 h to distinguish ‘acute’ from ‘chronic’ 
hyponatraemia. Brain oedema seems to occur more frequently when hyponatraemia de-
velops in <48 h [73, 74, 75,76]. Experimental studies also suggest that the brain needs 48 
h to adapt to a hypotonic environment, achieved mainly by extruding sodium, potassium, 
chloride and organic osmoles from its cells [77, 78,79]. Before adaptation, there is a risk of 
brain oedema because the lower extracellular osmolality promotes a shift of water into the 
cells. However, once adaptation is completed, brain cells can again sustain damage if the 
serum sodium concentration increases too rapidly. Breakdown of the myelin sheath insu-
lating individual neurons can result in what is called the osmotic demyelination syndrome 
[80, 81,82, 83]. Consequently, it is important to distinguish between acute and chronic hy-
ponatraemia to assess whether someone is at a greater risk of immediate brain oedema 
than of osmotic demyelination [84]. Unfortunately, in clinical practice, the distinction be-
tween acute and chronic hyponatraemia is often unclear, particularly for patients present-
ing to the emergency room. It is often unknown when the serum sodium concentration has 
started decreasing. If classifying hyponatraemia as acute or chronic is not possible, we have 
decided to consider hyponatraemia as being chronic, unless there are reasons to assume 
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it is acute (Table 7.8). There is a good reason for this approach. Chronic hyponatraemia is 
much more common than acute hyponatraemia and should be managed accordingly to 
avoid osmotic demyelination [85, 86].
Classification based on symptoms
We have divided symptoms of hyponatraemia into ‘moderately severe’ and ‘severe’. The dis-
tinction is based on selected observations in acute hyponatraemia; those who subsequently 
die more often experience what we define as severe symptoms than those who live [73, 74]. 
Moderately severe symptoms caused by brain oedema are less frequently associated with 
death. Nevertheless, they may rapidly progress to more severe symptoms associated with an 
adverse outcome.
We have purposefully omitted the category ‘asymptomatic’ as we believed this might 
create confusion. Patients are probably never truly ‘asymptomatic’ in the strictest sense of 
the word. Very limited and subclinical signs such as mild concentration deficits are seen 
even with mild hyponatraemia [13].
A classification based on symptoms aims to reflect the degree of brain oedema and 
the extent of immediate danger. It allows matching treatment to the immediate risk, with 
more aggressive treatment for symptoms that are more severe. Nevertheless, a classifica-
tion based only on symptom severity has several shortcomings. First, symptoms of acute 
and chronic hyponatraemia may overlap [18]. Secondly, patients with acute hyponatraemia 
can present without clear symptoms, but go on to develop moderately severe to severe 
symptoms within hours [73]. Thirdly, symptoms of hyponatraemia are non-specific. Conse-
quently, assessment of symptoms needs to happen with caution. Clinicians need to be wary 
that symptoms can be caused by conditions other than hyponatraemia, by other conditions 
in combination with hyponatraemia or by conditions that cause hyponatraemia. In general, 
one should be particularly careful when attributing moderately severe to severe symptoms 
to hyponatraemia when the biochemical degree of hyponatraemia is only mild (Table 7.5).
Classification based on serum osmolality
As this guideline aimed to cover the aspects of diagnosis and treatment specifically of 
hypotonic hyponatraemia, we needed to define what distinguishes hypotonic from non-
hypotonic hyponatraemia. Because this distinction is a necessary first step in the diagnostic 
evaluation of any hyponatraemia, we have devoted a separate section to this topic (section 
6.2). For reasons of completeness, we briefly mention it here. A measured serum osmolal-
ity <275 mOsm/kg always indicates hypotonic hyponatraemia, as effective osmolality can 
never be higher than total or measured osmolality. By contrast, if calculated osmolality is 
<275 mOsm/kg, hyponatraemia can be hypotonic, isotonic or hypertonic, depending on 
which osmotically active agents are present and whether or not they are incorporated in 
the formula.
Classification based on volume status
Patients with hyponatraemia may be hypovolaemic, euvolaemic or hypervolaemic [87]. 
Nagler.indb   208 15/09/2015   16:14:51
European guideline on diagnosis and treatment of hyponatraemia
209
Many traditional diagnostic algorithms start with a clinical assessment of volume status 
[88]. However, it is often not clear whether volume status in this context refers to the ex-
tracellular fluid volume, to the effective circulating volume or to the total body water. In 
addition, the sensitivity and specificity of clinical assessments of volume status are low, po-
tentially leading to misclassification early in the diagnostic tree [89, 90]. Therefore, we have 
used the terms ‘effective circulating volume’ and ‘extracellular fluid volume’ throughout the 
text to reduce ambiguity.
Note of caution
We wanted the classification of hyponatraemia to be consistent, easy to use and helpful 
for both differential diagnosis and treatment. Hyponatraemia can be classified according to 
different factors, each with advantages and pitfalls depending on the clinical setting and 
situation. We have prioritised the criteria such that we would obtain a classification that 
would be clinically relevant and as widely applicable as possible.
Nevertheless, the user should keep in mind that differential diagnosis of hyponatraemia 
is difficult and no classification can be 100% accurate in every situation. We emphasise that 
the different classifications of hyponatraemia are not mutually exclusive and that classifica-
tion should always occur with the clinical condition and the possibility of combined causes 
of hyponatraemia in mind.
Questions for future research
• Is it possible to define thresholds of serum sodium concentration that categorise sepa-
rate entities in terms of management and outcomes?
• Is 48 h the best threshold to separate acute from chronic hyponatraemia?
• Is it possible to identify symptoms or parameters that can reliably differentiate acute 
from chronic hyponatraemia?
Confirming hypotonic and excluding non-hypotonic hyponatraemia
• We recommend excluding hyperglycaemic hyponatraemia by measuring the serum 
glucose concentration and correcting the measured serum sodium concentration for 
the serum glucose concentration if the latter is increased (1D).
• Hyponatraemia with a measured osmolality <275 mOsm/kg always reflects hypotonic 
hyponatraemia (not graded).
• Accept as ‘hypotonic hyponatraemia’ a hyponatraemia without evidence for causes of 
non-hypotonic hyponatraemia as listed in Table 7.10 (not graded).
Advice for clinical practice
Estimates of the serum sodium concentration corrected for the presence of hyperglycae-
mia can be obtained from the following equations [31]:
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Corrected serum [Na+]= measured [Na+] + 2.4 * 
[Glucose (mg/dL)  - 100 mg/dL] 
 100 mg/dL
Corrected serum [Na+]= measured [Na+] + 2.4 * 
[Glucose (mmol/L)  - 5.5 mmol/L] 
 5.5 mmol/L
Na+, serum sodium concentration; glucose, serum glucose concentration.
This translates into adding 2.4 mmol/l to the measured serum sodium concentration 
for every 5.5 mmol/l (100 mg/dl) incremental rise in serum glucose concentration above a 
standard serum glucose concentration of 5.5 mmol/l (100 mg/dl).
Alternatively, the estimated value of the corrected serum sodium concentration across a 
range of serum glucose concentrations can be obtained from Table 7.9.
Rationale
• Why the question?
Non-hypotonic hyponatraemia does not cause brain oedema and is managed differ-
ently from hypotonic hyponatraemia. As this guideline covers management of hypotonic 
hyponatraemia, confirmation of hypotonicity is a prerequisite.
 Table 7.9. Association between serum glucose concentration, measured serum sodium. 
and corrected serum sodium concentration.
 Measured [Glucose] (mg/dL)  
100 200 300 400 500 600 700 800  
Measured 
[Na+] (mmol/L) True [Na
+] (mmol/L)  
135 135 137 140 142 145 147 149 152  
130 130 132 135 137 140 142 144 147  
125 125 127 130 132 135 137 139 142  
120 120 122 125 127 130 132 134 137  
115 115 117 120 122 125 127 129 132  
110 110 112 115 117 120 122 124 127  
105 105 107 110 112 115 117 119 122  
100 100 102 105 107 110 112 114 117  
95 95 97 100 102 105 107 109 112  
90 90 92 95 97 100 102 104 107  
85 85 87 90 92 95 97 99 102  
80 80 82 85 87 90 92 94 97  
75 75 77 80 82 85 87 89 92  
70 70 72 75 77 80 82 84 87  
Calculated using equation from Hillier TA et al. Am J Med 1999; 106: 399-403.
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• What are the criteria based on?
There are broadly three categories of non-hypotonic hyponatraemia: hyponatraemia in 
the presence of a surplus of ‘effective’ osmoles, hyponatraemia in the presence of a surplus 
of ‘ineffective’ osmoles and pseudohyponatraemia (Table 7.10) [30, 34, 36, 88, 91].
Effective osmoles
Exogenous or endogenous solutes to which cell membranes are impermeable are re-
stricted to the extracellular fluid compartment and are effective osmoles because they cre-
ate osmotic pressure gradients across cell membranes leading to osmotic movement of 
water from the intracellular to the extracellular compartment [34, 36]. Because dilutional 
hyponatraemia results from the water shift from the intracellular to the extracellular com-
partment, there is no risk of brain oedema. Depending on the serum concentration of ef-
fective osmoles, the resulting non-hypotonic hyponatraemia can be isotonic or hypertonic. 
The prime example is hyperglycaemia [31]. Others include infusion of mannitol or perio-
perative absorption of irrigation fluids such as glycine [32, 33]. The latter most frequently 
occurs during transurethral resection of the prostate (TURP) and is therefore also referred 
to as ‘TURP-syndrome’. Although TURP syndrome causes isotonic hyponatraemia and hence 
does not cause brain oedema, neurological symptoms may develop due to accumulation of 
ammonia, serine or glyoxylate from the metabolism of glycine [92, 93].
It is important to understand the kinetics of non-hypotonic hyponatraemia in the pres-
ence of effective osmoles. When glucose, mannitol or glycine are metabolised or excreted, 
serum osmolality decreases. This reduces the osmotic gradient, resulting in less water being 
pulled from the cells and spontaneously limiting the degree of hyponatraemia. It explains 
why during treatment of diabetic ketoacidosis or the hyperosmolar hyperglycaemic state a 
 Table 7.10. Causes of non-hypotonic hyponatraemia.
Setting Serum osmolality Examples 
Presence of “effective” osmoles that 
raise serum osmolality and can cause 
hyponatraemia 
Isotonic or 
hypertonic 
Glucose [31] 
Mannitol [32]
Glycine [33]
Histidine-tryptophane-ketoglutarate [245]
Hyperosmolar radiocontrast media [246]
Maltose [247] 
Presence of “ineffective” osmoles that 
raise serum osmolality but do not 
cause hyponatraemia 
Isotonic or 
hyperosmolar 
Urea[36]  
Alcohols [36] 
Ethylene-glycol [36] 
Presence of endogenous solutes 
that cause pseudohyponatraemia 
(laboratory artifact) 
Isotonic Triglycerides [99] , cholesterol [99], protein
Intravenous immunoglobulins [98]
Monoclonal gammapathies [248]
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decrease in serum glycaemia leads to a ‘spontaneous’ rise in the serum sodium concentra-
tion. If the serum glucose concentration drops to a greater extent than the serum sodium 
concentration rises, serum effective osmolality will decrease. This can lead to brain oedema 
[35, 94]. Consequently, calculating ‘effective’ osmolality during treatment is important [35].
Ineffective osmoles
Solutes to which cell membranes are permeable are ineffective solutes because they do 
not create osmotic pressure gradients across cell membranes and therefore are not associ-
ated with water shifts [36, 91]. Consequently, they do not cause hyponatraemia. In other 
words, although the presence of ineffective osmoles will make any existing hyponatraemia 
isomolar or hyperosmolar, the cause of hyponatraemia should be sought elsewhere. The 
serum is in fact hypotonic and water will still move from the extracellular to the intracellular 
compartment. It means patients are still at risk of brain oedema if hyponatraemia develops 
quickly. Examples of ineffective osmoles include urea, ethanol and methanol (Table 7.10).
Pseudohyponatraemia
Pseudohyponatraemia is a laboratory artefact that occurs when abnormally high con-
centrations of lipids or proteins in the blood interfere with the accurate measurement of 
sodium [30, 95, 96, 97]. Pseudohyponatraemia still occurs despite the use of ion-selective 
electrodes [30]. This is because venous blood samples are always diluted and a constant 
distribution between water and the solid phase of serum is assumed when the serum so-
dium concentration is calculated (Figure 7.5). This is called indirect ion-selective electrode 
measurement and used in large-scale analysers, e.g. in central laboratories. Serum osmo-
lality is measured in an undiluted sample, and in case of pseudohyponatraemia (isotonic 
hyponatraemia), the result will be within the normal range. Other methods for diagnos-
ing pseudohyponatraemia include direct potentiometry using a blood gas analyser (i.e. 
direct ion-specific electrode measurement) in which case no dilution of the sample oc-
curs, or measurement of serum triglycerides, cholesterol and total protein concentration 
[30,  97,  98]. Differences between direct and indirect ion-specific electrode measurement 
of 5–10% have been reported in hypotonic hyponatraemia [99, 100]. Switching between 
indirect and direct ion-specific electrode measurements should be avoided in this situation.
• How did we translate this into a diagnostic strategy?
Because hyperglycaemia is by far the most common cause of non-hypotonic hyponatrae-
mia, we have added excluding hyperglycaemic hyponatraemia in our diagnostic algorithm 
and detailed how it can be done. In addition, we have added excluding other causes of 
non-hypotonic hyponatraemia listed in Table 7.10. How this should be done is beyond the 
scope of this guideline.
The ability to measure serum osmolality may vary from centre to centre, especially out 
of office hours. During the discussions within the guideline development group, the im-
portance of measured urine osmolality for the differential diagnosis of hyponatraemia was 
underscored. Hence, we reasoned it would be illogical not to recommend an additional 
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measurement of serum osmolality because it is not always available. However, although 
measuring serum osmolality in all patients with hyponatraemia may seem useful, there are 
no hard data confirming this improves diagnosis or outcome. Hence, we equally accept al-
ternative approaches for ruling out non-hypotonic hyponatraemia. These approaches in-
clude evaluating the clinical context (e.g. infusion of mannitol or recent urological surgery), 
measuring the serum concentration of additional osmoles (e.g. urea, lactate and alcohol) or 
measuring the serum concentration of analytes that can cause pseudohyponatraemia (e.g. 
serum triglycerides, cholesterol and total protein).
Questions for future research
• Is the factor with which to correct the serum sodium concentration for glycaemia valid 
for all ranges of glycaemia and applicable to all patients?
• What is the incidence of pseudohyponatraemia?
• Does measuring serum osmolality in all patients with hyponatraemia improve the diag-
nostic process and outcomes of hyponatraemia?
Which parameters to be used for differentiating causes of hypotonic hyponatraemia?
• We recommend interpreting urine osmolality of a spot urine sample as a first step (1D).
• If urine osmolality is ≤100 mOsm/kg, we recommend accepting relative excess water 
intake as a cause of the hypotonic hyponatraemia (1D).
• If urine osmolality is >100 mOsm/kg, we recommend interpreting the urine sodium 
concentration on a spot urine sample taken simultaneously with a blood sample (1D).
• If urine sodium concentration is ≤30 mmol/l, we suggest accepting low effective 
arterial volume as a cause of the hypotonic hyponatraemia (2D).
• If urine sodium concentration is >30 mmol/l, we suggest assessing extracellular fluid 
status and use of diuretics to further differentiate likely causes of hyponatraemia (2D).
• We suggest against measuring vasopressin for confirming the diagnosis of SIADH (2D).
Advice for clinical practice
• Correct interpretation of laboratory measurements requires contemporaneous collec-
tion of blood and urine specimens.
• For practical reasons, urine osmolality and sodium concentration are best determined in 
the same urine sample.
• If clinical assessment indicates that the volume of extracellular fluid is not overtly in-
creased and the urine sodium concentration is >30 mmol/l, exclude other causes of hy-
potonic hyponatraemia before implicating SIAD. Consider using the diagnostic criteria 
listed in Table 7.6 and look for known causes of SIAD.
• Consider primary or secondary adrenal insufficiency as an underlying cause of the hypo-
tonic hyponatraemia.
• Kidney disease complicates differential diagnosis of hyponatraemia. Besides possibly 
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contributing to hyponatraemia, the ability of the kidneys to regulate urine osmolality 
and urine sodium is often diminished, much as with the use of diuretics. As urine osmo-
lality and sodium may no longer reflect the effects of regular hormonal axes regulating 
sodium homeostasis, any diagnostic algorithm for hyponatraemia must be used with 
caution in patients with kidney disease.
• The water-loading test is generally not helpful for differential diagnosis of hypotonic hy-
ponatraemia and may be dangerous in this setting.
Rationale
• Why this question?
Hypotonic hyponatraemia has many possible underlying causes. These include, but are 
not limited to, non-renal sodium loss, diuretics, third spacing, adrenal insufficiency, SIAD, 
polydipsia, heart failure, liver cirrhosis and nephrotic syndrome (see sections 5.6 and 5.8). 
Clinicians have traditionally used the clinical assessment of ‘volume status’ for classifying 
hyponatraemia as hypovolaemic, euvolaemic or hypervolaemic [87,  101,  102]. However, 
clinical assessment of volume status is generally not very accurate [90]. Hence, we wanted 
to know which tests are most useful in differentiating causes of hypotonic hyponatraemia, 
in which order we should use them and what threshold values have the highest diagnostic 
value.
• What did we find?
Clinical assessment of fluid status
We found two studies indicating that in patients with hyponatraemia, clinical assessment 
of volume status has both low sensitivity (0.5–0.8) and specificity (0.3–0.5) [89, 103]. Simi-
larly, it seems that clinicians often misclassify hyponatraemia when using algorithms that 
start with a clinical assessment of volume status [88]. Using an algorithm in which urine os-
molality and urine sodium concentration are prioritized over assessment of volume status, 
physicians in training had a better diagnostic performance than senior physicians who did 
not use the algorithm [104].
Urine osmolality
In the evaluation of hyponatraemia, urine osmolality is used to assess vasopressin ac-
tivity [84]. Unfortunately, we found no study evaluating the sensitivity and specificity of a 
particular threshold. Physiologically, one would expect maximally dilute urine, in the pres-
ence of hypotonic hyponatraemia, unless hypo-osmolality fails to fully suppress vasopres-
sin release. In hyponatraemia primarily caused by excess water intake, vasopressin release 
is suppressed resulting in urine osmolality usually <100 mOsm/kg [105]. By contrast, in case 
of non-suppressed vasopressin activity, urine osmolality usually exceeds serum osmolality 
[106]. This leaves a ‘grey area’ for urine osmolalities between 100 mOsm/kg and the value 
of the serum osmolality [84]. In this range, one cannot be clear about the presence or ab-
sence of vasopressin activity and excessive fluid intake may outweigh only moderately sup-
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pressed vasopressin activity [85].
Urine sodium concentration
We found five studies assessing diagnostic accuracy of urine sodium concentration for 
differentiating hypovolaemia from euvolaemia or hypervolaemia. All studies used a rise in 
serum sodium concentration after the infusion of 0.9% sodium chloride as the reference 
standard for diagnosing hypovolaemia [89]. Four studies assessed the sensitivity and speci-
ficity of a urine sodium concentration >30 mmol/l for diagnosis of euvolaemia vs hypovol-
aemia [89, 103, 107, 108]. All found similarly high sensitivity estimates ranging from 0.87 
to 1.0 but variable specificity estimates ranging from 0.52 to 0.83 [89, 103, 108]. Fenske et 
al. also included hypervolaemic patients. They assessed the same threshold for distinguish-
ing hypovolaemia from euvolaemia and hypervolaemia but analysed patients with and 
without diuretics separately [107]. A urine sodium concentration >30 mmol/l had high es-
timated sensitivities of 1.0 and 0.94 respectively in patients off and on diuretics, but low 
specificities of 0.69 and 0.24 respectively [107]. Others evaluated the diagnostic accuracy 
of a urine sodium concentration >50 mmol/l [109] and >20 mmol/l [109] but found lower 
sensitivities and specificities respectively than with a threshold of 30 mmol/l.
Other laboratory tests
Several other diagnostic laboratory tests have been evaluated for their ability to dis-
tinguish euvolaemia from hypovolaemia and hypervolaemia in patients treated with and 
without diuretics. These tests include serum urea concentration, serum uric acid concen-
tration, fractional sodium excretion, fractional uric acid excretion, fractional urea excretion 
and plasma copeptin concentration [103, 107, 108, 110]. Overall, fractional excretion of uric 
acid using a threshold of >12% seemed most useful for distinguishing hyponatraemia due 
to SIAD from non-SIAD hyponatraemia in patients under diuretics with a sensitivity of 0.86 
and specificity of 1.0. In comparison with urine sodium concentration, fractional uric acid 
excretion may be a better test for differentiating hyponatraemia in patients who are also 
treated with diuretic therapy, but these results need to be confirmed in a separate cohort 
before this parameter can be recommended for routine use clinically [107].
Diagnostic difficulty with diuretics
The diagnostic difficulty we face with diuretics is that patients on these medications 
may have increased, normal or decreased extracellular and circulating volume and can 
have increased or decreased urine sodium concentration, depending on the timing of the 
most recent tablet, irrespective of their underlying volume status. The natriuresis induced 
by diuretics may cause ‘appropriate’ vasopressin release and subsequently hyponatraemia 
because of a decrease in circulating volume. Finally, diuretics may cause a SIAD-like state 
characterised by normal or mildly increased extracellular fluid volume [38, 111].
Urine sodium concentration can also be low in patients with heart failure or liver cirrho-
sis, due to reduced effective circulating arterial volume, even when they are taking diuretics 
(diuretic resistance) [112] (Appendix 6. Summary tables 1A and 1B).
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• How did we translate the evidence into a differential diagnostic strategy?
We translated the diagnostic evidence into a diagnostic decision tree, leading to a point 
where specific underlying causes can be derived from the clinical setting or history (Fig-
ure 7.6). However, for obvious reasons, this diagnostic tree is a simplification and does not 
guarantee completeness in each individual. Of note, severely symptomatic hyponatraemia 
always requires immediate treatment, which should be prioritised over further diagnostic 
Figure 7.6. Algorithm for the diagnosis of hyponatraemia.
ECF – extracellular fluid
HYPONATRAEMIA
HYPOTONIC HYPONATRAEMIA
NO
NO
YES
URINE OSMOLALITY
> 100 mOsm/kg
URINE SODIUM CONCENTRATION
EXCLUDE HYPERGLYCAEMIA AND OTHER CAUSES
OF NON-HYPOTONIC HYPONATRAEMIA
Consider immediate treatment
with hypertonic saline
(chapter 9)
ACUTE OR SEVERE
SYMPTOMS?
≤ 100 mOsm/kg
≤ 30 mmol/L > 30 mmol/L
Consider
- Primary polydipsia
- Low solute intake
- Beer potomania
YES
If ECF expanded consider
- Heart failure
- Liver cirrhosis
- Nephrotic syndrome
If ECF reduced consider 
- Diarrhea and vomiting
- Third spacing
- Remote diuretics
If ECF reduced consider
- Vomiting
- Primary adrenal insufficiency
- Renal salt wasting
- Cerebral salt wasting
- Occult diuretics
If ECF normal consider
- SIAD
- Secondary adrenal insufficiency
- (Hypothyroidism)
- Occult diuretics
Consider 
- Diuretics
- Kidney disease
- All other causes
DIURETICS OR 
KIDNEY DISEASE?
LOW EFFECTIVE ARTERIAL
BLOOD VOLUME
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differentiation.
Urine osmolality
Although there are no diagnostic test accuracy studies assessing optimal thresholds for 
identifying vasopressin activity, a urine osmolality ≤100 mOsm/kg on a spot urine sample 
always indicates maximally dilute urine. Hyponatraemia primarily caused by excess water 
intake or (beer) potomania with low solute intake belongs to this category [53, 113]. Be-
cause determining urine osmolality is a simple method for confirming an excess of fluid 
intake relative to solute intake, we recommend it as a first step in the diagnostic strategy.
Urine sodium concentration
A urine osmolality >100 mOsm/kg should trigger additional diagnostic testing to deter-
mine the underlying cause of hyponatraemia: ultimately classified into hyponatraemia with 
increased, normal or reduced extracellular fluid volume. Because clinical assessment of fluid 
status is often difficult and may lead clinicians down the wrong path, we have consciously 
steered away from the traditional approach of including it in the algorithm here. Instead, we 
recommend determining urine sodium concentration on a spot urine sample.
It is important to collect the serum and urine sample around the same time to allow cor-
rect interpretation of the values. We have selected a urine sodium concentration threshold 
of 30 mmol/l because several studies indicated good sensitivity and acceptable specificity 
in distinguishing hypovolaemia from euvolaemia or hypervolaemia [89,103, 107, 108]. This 
means that a urine sodium concentration ≤30 mmol/l suggests low effective arterial blood 
volume, even in patients on diuretics.
Diagnostic difficulty with diuretics
We suggest interpreting urine sodium concentrations >30 mmol/l with caution if pa-
tients are taking diuretics. In patients using diuretics, a fractional excretion of uric acid <12% 
may be better than urine sodium concentration to differentiate reduced effective circulat-
ing volume from SIAD as the underlying cause of hyponatraemia, although this assertion 
needs further confirmation [107]. We acknowledge that it may also be difficult to obtain the 
necessary measurements for calculating fractional uric acid excretion. For these reasons, we 
have refrained from advising to routinely calculate it in clinical practice.
Instead, we have taken a more pragmatic approach. First, we suggest that in patients 
taking diuretics, the diuretics be considered a contributing factor to hyponatraemia. Keep 
in mind that patients may not be aware they are taking diuretics or that their use may not 
have been recorded.
Although all types of diuretics have been associated with hyponatraemia, thiazide diu-
retics are most commonly the culprit [39]. Potassium-sparing diuretics such as mineralo-
corticoid receptor blockers and amiloride may also cause hyponatraemia. It occurs less 
frequently with loop diuretics because they interfere with the renal concentrating mecha-
nism [17]. Importantly, the use of diuretics does not exclude other causes of hyponatraemia. 
Other causes require consideration especially if hyponatraemia persists after cessation of 
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the diuretic (unresolved hyponatraemia).
Clinical assessment of fluid status
In the absence of diuretics, a clinical assessment of the volume status may aid further 
differential diagnosis. Although we have avoided it previously, we feel using it this far down 
the algorithm is less likely to lead to misclassification. There are fewer possible causes and 
they are easier to distinguish from one another. Based on the combination of urine sodium 
concentration and clinical assessment of extracellular fluid volume, we can define four clini-
cal categories that naturally suggest a number of underlying causes (Figure 7.6). The patho-
physiology of these conditions is detailed in section 5.
Unresolved hyponatraemia
We have labelled hyponatraemia ‘unresolved’ if it persists after cause-specific treatment 
(see section 7). If hyponatraemia is unresolved, the initial diagnosis of the underlying cause 
was probably wrong or only part of the explanation. Reassessment using the diagnostic 
algorithm may help. One may also want to consider seeking expert diagnostic advice.
A special note on SIAD
SIAD is a diagnosis of exclusion. It fits the category of hyponatraemia with a urine osmo-
lality >100 mOsm/kg, urine sodium concentration ≥30 mmol/l and normal extracellular flu-
id volume, but formal diagnosis requires exclusion of other possible causes of hyponatrae-
mia. One such possible cause is adrenal insufficiency. In secondary adrenal insufficiency, 
hypocortisolism stimulates vasopressin release and like in SIAD, hyponatraemia develops 
through non-suppressed vasopressin activity [114, 115]. Primary adrenal insufficiency can 
present with hyperkalaemia and orthostatic hypotension but may occur without signs of re-
duced extracellular fluid volume and indeed resemble SIAD [40, 116, 117, 118]. Hyponatrae-
mia due to hypothyroidism is very rare other than in myxoedema coma, when there is also 
a decrease in cardiac output and glomerular filtration rate [49, 51]. In 2006, Warner et al. [50] 
did identify a correlation between newly diagnosed hypothyroidism and decreased serum 
sodium but found this effect to be small and clinically irrelevant.
It is important to consider whether the diagnostic criteria for SIAD are met (Table 7.6) 
and look for known causes of inappropriate antidiuresis (Table 7. 7) [29, 45]. In theory, a 
diagnosis of SIAD requires all essential criteria to be met. If they are not, the presence of 
supplemental criteria increases the likelihood of SIAD. The original supplemental criteria for 
SIADH included an inappropriately elevated vasopressin concentration relative to serum 
osmolality. Although there was no systematic evaluation of the value of plasma vasopres-
sin measurements, the guideline development group believed that it does not contribute 
to the diagnosis in practice, mainly due to the technical difficulties in measurement, and of 
interpretation due to the variable relationship between vasopressin concentrations and the 
resulting electrolyte-free water excretion. The guideline development group therefore feels 
that measurement of vasopressin cannot be recommended.
The original supplemental criteria for SIADH included an abnormal result of a water-load-
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ing test to distinguish it from reset osmostat. However, we did not find data by which we 
could assess the value of water-loading tests. In addition, during group discussions, a fear of 
water-loading tests in patients with hypotonic hyponatraemia was expressed, as they may 
aggravate hypotonicity. Ultimately, it was decided to issue a warning against using it as a 
diagnostic test in SIAD.
Cerebral salt wasting is a rare condition that has been observed in patients with intracra-
nial disorders such as subarachnoid bleeding [41]. It can reduce extracellular fluid volume 
due to profound natriuresis. A very high urine sodium concentration, a high serum urea, 
orthostatic hypotension and a low central venous pressure argue in favour of cerebral salt 
wasting (Table 7. 11) [42].
Questions for future research
• What is the diagnostic performance of the new diagnostic algorithm included in this 
guideline?
• Can the addition of newer diagnostic parameters such as uric acid or copeptin or the 
replacement of the classical parameters by novel ones further improve the accuracy of 
the diagnosis of hyponatraemia?
• Is it still necessary to exclude hypothyroidism in the differential diagnosis of hyponatrae-
mia?
Treatment of hypotonic hyponatraemia
How to use the treatment recommendations
The advice provided in this section follows a specific hierarchy as illustrated in Figure 
7.7. Individual recommendations and statements can only be correctly interpreted and im-
plemented if considered within this structure. This is a consequence of the choice to use 
different classifications for hyponatraemia, as explained in section 6.1.
Table 7.11. Differences between SIADH and cerebral salt wasting.
SIADH Cerebral salt wasting
Serum urea concentration Normal – low Normal – high
Serum uric acid concentration Low Low
Urine volume Normal – low High
Urine sodium concentration > 30 mmol/L >> 30 mmol/L
Blood pressure Normal Normal – orthostatic hypotension
Central venous pressure Normal Low
Adapted from Sherlock M et al. Clin Endocrinol 2006; 64: 250-254.
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For a correct interpretation of the algorithm in question, it is crucial to understand that 
for correctly classifying symptoms as ‘severe’ or ‘moderately severe’, there must be sufficient 
confidence that the symptoms are caused by hyponatraemia. If hyponatraemia is mild and 
symptoms are severe or moderately severe (Table 7.5), the guideline development group 
advises to only accept causality in exceptional cases. Consequently, generally, sections 7.1, 
7.2 and 7.3 are not applicable when hyponatraemia is mild.
It is also essential to understand that the guideline development group distinguishes 
between targets and limits. A target is a goal one is aiming for; it is the change in serum 
sodium concentration that one wishes and expects to achieve with a particular treatment. 
Figure 7.7. Algorithm for the management of hypotonic hyponatraemia.
NO
MODERATELY SEVERE SYMPTOMS?
ACUTE HYPONATRAEMIA?
YES
NOYES
NOYES
REDUCED CIRCULATING VOLUME?
SEVERE SYMPTOMS?
Go to chapter 9.1
Hyponatraemia
with severe symptoms
Go to chapter 9.2
Hyponatraemia with 
moderately severe symptoms
Go to chapter 9.3
Acute hyponatraemia without severe 
or moderately severe symptoms
Go to chapter 9.4.1
Chronic 
hyponatraemia 
YES NO
EXPANDED EXTRACELLULAR FLUID?
YES NO
Go to chapter 9.4.4
Reduced circulating volume
Go to chapter 9.4.2
Expanded extracellular fluid
Go to chapter 9.4.3
SIAD
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By contrast, a limit is a change in serum sodium concentration one does not want to exceed 
and if surpassed, requires prompt counter-regulating intervention as described in section 
7.5. In addition, the reader should bear in mind that the absolute numbers provided as ‘tar-
gets’ or ‘limits’ should always be interpreted in the clinical context of the individual patient.
Hyponatraemia with severe symptoms
First-hour management, regardless of whether hyponatraemia is acute or chronic
• We recommend prompt i.v. infusion of 150 ml 3% hypertonic over 20 min (1D).
• We suggest checking the serum sodium concentration after 20 min while repeating an 
infusion of 150 ml 3% hypertonic saline for the next 20 min (2D).
• We suggest repeating therapeutic recommendations 7.1.1.1 and 7.1.1.2 twice or until a 
target of 5 mmol/l increase in serum sodium concentration is achieved (2D).
• Manage patients with severely symptomatic hyponatraemia in an environment where 
close biochemical and clinical monitoring can be provided (not graded).
Follow-up management in case of improvement of symptoms after a 5 mmol/l increase in serum 
sodium concentration in the first hour, regardless of whether hyponatraemia is acute or chronic
• We recommend stopping the infusion of hypertonic saline (1D).
• We recommend keeping the i.v. line open by infusing the smallest feasible volume of 
0.9% saline until cause-specific treatment is started (1D).
• We recommend starting a diagnosis-specific treatment if available, aiming at least to 
stabilise sodium concentration (1D).
• We recommend limiting the increase in serum sodium concentration to a total of 10 
mmol/l during the first 24 h and an additional 8 mmol/l during every 24 h thereafter 
until the serum sodium concentration reaches 130 mmol/l (1D).
• We suggest checking the serum sodium concentration after 6 and 12 h and daily after-
wards until the serum sodium concentration has stabilised under stable treatment (2D).
Follow-up management in case of no improvement of symptoms after a 5 mmol/l increase in 
serum sodium concentration in the first hour, regardless of whether hyponatraemia is acute or 
chronic
• We recommend continuing an i.v. infusion of 3% hypertonic saline or equivalent 
aiming for an additional 1 mmol/l per h increase in serum sodium concentration (1D).
• We recommend stopping the infusion of 3% hypertonic saline or equivalent when the 
symptoms improve, the serum sodium concentration increases 10 mmol/l in total or 
the serum sodium concentration reaches 130 mmol/l, whichever occurs first (1D).
• We recommend additional diagnostic exploration for other causes of the symptoms 
than hyponatraemia (1D).
• We suggest checking the serum sodium concentration every 4 h as long as an i.v. 
infusion of 3% hypertonic saline or equivalent is continued (2D).
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Advice for clinical practice
• Prompt infusion of hypertonic saline may save lives. However, preparing a 3% hypertonic 
saline infusion takes time and errors may occur in calculating the required amount of 
sodium chloride. Therefore, it may be wise for the pharmacy to store pre-prepared 150 
ml bags of 3% hypertonic saline. It ensures that solutions are prepared under sterile con-
ditions, by either the pharmacist or the manufacturer, and are available for immediate 
infusion without having to prepare them on the spot.
• Consider using weight-based (2 ml/kg) rather than the fixed 150 ml infusion volumes of 
3% hypertonic saline in case of obviously deviant body composition.
• Do not expect patients with severe symptoms to completely recover immediately, as it 
may take some time for the brain to fully recover. Be aware that sometimes it may not be 
possible to assess an improvement in symptoms, e.g. because the patient is intubated 
and sedated. In these cases, we advise to follow guidance as described under 7.1.2.
• Keep in mind that if hypokalaemia is present, correction of the hypokalaemia will con-
tribute to an increase in serum sodium concentration.
• To achieve the 1 mmol/l per h increase advised in 7.1.2.1, the formula of Adrogué–Ma-
dias may be used, but keep in mind that the actual increase may exceed the calculated 
increase [87]:
Change in serum [Na+] = Infusate [Na
+] – Serum [Na+]
   Total body water + 1
Change in serum [Na+] = ( Infusate [Na
+] + Infusate [K+] ) – Serum [Na+]
   Total body water + 1
Na+, sodium concentration (mmol/l); K+, potassium concentration (mmol/l). The numera-
tor in formula 1 is a simplification of the expression in formula 2, with the value yielded by 
the equation (mmol/l). The estimated total body water (l) is calculated as a fraction of body 
weight. The fraction is 0.6 in non-elderly men and 0.5 in non-elderly women and 0.5 and 
0.45 in elderly men and women respectively. Normally, extracellular and intracellular fluids 
account for 40 and 60% of total body water respectively.
Rationale
• Why this question?
When hyponatraemia causes severe symptoms, it reflects the presence of brain oede-
ma. If not treated, death may rapidly follow. On the other hand, when hyponatraemia is 
chronic and the serum sodium concentration increases too rapidly, osmotic demyelination 
syndrome may develop and permanent brain damage may ensue. Infusion of hypertonic 
saline can rapidly raise the serum sodium concentration, but for clinicians, the indications, 
infusion speed and target serum sodium concentration are often unclear.
• What did we find?
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Overall, the body of evidence to base recommendations for this topic was limited. Sever-
al early case series reported the use of i.v. hypertonic saline as treatment for hyponatraemia 
[119,  120,  121,  122,  123,  124,125]. However, settings, biochemical severity, rate of devel-
opment, symptoms and co-interventions differed widely both between and within studies 
and were often difficult to assess. Insufficiently detailed reporting often made it difficult to 
assess the increases in serum sodium concentration that were attained and to what extent 
these studies were applicable to patients who present with severe symptoms according to 
our definitions.
In a case series published in 1982, seven patients with moderately severe to severe symp-
toms and profound hyponatraemia (mean serum sodium concentration 99 mmol/l) were 
treated with a 3% hypertonic saline i.v. infusion, resulting in a mean 2.4 ± 0.5 mmol/l per h 
increase in serum sodium concentration. Infusion rates differed between patients [120]. In 
1986, Worthley et al. reported five patients who presented with seizures caused by acute 
hyponatraemia. They were treated with 250 mmol sodium chloride, infused over 10 min 
[119]. Serum sodium concentrations increased with a mean of 7.4 ± 1.1 mmol/l after 1 h and 
neurological symptoms promptly improved in all five cases. In a retrospective chart review 
of 11 patients with acute hyponatraemia, Hsu saw similar clinical outcomes. After infusion 
of 250–750 ml 3% NaCl, presenting symptoms of seizures and delirium resolved, although 
averaged initial increases in serum sodium concentration were limited to 1.6 ± 0.5 mmol/l 
per h [85].
Woo et al. retrospectively described the results of a fixed protocol for correcting acute 
hyponatraemia in 49 neurosurgical patients: a 3% hypertonic saline infusion, starting at 20 
ml/h and adapted based on 6 h measurements of the serum sodium concentration. Serum 
sodium concentrations increased a mean 0.4 ± 0.4 mmol/l per h. There was minimal hyper-
natraemia [121]. The extent and type of symptoms were not reported.
We found one prospective non-comparative trial including 58 participants with pro-
found hyponatraemia (mean serum sodium concentration 114 mmol/l) and moderately 
severe to severe symptoms. Patients were treated according to a protocol in which 100 ml 
3% hypertonic saline was infused over 4 h with later adjustment according to biochemical 
response. After the initial infusion, the serum sodium concentration increased a median 2 
mmol/l (range 0–6 mmol/l). In 22%, the serum sodium concentration did not increase after 
the first infusion and 19% required 200 ml while 3% required 300 ml for an initial increase 
of 1 mmol/l [126].
Mohmand et al. [122] retrospectively reported 62 cases of hyponatraemia treated with 
3% hypertonic saline at a median infusion rate of 0.38 ml/kg per h. The treatment resulted 
in an average increase in serum sodium concentration of 0.5 ± 0.1 mmol/l per h with a mean 
total increase of 7.1 ± 0.6 mmol/l and 11.3 ± 0.7 mmol/l per h in the first and second 24 h. 
However, in 11 and 10% of cases, the increase was >12 mmol/l per 24 h and >18 mmol/l per 
48 h respectively. Among patients with an initial serum sodium concentration <120 mmol/l, 
the observed increase in serum sodium concentration exceeded the rise predicted by the 
Adrogué–Madias formula in 74% of cases, on average 2.4 times the predicted rise. The ex-
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tent of symptoms at presentation was not reported.
In another retrospective case series including 23 patients, Castello et al. [125] used an-
other formula to calculate sodium deficit in hyponatraemic patients with liver cirrhosis. The 
sodium deficit was corrected with 3% hypertonic saline. There was a good correlation (R = 
0.98) between the calculated sodium deficit and the amount of sodium used in correction. 
Symptoms resolved in all patients, but it is unclear to what extent symptoms were caused 
by hyponatraemia.
Forssell et al.  reported a case series of six patients with chronic hyponatraemia due to 
heart failure treated with 3% hypertonic saline and i.v. loop diuretics. They observed an 
increase in serum sodium concentration and no deterioration of heart failure. However, no 
numeric data with the patient as unit of analysis and no symptomatology were provided 
[123].
Musch & Decaux observed 17 patients with chronic asymptomatic hyponatraemia due 
to SIAD treated with i.v. 0.9% saline. On average, the serum sodium concentration increased 
only slightly and indeed decreased in up to 1/3 of cases [124].
Sood et al. [127] assessed the efficacy of both 1–2 μg parenteral desmopressin and hy-
pertonic saline for the correction of hyponatraemia in a single centre, retrospective cohort 
study including 24 patients. Hypertonic saline was infused at rates calculated to keep the 
increase in serum sodium concentration <6 mmol/l over 24 h (using the Adrogué–Madias 
formula). The combination treatment produced an increase in serum sodium concentration 
of 5.8 ± 2.8 mmol/l at 24 h and an additional 4.5 ± 2.2 mmol/l at 48 h. None of the patients 
had an increase in serum sodium concentration exceeding 12 mmol/l during the first 24 h 
or 18 mmol/l during the first 48 h. There was no significant difference between actual and 
predicted increases in serum sodium concentration during the first 24 h.
Osmotic demyelination syndrome is a rare but dramatic complication that occurs in 
chronic hyponatraemia when the serum sodium concentration increases too rapidly [128].
We found 54 cases (63% female, median age 45 years, interquartile range 45–58 years) 
of osmotic demyelination syndrome published since 1997: 45 individual case reports and 
three case series including a total of nine patients [72, 129, 130, 131, 132, 133, 134, 135, 1
36, 137,138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150,151, 152, 153, 154, 15
5, 156, 157, 158, 159, 160, 161, 162, 163,164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 1
74, 175]. In 96% (52/54), the diagnosis of osmotic demyelination syndrome was based on 
magnetic resonance imaging. Important details such as onset and cause of hyponatraemia, 
initial symptoms and their evolution, presence of other risk factors for osmotic demyelina-
tion syndrome and timing of osmotic demyelination syndrome symptoms in relationship 
to the increase in sodium concentration were generally poorly reported. In 6% (3/54), data 
were insufficient to allow estimation of the 24 and/or 48 h correction speed. In 96% (52/54) 
of cases, the initial serum sodium concentration was <120 mmol/l, in 85% (46/54) <115 
mmol/l. In 87% (47/54), the sodium concentration increased ≥12 mmol/l during the first 24 
h or ≥20 mmol/l during the first 48 h. Only 7% of cases (4/54) developed osmotic demyelina-
tion syndrome at lower correction rates [72, 136, 137, 165]. Two of these patients developed 
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osmotic demyelination syndrome with serum sodium concentration increases of 10– <12 
mmol/l during the first 24 h and <18 mmol/l in 48 h [72,136]. Both patients (men) had a his-
tory of alcohol abuse as a risk factor for osmotic demyelination syndrome, and it is therefore 
unclear whether the neurological condition was caused by the speed of increase in serum 
sodium concentration. In another case, a woman with a history of alcohol abuse and hy-
pokalaemia developed osmotic demyelination syndrome associated with an increase in se-
rum sodium concentration limited to 2 mmol/l during 24 h and 4 mmol/l during 48 h [137]. 
Finally, in a further case, a woman developed osmotic demyelination syndrome after the 
serum sodium concentration increased by 15 mmol/l within the first 48 h of treatment; the 
24 h limit could not be calculated. The quality of the reporting did not allow a reasonable 
assumption of causality [165] (Appendix 6. Summary tables 2A, 2B, 13A).
• How did we translate the evidence into the statement?
First-hour management
Severe symptoms mostly result from brain oedema caused by an acute drop in effective 
osmolality or by rapid further decrease in pre-existing chronic hyponatraemia [73]. Severely 
symptomatic hyponatraemia is a dangerous condition, which may lead to permanent brain 
damage or death if left untreated [73]. Although the available data stem from small series, 
they do suggest that the situation can be reversed by rapidly increasing the serum sodium 
concentration in the first hour [85, 119]. Given the immediate risk of severe neurological 
damage, reducing brain oedema should be prioritised in severely symptomatic hyponatrae-
mia as this threat overrules that of possibly inducing osmotic demyelination or fluid over-
load.
If severe symptoms are caused by hyponatraemia, then small increases in effective os-
molality by small increases in serum sodium concentration may be sufficient to improve 
them and to prevent brain stem herniation [119]. The infusion of 3% hypertonic saline is an 
effective way to rapidly increase the serum sodium concentration. Observational data and 
clinical experience indicate that a 5 mmol/l increase in serum sodium concentration can be 
sufficient to improve symptoms [176]. Most reports use a total of 500 ml of fluid. Although 
there is no evidence in published research to support the assertion, the guideline develop-
ment group believed working with (repeated) 150 ml infusions, given every 20 min, may be 
a reasonable and safer approach. This approach allows monitoring of the change in serum 
sodium concentration in relationship to the clinical response and aims to manage the risk of 
overly rapid correction. We suggest repeating the 150 ml infusions of 3% hypertonic saline 
until the serum sodium concentration has increased 5 mmol/l, or until the symptoms im-
prove, whichever comes first. There was no consensus in the guideline development group 
on whether these volumes are best given in continuous infusion (preferred by most) or by 
a slow i.v. injection. Some guideline development group members argued that the dose 
should be adapted to the weight of the patient, to avoid both over- and under-correction. 
Others argued that it may be difficult to assess weight correctly in the clinical environment 
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and that it was unclear whether actual weight or weight adjusted for body composition 
should be used (e.g. should obese patients have different weight-adjusted treatment regi-
mens from muscular patients or patients with oedema). There was unanimous agreement 
that weight-dependent dose adaptation should be considered in patients with body com-
position clearly outside the range commonly seen in practice.
There was some concern regarding the availability of 3% hypertonic saline. The guideline 
development group agreed that hospitals should make an effort to have this solution avail-
able in their pharmacy. Prompt infusion of hypertonic saline may save lives and preparing 
a 3% hypertonic saline infusion takes time. In addition, errors may occur from having to 
calculate the required amount of sodium chloride in emergency.
Finally, given the severity of the neurological symptoms and the possibility of requiring 
airway protection or haemodynamic support, we feel these patients require management 
in an environment where close supervision can be provided.
Follow-up management: symptom improvement
If the symptoms improve after a 5 mmol/l increase in serum sodium concentration, we 
recommend stopping the infusion and starting cause-specific treatment to maintain the 
achieved serum sodium concentration. Systematic review of the cases of osmotic demyeli-
nation syndrome published during the past 15 years generally supports restricting increas-
es in serum sodium concentration <10 mmol/l in the first 24 h and <18 mmol/l in the first 
48 h. It is very difficult, if not impossible, to set ‘safe’ rate limits for correcting hyponatraemia. 
The risk of developing the osmotic demyelination syndrome seems to depend not only on 
the rate of increase in serum sodium concentration but also on associated underlying risk 
factors, such as a history of alcohol abuse, liver disease, use of thiazides or antidepressant 
medications and the original biochemical degree and duration of hyponatraemia. Although 
case-based data do not allow incidence or risk estimation, only two cases of osmotic demy-
elination syndrome have been reported with correction speeds below these limits.
We should reemphasise that limits are different from aims. The capacity of the kidneys 
to excrete electrolyte-free water can vary substantially during treatment and the actual 
change in serum sodium concentration may be unpredictable. Correction speeds frequent-
ly exceed those predicted by the Adrogué–Madias formula, even by as much as five times 
that predicted [122]. This reflects interplay between a number of factors: suppression of 
appropriate endogenous vasopressin secretion by fluid and salt loading, the natural history 
of the underlying condition and the potential impact of cause-specific treatments. Given 
the uncertainty in biochemical response to treatment, the guideline development group 
believes that the increase in serum sodium concentration aimed for initially should be suf-
ficient to allow an appropriate margin of safety. Based on an extensive systematic review of 
available case reports, the guideline development group agreed that a correction rate of 
10 mmol/l during the first 24 h and 18 mmol/l during the first 48 h is probably a safe limit.
We advise close monitoring of serum sodium concentrations during the first 24 h of treat-
ment and daily thereafter. It can be speculated that administering desmopressin makes the 
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Androgué–Madias formula more accurate in clinical practice, as it removes one of the vari-
ables during treatment, by clamping urine electrolyte-free water excretion at a constant lev-
el. A retrospective observational study has indicated that combined use of 1–2 μg i.v. desm-
opressin with hypertonic saline may allow gradual increase in serum sodium concentration 
without risking overcorrection. The study involved physicians with extensive experience in 
treating hyponatraemia. The guideline development group believes that these results are 
interesting but require confirmation before advocating it as a general practice. For manage-
ment in case of accidental overcorrection, we refer to section 7.5.
Follow-up management: no symptom improvement
If the symptoms do not improve after a 5 mmol/l increase in serum sodium concentration 
during the first hour, other explanations for the symptoms should be explored. Depending 
on the clinical history, additional neurological investigations such as imaging may be help-
ful. We advise attempting a further increase in serum sodium concentration of 1 mmol/l by 
infusing 3% hypertonic saline while additional avenues are explored. If symptoms do not 
improve after a 10 mmol/l increase in serum sodium concentration, it is (even more) likely 
they are caused by something other than hyponatraemia. Hence, we believe that serum 
sodium concentration should not increase >10 mmol/l during the first 24 h (the first 5 mmol 
included), even if symptoms do not improve. The guideline development group also recom-
mends stopping hypertonic saline if the serum sodium concentration reaches 130 mmol/l. 
Similar to the reasoning above, it is unlikely that symptoms are caused by hyponatraemia if 
they persist after the serum sodium concentration has reached 130 mmol/l.
Suggestions for future research
• Development and testing of assessment models (based on easily measurable variables 
such as height, sex and weight) that would enable accurate and reliable prediction of the 
expected increase in serum sodium concentration in response to a given i.v. sodium load.
• Prospective, standardised, multicentre registry to collect data relating to the increase in 
serum sodium concentration and clinical response and to facilitate determining the safe 
upper speed limit for correcting hyponatraemia.
Hyponatraemia with moderately severe symptoms
• We recommend starting prompt diagnostic assessment (1D).
• Stop, if possible, medications and other factors that can contribute to or provoke 
hyponatraemia (not graded).
• We recommend cause-specific treatment (1D).
• We suggest immediate treatment with a single i.v. infusion of 150 ml 3% hypertonic 
saline or equivalent over 20 min (2D).
• We suggest aiming for a 5 mmol/l per 24-h increase in serum sodium concentration (2D).
• We suggest limiting the increase in serum sodium concentration to 10 mmol/l in the first 
24 h and 8 mmol/l during every 24 h thereafter, until a serum sodium concentration of 
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130 mmol/l is reached (2D).
• We suggest checking the serum sodium concentration after 1, 6 and 12 h (2D).
• We suggest additional diagnostic exploration for other causes of the symptoms if the 
symptoms do not improve with an increase in serum sodium concentration (2D).
• We suggest considering to manage the patient as in severely symptomatic hyponatrae-
mia if the serum sodium concentration further decreases despite treating the underlying 
diagnosis (2D).
Rationale
• Why this question?
Hyponatraemia with moderately severe symptoms is a dangerous condition. Although 
the immediate threat to life is less pronounced than for hyponatraemia with severe symp-
toms, any further decline in serum sodium concentration can cause the clinical situation to 
deteriorate very rapidly. However, were the serum sodium concentration to increase too 
rapidly, osmotic demyelination syndrome might develop if hyponatraemia is chronic and 
permanent brain damage may ensue. For clinicians, it is often unclear which treatments 
should be used or what increases in serum sodium concentration they should pursue.
• What did we find?
Overall, the body of evidence on which to base recommendations was very limited and 
similar to that for hyponatraemia with severe symptoms (see section 7.1).
• How did we translate the evidence into the statement?
Although hyponatraemia with moderately severe symptoms is a dangerous condition, 
the immediate threat is less pronounced than for hyponatraemia with severe symptoms. 
Consequently, in the balance between benefits and harms, the reduced immediate threat 
from hyponatraemia shifts the priority to preventing a further decrease in serum sodium 
concentration rather than inducing a rapid increase. The target increase in serum sodium 
concentration we advise, therefore, is also smaller and the motivation for infusing hyper-
tonic saline is less strong. In our opinion, there is time for diagnostic testing and treatment 
can be directed towards the specific diagnosis.
Suggestions for future research
None.
Acute hyponatraemia without severe or moderately severe symptoms
• Make sure that the serum sodium concentration has been measured using the same 
technique used for the previous measurement and that no administrative errors in sam-
ple handling have occurred (not graded).
• If possible, stop fluids, medications and other factors that can contribute to or provoke 
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hyponatraemia (not graded).
• We recommend starting prompt diagnostic assessment (1D).
• We recommend cause-specific treatment (1D).
• If the acute decrease in serum sodium concentration exceeds 10 mmol/l, we suggest a 
single i.v. infusion of 150 ml 3% hypertonic saline or equivalent over 20 min (2D).
• We suggest checking the serum sodium concentration after 4 h, using the same tech-
nique as used for the previous measurement (2D).
Rationale
• Why this question?
We have defined ‘acute’ hyponatraemia as hyponatraemia that is documented to exist 
<48 h (section 6.1.2). Although the absence of moderately severe to severe symptoms in-
dicates that the patient is not suffering clinically important brain oedema, adaptation has 
not occurred and any further decline in serum sodium concentration may rapidly worsen 
the clinical situation. Because adaptation has not been completed, the theoretical risk of 
osmotic demyelinating syndrome through overly rapid correction is less of a worry. For cli-
nicians, it is often unclear which treatments should be used or what increases in serum 
sodium concentration they should pursue.
• What did we find?
We found one pseudo-randomised trial including eight participants of the 161 km long 
2009 Western States Endurance Run, who had a serum sodium concentration <135 mmol/l 
at the end of their run without neurological symptoms. Participants were randomised based 
on their registration number to either oral rehydration with 100 ml 3% hypertonic saline so-
lution or a single i.v. infusion of 100 ml 3% saline. After 1 h, the serum sodium concentration 
was 4.3 mmol/l higher for the participants receiving i.v. fluids than for the patients receiving 
oral rehydration. Reliability of the results was affected by a 1 mmol/l higher serum sodium 
concentration at baseline in patients receiving i.v. fluids, inadequate randomisation, lack 
of untreated controls and the open-label design (Appendix 6. Summary tables 2A and 2B).
• How did we translate the evidence into the statement?
As is often the case for hyponatraemia, the evidence for a particular management strat-
egy in patients with acute hyponatraemia without moderately severe or severe symptoms is 
poor. Hence, recommendations are largely based on translation from physiology, laboratory 
and animal data and clinical experience. The absence of severe symptoms indicates that the 
brain has not yet developed clinically important brain oedema. Similarly to hyponatraemia 
with moderately severe symptoms, it shifts the priority from inducing a rapid increase to 
preventing a further decrease in serum sodium concentration. Again, the motivation for in-
fusing hypertonic saline is less strong than for hyponatraemia with severe symptoms. In the 
opinion of the guideline development group, there is time for diagnostic testing. Treatment 
can be diagnosis specific, although a single infusion of 150 ml 3% hypertonic saline may be 
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wise to avoid a further drop in serum sodium concentration regardless of underlying cause.
Because the brain has not had the time to adapt fully to its hypotonic environment when 
hyponatraemia is acute, we believe the risk of osmotic demyelination after overly rapid in-
crease is less of a concern. The available data on osmotic demyelinating syndrome seem to 
support that this position is correct. This is why we set no limit or aim for the correction in 
acute hyponatraemia. This contrasts with our recommendations for hyponatraemia with 
moderately severe or severe symptoms because in these settings we advise to initiate treat-
ment regardless of whether hyponatraemia is acute or chronic.
Different techniques to measure serum sodium concentration might result in different 
results. Therefore, when a sudden decrease in serum sodium concentration between two 
measurements is observed, it is advisable to first check consistency of measurement.
Suggestions for future research
Prospective, large-scale, registration-based data collection to facilitate impact evaluation 
of the proposed management strategy on end-points of clinical response and overcorrec-
tion rate.
Chronic hyponatraemia without severe or moderately severe symptoms
General management
• Stop non-essential fluids, medications and other factors that can contribute to or pro-
voke hyponatraemia (not graded).
• We recommend cause-specific treatment (1D).
• In mild hyponatraemia, we suggest against treatment with the sole aim of increasing the 
serum sodium concentration (2C).
• In moderate or profound hyponatraemia, we recommend avoiding an increase in serum 
sodium concentration of >10 mmol/l during the first 24 h and >8 mmol/l during every 
24 h thereafter (1D).
• In moderate or profound hyponatraemia, we suggest checking the serum sodium con-
centration every 6 h until the serum sodium concentration has stabilised under stable 
treatment (2D).
• In case of unresolved hyponatraemia, reconsider the diagnostic algorithm and ask for 
expert advice (not graded).
Patients with expanded extracellular fluid
• We recommend against a treatment with the sole aim of increasing the serum sodium 
concentration in mild or moderate hyponatraemia (1C).
• We suggest fluid restriction to prevent further fluid overload (2D).
• We recommend against vasopressin receptor antagonists (1C).
• We recommend against demeclocycline (1D).
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Patients with SIAD
• In moderate or profound hyponatraemia, we suggest restricting fluid intake as first-line 
treatment (2D).
• In moderate or profound hyponatraemia, we suggest the following can be considered 
equal second-line treatments: increasing solute intake with 0.25–0.50 g/kg per day of 
urea or a combination of low-dose loop diuretics and oral sodium chloride (2D).
• In moderate or profound hyponatraemia, we recommend against lithium or demeclocy-
cline (1D).
• In moderate hyponatraemia, we do not recommend vasopressin receptor antagonists 
(1C).
• In profound hyponatraemia, we recommend against vasopressin receptor antagonists 
(1C).
Patients with reduced circulating volume
• We recommend restoring extracellular volume with i.v. infusion of 0.9% saline or a bal-
anced crystalloid solution at 0.5–1.0 ml/kg per h (1B).
• Manage patients with haemodynamic instability in an environment where close bio-
chemical and clinical monitoring can be provided (not graded).
• In case of haemodynamic instability, the need for rapid fluid resuscitation overrides the 
risk of an overly rapid increase in serum sodium concentration (not graded).
Advice for clinical practice
• A sudden increase in urine output to >100 ml/h signals increased risk of overly rapid rise 
in serum sodium concentration. If vasopressin activity is suddenly suppressed, as hap-
pens when intravascular volume is restored in hypovolaemia, free water clearance can 
dramatically increase, resulting in serum sodium concentrations rising more rapidly than 
expected. If urine output suddenly increases, we would advise measuring the serum so-
dium concentration every 2 h until it has stabilised under stable treatment. The implicit 
advice to monitor urine output does not imply that we advise a bladder catheter solely 
for this purpose. Most patients will be able to void spontaneously and collect urine for 
output monitoring.
• As a means of increasing solute intake, we suggest daily intake of 0.25–0.50 g/kg urea 
can be used. The bitter taste can be reduced by combining it with sweet-tasting sub-
stances. The pharmacist may be asked to prepare the following as sachets: urea 10 g + 
NaHCO3 2 g + citric acid 1.5 g + sucrose 200 mg to be dissolved in 50–100 ml water. This 
will result in a more palatable, slightly sparkling solution.
Rationale
• Why this question?
Chronic hyponatraemia is common and associated with an increased risk of death, both 
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in and out of hospital [17]. However, it is unclear whether risk of death further increases as 
individual sodium concentrations decrease, and data on the exact association between se-
rum sodium concentration and death are contradictory [19]. In addition, it remains unclear 
whether hyponatraemia itself or the underlying disease explains the higher mortality risk. 
It is also unclear whether treating hyponatraemia improves patient outcome. Finally, even if 
we decide to treat, it is often unclear what treatment option is most appropriate.
• What did we find?
We identified two systematic reviews comparing a vasopressin receptor antagonist (one 
of conivaptan, lixivaptan, satavaptan or tolvaptan) vs placebo. A first review, published in 
2010, included 15 randomised controlled trials and 1619 participants up to 2009 [177]. 
Overall, vasopressin receptor antagonists modestly increased serum sodium concentration 
after 3–7 days (mean difference (MD) 5.27 mmol/l, 95% CI 4.27–6.26) and up to 1 month (MD 
3.49 mmol/l, 95% CI 2.56–4.41). There was no significant reduction in risk of death and there 
were similar numbers of adverse and serious adverse events. Although there had been no 
reports of osmotic demyelination syndrome, risk of a rapid increase in serum sodium con-
centration was 10% when treated with a vasopressin receptor antagonist and 2.5 times 
higher than when treated with placebo (relative risk (RR) 2.52, 95% CI 1.26–5.06).
A second review, published in 2011, included 11 randomised trials and 1094 participants 
up to May 2010 [178]. Overall, results were consistent with the earlier review. There was 
a modest increase in serum sodium concentration at 5 days (MD 5.70, 95% CI 4.10–7.40) 
and up to 1 month (MD 4.60, 95% CI 3.60–5.50). There was no significant reduction in risk 
of death (odds ratio (OR) 0.67, 95% CI 0.38–1.18), no significant increased risk of adverse 
events, no reports of osmotic demyelination syndrome but a three times higher odds for 
rapid increases in serum sodium concentration (OR 3.03, 95% CI 1.82–5.05).
We identified five additional trials published since 2010, increasing the total sample size 
to 20 trials and 2900 participants [179, 180, 181,182, 183, 184, 185, 186, 187, 188, 189, 190
, 191, 192, 193, 194,195, 196, 197]. Overall, most participants had only mild to moderate 
hyponatraemia at onset with average sodium concentrations ranging between 124 and 
135 mmol/l. Quality of the evidence was generally reduced by risk of bias due to difficul-
ties with blinding participants, potentially unbalanced use of fluid restriction, incomplete 
outcome reporting and industry sponsorship. When we updated the earlier meta-anal-
yses by Rozen-Zvi  et al. with the additional data, we found that compared with placebo, 
vasopressin receptor antagonists did not reduce the number of deaths (RR 1.08, 95% CI 
0.80–1.46). When study results were sub-grouped according to volume status, a signal 
appeared indicating a possibly increased risk of death for hypervolaemic patients treated 
with a vasopressin receptor antagonist in comparison with placebo. However, results were 
not statistically significant and sample sizes were small (Appendix 6, Summary tables 10A 
and 10B). No study reported a measure of quality of life, validated for hyponatraemia [188]. 
Combined analysis showed a modest increase in serum sodium concentration in the vaso-
pressin antagonist group vs placebo both at 3–7 days (MD 4.30, 95% CI 3.51–4.95 mmol/l) 
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and up to 7 months (MD 3.49 mmol/l, 95% CI 3.59–5.02). There was no difference in adverse 
events (RR 1.01, 95% CI 0.94–1.09), serious adverse events (RR 1.04, 95% CI 0.91–1.20) or 
adverse events requiring drug discontinuation (RR 0.85, 95% CI 0.61–1.19) in patients with 
hyponatraemia. However, the risk for rapid sodium increase was 60% higher when treated 
with a vasopressin receptor antagonist (RR 1.61, 95% CI 1.11–2.33), indicating that per 1000 
patients treated, 26 more would have an overly rapid correction. Results were consistent 
across different vasopressin receptor antagonists (tolvaptan, conivaptan, lixivaptan and sa-
tavaptan) and thresholds for rapid sodium correction, indicating a class effect. We found 
no published reports of osmotic demyelination syndrome occurring after an overly rapid 
increase during treatment with a vasopressin receptor antagonist. In March 2012, however, 
the company marketing tolvaptan issued a statement saying that there had been reports 
of neurological sequelae in patients treated with tolvaptan where the correction of serum 
sodium had exceeded the suggested rate [198]. In April 2013, the U.S. Food and Drug Ad-
ministration issued a Drug Safety communication based on serious adverse events in a trial 
where tolvaptan was studied as treatment for delaying the evolution of autosomal domi-
nant polycystic kidney disease [199]. Three patients developed serious liver injury, the earli-
est case 3 months after initiating tolvaptan. In addition, 42 of 958 participants (4.4%) treated 
with tolvaptan vs five of 484 (1.0%) treated with placebo developed alanine aminotrans-
ferase elevations greater than three times the upper limit of normal [200]. Drug doses ad-
ministered were higher than those that were used in hyponatraemia.
We found one trial (nine participants) that compared oral demeclocycline vs placebo, re-
porting only a modest and non-significant difference in serum sodium concentration increase 
at 3 weeks (MD 2.7 mmol/l, 95% CI −0.7 to 6.2) [201]. We identified no systematic reviews or 
randomised controlled trials evaluating the benefits and harms of urea, lithium, mannitol, 
loop diuretics, phenytoin or fluid restriction. We found several case series demonstrating 
an increase in serum sodium concentration after 2–7 days for urea [202, 203, 204, 205, 206], 
demeclocycline [207], loop diuretics in combination with oral NaCl [123, 125, 208], pheny-
toin [209] and fluid restriction [210]. We also identified case series of patients experienc-
ing an increase in serum sodium over a longer time period of up to 12 months for urea 
[211, 212, 213], up to 3 weeks for demeclocycline [214, 215, 216, 217, 218, 219], up to 20 
weeks for lithium [220], up to 150 days for furosemide with oral NaCl [221] and up to 30 days 
in phenytoin [220].
We also found several observational reports of acute kidney injury with demeclocycline 
[214, 215, 218, 219, 222, 223, 224, 225, 226, 227,228, 229, 230, 231, 232]; a single case report 
of confusion and somnolence with lithium [220] and unspecified neurological abnormali-
ties with phenytoin [233]. Finally, we identified two reports of adverse events with fluid 
restriction. The first was a retrospective study using data generated in a randomised con-
trolled trial evaluating tranexamic acid in patients with severe subarachnoid bleeding. In 
44 participants with hyponatraemia, 80% developed subsequent cerebral infarction when 
given <1000 ml of fluids a day vs 33% when not fluid restricted. The very specific setting 
makes the data of limited value to other settings. The small sample size, lack of adjustment 
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for confounding and the heterogeneity of hyponatraemia within the study group limit its 
value for causal inference. The second study included two cases of osmotic demyelination 
syndrome that occurred after restriction of fluid intake to 750 ml daily. The first case oc-
curred in a man with hyponatraemia probably due to polydipsia and low solute intake, the 
second in a woman with hyponatraemia due to thiazides, which were stopped on admis-
sion. In both cases, the serum sodium concentration increased with >19 mmol/l during the 
first 24 h and causal association between fluid restriction and subsequent demyelination 
appear to be limited [234, 235] (Appendix 6. Summary tables 3A to 12B).
• How did we translate the evidence into the statement?
General management
Many people take medications that can provoke or contribute to hyponatraemia. It 
makes sense to check whether patients with hyponatraemia are taking any such medica-
tions, to reconsider their necessity and to stop them if perceived benefits do not outweigh 
perceived harms. Likewise, it seems logical to stop unnecessary fluids, discourage excessive 
oral water drinking and treat any underlying condition that can be improved.
We found no comparative studies of the different available treatment strategies for 
chronic hyponatraemia. Taking into account the absence of evidence that treating chronic 
hyponatraemia results in improvement of patient-relevant outcomes, the guideline devel-
opment group judged that our primary concern was avoiding harm through treatment.
In patients with chronic mild hyponatraemia, we found no evidence that correcting hy-
ponatraemia itself improves patient-important outcomes. All interventions can cause ad-
verse events. We therefore advise against active interventions with the sole aim of increas-
ing the serum sodium concentration.
One could argue the same holds for moderate or even profound hyponatraemia. For 
these conditions too, there is little or no evidence to support treatment. However, different 
members in the guideline development group felt uncomfortable in advocating no treat-
ment for moderate or profound chronic hyponatraemia, highlighting the risk of a sudden, 
further deterioration leading to severe or moderately severe symptoms. Therefore, it was 
accepted that the risk–benefit balance for the different biochemical degrees of chronic hy-
ponatraemia, and of the underlying diagnosis, would be evaluated separately.
One important, potential harm is development of osmotic demyelination syndrome 
when the serum sodium concentration rises too rapidly. Systematic review of the cases of 
osmotic demyelinating syndrome published during the past 15 years generally support 
avoiding increases in serum sodium concentration >10 mmol/l in the first 24 h and >18 
mmol/l in the first 48 h, regardless of treatment type. It is very difficult, if not impossible, to 
set ‘safe’ speed limits for rate of correction. Risk of development of osmotic demyelination 
syndrome seems to depend not only on the speed of increase in serum sodium concentra-
tion but also on associated underlying risk factors: alcohol abuse, liver disease, use of thi-
azides or antidepressant medications, the original biochemical degree and the duration of 
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hyponatraemia. Although case-based data do not allow incidence or risk estimation, only 
two cases have been reported with correction speeds below these limits. In the majority of 
cases, correction speeds largely exceed them. We should be clear that limits are different 
from aims. As there is no clear evidence that correcting chronic hyponatraemia improves 
patient-important outcomes, we did not formulate aims. If you wish to avoid surpassing a 
certain 24-h limit, serum sodium concentration needs to be measured more frequently than 
once daily to allow adjusting treatment to the observed change. The 6-h measurement is 
somewhat arbitrary, chosen to manage a balance between allowing change in treatment 
and practicality. At this point in time, there are insufficient data on incidence of osmotic de-
myelination syndrome and influence of measurement timing to give a more informed view.
Expanded extracellular fluid volume
There are insufficient data to suggest that increasing serum sodium concentration im-
proves patient-important outcomes in moderate hyponatraemia with expanded extracel-
lular fluid volume, such as seen in liver cirrhosis or heart failure. Given treatments directed 
solely at increasing serum sodium concentration have inherent risks of overcorrection and 
other adverse effects, we believed that the balance was in favour of not treating in case 
of mild or moderate hyponatraemia in patients with expanded extracellular volume. For 
patients with profound hyponatraemia in this setting, the guideline development group 
acknowledged that it might be reasonable to avoid further decreases in serum sodium 
in certain patients, although there are no published data to support this view. Hence, the 
guideline development group refrained from making any statement regarding whether or 
not to treat this category of patients. Clearly, fluid restriction in this setting can be used as a 
means to reduce further fluid overload.
On systematic review of data in this specific patient category, there appeared to be an 
increased number of deaths in those patients treated with vasopressin receptor antagonists 
in comparison with those treated with placebo. Although results were not statistically sig-
nificant and sample sizes were small, the guideline development group believed the signal 
that active treatment may actually worsen outcomes was sufficient to recommend against 
vasopressin receptor antagonists in this specific category. The side effects reported for de-
meclocycline and lithium were such that we recommend not using them for any degree of 
hyponatraemia.
Syndrome of inappropriate antidiuresis
Although there is little to no formal evidence that fluid restriction increases serum so-
dium concentration more than placebo, clinical experience generally supports its use, pro-
vided fluid restriction is strictly adhered to. Similarly, there is no good evidence that fluid 
restriction is associated with important adverse effects, other than poor patient acceptabil-
ity. In the cases mentioned above, we believed it was unlikely that fluid restriction played 
a causal role in the development of osmotic demyelination syndrome. Hence, the guide-
line development group unanimously preferred fluid restriction as first-line treatment. As a 
second-line treatment, we suggest an increased intake of osmotic solutes to enhance clear-
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ance of water. We agreed that oral urea might be the most practical method to achieve 
increased solute intake. The guideline group acknowledged the bitter taste of urea, which 
might reduce acceptability. However, we believed that this could be solved by combining 
urea with sweet-tasting substances as described in the recipe provided in the advice for 
clinical practice. The guideline development group did not consider availability of urea a 
problem as it is used in many other pharmacological preparations.
For demeclocycline and lithium, there is some evidence of possible harm, so we advise 
against their use for management of any degree of chronic hyponatraemia in patients with 
SIAD.
Although vasopressin receptor antagonists do increase serum sodium, the guideline 
development group judged that based on current evidence, these drugs cannot be rec-
ommended. Indeed, the risk benefit ratio seems to be negative: there is no proven out-
come benefit aside from increase in serum sodium concentrations, while there are increas-
ing concerns on safety. The most prominent safety-related factor is the increased risk for 
overly rapid correction of hyponatraemia. As this risk is greatest in patients with profound 
hyponatraemia, the guideline development group wanted to recommend against the use 
of vasopressin receptor antagonists in this specific patient group. In addition, our concern 
around the toxicity profile of these compounds was increased by reports from the U.S. Food 
and Drug Administration warning for hepatotoxicity associated with the use of high tolvap-
tan doses in autosomal dominant polycystic kidney disease.
Patients with contracted extracellular volume
Hyponatraemia with reduced extracellular fluid volume may require a different ap-
proach to other causes of hyponatraemia. Patients with hyponatraemia and a contracted 
extracellular fluid volume have a combination of a true sodium and water deficit. They also 
have appropriate vasopressin secretion and hence diminished electrolyte-free water clear-
ance, simultaneously resulting in dilutional hyponatraemia. Although hyponatraemia with 
reduced extracellular fluid volume is common in clinical practice, we did not find specific 
studies addressing management from the perspective of treating hyponatraemia. Given 
the absence of formal evidence in this setting, recommendations are based on direct trans-
lation of pathophysiology to clinical practice.
Patients with hyponatraemia and reduced extracellular fluid volume lack water as well as 
sodium. Consequently, replenishing both deficits with isotonic saline seems logical. How-
ever, isotonic saline is characterised by an unphysiologically high concentration of chloride, 
which may impair renal function. Recent data have indicated that balanced crystalloid solu-
tions might be preferable for restoring volume deficits and these solutions are now com-
monly recommended in guidelines on volume replacement, although there is no published 
research specifically for hyponatraemia available [236, 237, 238].
If hyponatraemia is caused by a contracted extracellular fluid volume, restoring this 
volume will suppress vasopressin secretion causing electrolyte-free water excretion to in-
crease. Therefore, these patients are at high risk of an overly rapid increase in serum sodium 
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concentration. Sudden increases in urine output can act as a warning signal that overly 
rapid correction of hyponatraemia is imminent.
In patients who are haemodynamically unstable, the immediate risk of decreased organ 
perfusion is more important than the potential risk of overly rapid increases in serum so-
dium concentration. Hence, the need for volume resuscitation overrides any concerns for 
overly rapid correction of hyponatraemia. These patients are best managed in an environ-
ment where close monitoring, including frequent and swift sampling of serum and deter-
mination of its sodium concentration, is possible. In the case of imminent overcorrection, 
we suggest to continue fluid loading (if still needed) with free water, e.g. glucose solutions.
Suggestions for future research
More high-quality randomised, head-to-head comparison trial data for all potential 
treatments using longer term health outcomes such as death, quality of life and cognitive 
function.
What to do if hyponatraemia is corrected too rapidly?
• We recommend prompt intervention for re-lowering the serum sodium concentration 
if it increases >10 mmol/l during the first 24 h or >8 mmol/l in any 24 h thereafter (1D).
• We recommend discontinuing the ongoing active treatment (1D).
• We recommend consulting an expert to discuss if it is appropriate to start an infusion of 
10 ml/kg body weight of electrolyte-free water (e.g. glucose solutions) over 1 h under 
strict monitoring of urine output and fluid balance (1D).
• We recommend consulting an expert to discuss if it is appropriate to add i.v. desmopres-
sin 2 μg, with the understanding that this should not be repeated more frequently than 
every 8 h (1D).
Rationale
• Why this question?
Interrupting the underlying mechanisms that cause hyponatraemia can lead to sudden 
and rapid increases in serum sodium concentration. Overly rapid increases in serum sodium 
concentration can have dramatic consequences if osmotic demyelinating syndrome devel-
ops. For clinicians, it is often unclear what to do when overly rapid correction occurs.
• What did we find?
Although the exact incidence of overly rapid correction is unknown and depends on its 
definition, overly rapid increases in serum sodium concentration appear to be common. A 
small retrospective single-centre study including 62 participants treated with hypertonic 
saline reported correction in 11% at 24 h and in an additional 10% at 48 h [122].
Among those with a serum sodium concentration <120 mmol/l, the observed increase 
exceeded the rise predicted by the Adrogué–Madias formula in 74%. In patients with overly 
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rapid correction, the average increase in serum sodium concentration was 2.4 times that of 
the predicted increase. Inadvertent overly rapid correction was due to documented water 
diuresis in 40% of cases.
We found no randomised controlled trials and only two small observational studies on 
interventions for reversing overly rapid correction of hyponatraemia. In the first of these, a 
retrospective single-arm cohort study, six patients were given desmopressin after a 24-h 
increase in serum sodium concentration of 12 mmol/l had already been reached. Correction 
exceeding a 48-h limit of 18 mmol/l was avoided in five of the six. An additional 14 patients 
were given desmopressin in an attempt to prevent overcorrection after serum sodium con-
centration had increased 1–12 mmol/l. All patients had corrections below the 24- and 48-h 
limits [239].
The second, a small single-centre single-arm retrospective cohort study included 24 par-
ticipants [127]. A combination of 1–2 μg parenteral desmopressin and hypertonic saline 
was infused at speeds calculated (using the Adrogué–Madias formula) to keep the increase 
in serum sodium concentration <6 mmol/l over 24 h. The combined treatment produced an 
increase in serum sodium concentration of 5.8 ± 2.8 mmol/l at 24 h and an additional 4.5 
± 2.2 mmol/l at 48 h. None of the patients had an increase in serum sodium concentration 
exceeding 12 mmol/l during the first 24 h or 18 mmol/l during the first 48 h. There was no 
significant difference between actual and predicted increases in serum sodium concentra-
tion during the first 24 h.
• How did we translate the evidence into the statement?
The incidence of overly rapid correction of hyponatraemia depends on the thresholds 
used to define overly rapid correction. The limited data we have seem to indicate that se-
rum sodium concentrations are increased >10 mmol/l during the first 24 h and >8 mmol/l 
every 24 h thereafter fairly frequently. The incidence of osmotic demyelinating syndrome 
resulting from overly rapid increases in serum sodium concentration is unknown. As infor-
mation in this area is still only derived from case reports and small case series, it is probably 
very low. Given the dramatic consequences of osmotic demyelinating syndrome, it is clear 
that overly rapid increases should be avoided when treatment for hyponatraemia is started. 
Similarly, it makes sense to stop the active treatment of hyponatraemia if the increase in 
serum sodium concentration exceeds the limits we previously defined.
In established overly rapid correction, the benefits and harms of active treatments to 
re-lower serum sodium concentration have not been well studied. Nevertheless, the guide-
line development group feels that the dramatic consequences of osmotic demyelinating 
syndrome warrant an attempt to re-lower the serum sodium concentration in case of overly 
rapid correction using an active intervention.
It is plausible that overly rapid correction occurs more readily in conditions where treat-
ment of the underlying cause results in restoration of the kidneys’ capacity to excrete 
electrolyte-free water. Examples of such conditions include, but are not limited to, volume 
repletion in hypovolaemia, treatment of glucocorticoid deficiency, withholding thiazides, 
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withholding other drugs known to cause SIAD and lowering fluid intake in primary poly-
dipsia. Based on these theoretical considerations, clinical experience and limited data, we 
believe that infusing electrolyte-free water (e.g. 5% glucose solutions) and/or injecting 
desmopressin can be used in experienced hands to re-lower serum sodium concentration 
in case of overly rapid correction.
However, the guideline development group was reluctant to advise it strongly without 
consulting an expert. Large multi-centre trials with these interventions are lacking. Overly 
rapid correction of hyponatraemia may indicate the presence of a complex case, where the 
effect of further treatment may be even more difficult to predict. We consider that seeking 
additional expertise may be the safest option in these conditions.
Suggestions for future research
• Additional prospective studies examining the combination of desmopressin and hy-
pertonic saline to correct hyponatraemia and to avoid further overcorrection in those 
having already attained the correction limits are needed to further evaluate both the 
outcome benefits and harms of such a strategy.
• The combination of desmopressin and free water to reverse overcorrection needs further 
study.
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 General discussion
With this thesis, I aimed to contribute to evidence based practice in Nephrol-ogy. Not so much by expanding the theory of evidence based medicine, but by applying currently accepted methods to various aspects of evidence 
synthesis covering a wide array of clinical questions. Most of the work occurred as part of 
larger guideline development projects within European Renal Best Practice (ERBP), the of-
ficial guideline development body of the European Renal Association – European Dialysis 
and Transplant Association (ERA-EDTA). In what follows, I will summarize the main results of 
each work, discuss their implication for practice and reflect on what I have learned from the 
experience. 
Benefits and harms of interventions for children with primary vesicoureteric reflux
Primary VUR is thought to be a maturational defect, predisposing children for UTI, and 
renal involvement during UTI, and subsequently causing permanent kidney damage [1]. It is 
now recognised that at least some of the cortical defects detected after UTI are pre-existing 
developmental abnormalities rather than scars resulting from infection. What proportion 
of renal scarring is pre-existing and what proportion is secondary to infection remains un-
known and controversial. The same applies in the considering long-term implications for 
future kidney function and hypertension [2, 3]. 
Treatment has traditionally been targeted at preventing recurrent UTI under the assump-
tion this strategy would reduce the risk of symptomatic UTI and decrease involvement of 
the upper urinary tract; that it would mitigate kidney damage, and therefore reduce the risk 
of impaired renal function and hypertension in the future [4]. Long-term, low-dose antibiot-
ics have predominantly been used when spontaneous resolution of VUR was to be expect-
ed, or surgical or endoscopic correction of VUR if those chances were considered slim [5]. 
We concluded that clinical decision making should balance the possible, but uncertain, 
reductions in repeat UTI and kidney scarring with a threefold increase in the risk of devel-
oping antibiotic resistance, a small risk of adverse antibiotic effects, the cost and inconven-
ience of daily antibiotic administration for often prolonged periods, and the potential to 
increase community antibiotic resistance to not only the organisms that cause UTI but also 
to other pathogenic organisms that would have otherwise responded to these medications. 
Our review provided no compelling evidence that low-dose long-term antibiotic prophy-
laxis reduced the risk of recurrent UTI in children with VUR. The synthesis favoured antibi-
otic treatment, but individual sample sizes were small, confidence intervals wide, and data 
quality variable. However, a concurrent systematic review including children both with and 
without VUR did find the reduction in repeat symptomatic UTI was statistically significant, 
indicating our findings may have resulted from limited power in the analysis. The estimate 
of absolute risk reduction for children with VUR equalled 8%, corresponding to a need to 
treat between 12 and 13 children for 12 months to prevent one symptomatic UTI. Antibiotic 
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prophylaxis seemed to reduce the risk of new or progressive kidney damage by 3%, cor-
responding to a number needed to treat of 33. The magnitude of these effects need to be 
considered in conjunction with the weight of the outcomes in decision-making. Given the 
fact that repeat UTI is usually not life-treatening and the consequence of a kidney scar for 
long-term kidney function is unclear, numbers needed to treat of 13 and 33 respectively 
may be considered quite high.  
The incremental value of surgery over low-dose antibiotics largely remained uncertain. 
There was a small reduction in the risk of febrile UTI - with 8 children requiring surgery to 
prevent one episode of febrile UTI in 5 years - but not in symptomatic UTI overall. This mod-
est benefit should be balanced against the possible risks of the surgical procedure.  Cor-
recting VUR using endoscopic approaches could theoretically reduce surgical risk, but to 
date, the few available randomized trial data do not suggest the reduction in febrile UTI risk 
confers a systematic reduction in kidney damage. 
It is not unlikely that the grade of VUR modifies the effect various interventions have on 
the outcomes of interest. The studies assessing the effectiveness of antibiotic prophylaxis 
almost exclusively included children with lower grades of VUR (I to III), those evaluating the 
benefits and harms of surgical interventions exclusively included those with higher grades 
of VUR (IV to V). Although this represents the areas of perceived clinical uncertainty, it nec-
essarily precludes any assessment of differential effect of treatments for children with high 
versus low grade VUR. 
Sadly, our review did not identify any trials examining non-medical interventions, such 
as bladder and bowel management for dysfunctional elimination. In toilet-trained children 
with recurrent UTI, voiding postponement behaviours, incomplete emptying, and consti-
pation are extremely common and may be much more important etiologic factors in UTI 
recurrence than the reflux itself [6, 7].  
When we published our review in 2010, we suggested an additional well-designed, 
blinded and adequately powered study in children with VUR was needed to resolve the 
remaining uncertainty surrounding the benefit of antibiotic prophylaxis in preventing UTI 
and renal damage. In 2014, the results of such a study finally became available. The RIVUR 
study examined the effect of low-dose antibiotic treatment in children with various degrees 
of VUR on both symptomatic UTI and renal parenchymal injury assessed by DMSA scan [8]. 
The results confirmed our earlier findings of an 8% risk reduction in symptomatic UTI, but 
found the occurrence of renal scarring did not differ between the prophylaxis and placebo 
groups. To the inevitable question of whether I would advocate prophylactically treating 
children with long term-antibiotics after a first UTI, my answer, from a societal and profes-
sional perspective, would be no. 
Pharmacokinetics, efficacy and safety of antidepressants for depression in stage 3–5 
chronic kidney disease
At any given time and place, up to one quarter of the average dialysis unit will suffer 
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from major depression [9-11]. Even more will experience depressive symptoms. Aside from 
dramatically decreasing an often precarious quality of life to start with, it increases hospi-
talisation rates and shortens life expectancy [9, 12]. Accordingly, people with chronic kid-
ney disease identify improving psychosocial aspects of living with their illness among their 
most important research priorities [13]. In response ERBP considered clinical depression 
and specifically the treatment of depression with antidepressants a priority topic for recom-
mendation development.
Our systematic review found data were scarce and of generally poor quality. It showed 
that drug clearance in CKD3-5 was markedly reduced and dose-reduction necessary for sev-
eral antidepressants: selegiline, amitriptylinoxide, venlafaxine, desvenlafaxine, milnacipran, 
bupropion, reboxetine and tianeptine. In addition, it provided very limited evidence that 
treatment with antidepressants improved symptoms or overall quality of life. As such, we 
considered there was insufficient evidence for a general recommendation routinely advo-
cating medical treatment in patients with CKD3-5 who suffer depression. However, there is 
substantial evidence available for the general population as well as for patient groups with 
chronic illnesses other than CKD, and the prevalence is high, the consequences for quality 
of life are dramatic; and the side effects of the studied antidepressants in CKD 3-5 fairly mild. 
Hence we judged an 8 to 12-week trial – with preferably a serotonin re-uptake inhibitor - 
could be considered in patients suffering from moderate depression according to DSM-IV. 
To avoid pointless prolonged treatment, the effect should be evaluated at the end of the 
trial period and treatment stopped if it appeared ineffective.
We highlighted the lack of high-quality efficacy and safety data on the use of antide-
pressants in advanced CKD and the need for a well-designed RCT to clarify the balance 
between benefits and harms. When our systematic review went to press, we knew of one 
ongoing randomized trial, comparing sertraline to placebo with a 12-week follow-up, aim-
ing to include 200 patients (CAST-trial-NCT00946998). To this day, recruitment is still ongo-
ing. It seems astounding that a problem so great both in numbers and clinical ramifications, 
continues to receive so little attention; how so few high-quality data on pharmacological 
treatment of depression in CKD are available. This situation forces us to rely on extrapolated 
evidence obtained from other patient groups, which may be inappropriate for all sorts of 
reasons. Yet, there are grounds for optimism. In the past six years, two influential journals 
in nephrology each published a randomized trial supporting non-pharmacological behav-
ioural therapy for depression in CKD [14, 15]. Sample sizes were relatively small, and selec-
tion, performance and detection bias may have overestimated the effect sizes, but the focus 
on this topic shows an important shift of research towards patient-important issues.
European guideline on diagnosis and treatment of hypontraemia: rationale and 
projects
Hyponatraemia is the most common electrolyte disorder in clinical medicine. Every fifth 
patient admitted to hospital through an emergency unit will have hyponatraemia. Hy-
Nagler.indb   259 15/09/2015   16:14:54
Chapter 8
260
ponatraemic patients have a 30% increased risk of death during hospitalisation and remain 
admitted 14% longer relative to those without hyponatraemia [16-18]. Determining man-
agement of hyponatraemia has always been problematic. Hyponatraemia develops under 
a variety of conditions and is accordingly dealt with by clinicians with diverse interests and 
expertise. Over the years, the treatment dilemma has fostered diverse speciality-based ap-
proaches to diagnosis and treatment and resulted in sometimes inconsistent guideline rec-
ommendations [19]. 
Clinicians who are frequently confronted with hyponatraemia, have often faulted exist-
ing guidance for being  either too complex or too simplistic; for offering a diagnosis-, mech-
anism- or duration-based approach to treatment, failing to recognise that establishing the 
diagnosis, mechanism or duration of hyponatraemia may be difficult; for being biased by 
institution or speciality, limiting implementation across sites and clinical disciplines; for hav-
ing a biochemical focus, failing to prioritise clinical status in decisions on treatment; or fi-
nally for not being evidence based. 
Two evolving developments instigated European Renal Best Practice to re-examine the 
evidence for diagnosis and treatment of hyponatraemia: i) a clear recognition of the impor-
tance of evidence-based approaches to patient care to enhance quality, improve safety and 
establish a clear and transparent framework for service development and healthcare provi-
sion; ii) the advent of new diagnostics and therapeutics, highlighting the need for a valid, 
reliable and transparent process of evaluation to support key decisions [20]. 
To address this clinical dilemma we undertook two projects, which would feed the subse-
quent clinical practice guideline; a first intended to highlight both strengths and weakness-
es of existing guidance, and a second aiming to identify benefits and harms of treatments 
for chronic non-hypotonic hyponatraemia. 
Existing clinical practice guidelines and consensus statements on the diagnosis and 
treatment of hyponatraemia
Our review identified nine previously published guidance documents and showed that 
despite substantial similarities in proposed diagnostic tools, considerable differences in-
deed existed in classification thresholds, in when to initiate diagnostic work-up and in what 
sequence to order tests. Most existing guidance documents advocated similar first-line fluid 
treatments, but they differed somewhat in the limits for initial speed of increase in serum 
sodium concentration and which specific medications to use. Reasons for offering differing 
advice were undoubtedly multifactorial and at least partially related to limitations in the 
underlying evidence itself. Still, discrepancies between guidance documents could plau-
sibly have originated from differences in underlying methods of development with overall 
quality being suboptimal at best. 
This project was started as exploratory work prior to the development of the guideline, 
but finalised afterwards due to unforeseen delays in the peer review and editorial process 
for the projects’ publication. Consequently, the systematic review ended up including also 
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the European guideline itself and measured its quality against that of those that had been 
published before. Overall, we scored very well in the domains scope and purpose and great-
ly exceeded the scores for other guidelines in rigour of development, an aspect of guideline 
development we had felt very strongly about [21]. We hope the obtained scores truly reflect 
stringent application of methodological standards that resulted in a ‘trustworthy’ clinical 
practice guideline. Yet, as four of the authors of the comparative paper were involved as 
well in developing the guideline and all others were people close to the guideline develop-
ment group, one cannot rule out that a subconscious intellectual bias artificially inflated 
estimates of development rigour.
However, in the same analysis, the European guideline did not score equally well for 
other aspects related to guideline quality. We scored below 60%, which was poorer than 
a contemporary guideline, for applicability [22]. The score mostly reflected the absence of 
describing barriers to guideline implementation and failure to provide tools for putting the 
recommendations into practice. In part, guidelines are designed for practicioners to deal 
with the challenges of continuously growing medical knowledge and scientific information. 
They are designed to help make decisions at the moment care needs to be delivered. In 
its current format, mimicking a classic scientific paper, the European hyponatraemia docu-
ment is admittedly too long, too unstructured and fails to present information in a layered 
fashion. It is not unlikely this will limit the extent to which the guideline will reach its tar-
get audience and stimulate implementation. On the other hand, the guideline did provide 
an algorithm for diagnosis and treatment. Although this should increase the utility of the 
guideline, it is unclear to what extent it will truly improve implementation of the recom-
mendations. 
Benefits and harms of interventions for chronic non-hypovolaemic hypotonic 
hyponatraemia
Until about a decade ago, hyponatraemia rarely found itself truly in the spotlight, wheth-
er within scientific journals or at professional society meetings. Treatments for chronic hy-
ponatraemia had existed for years, but largely remained untested in the randomized trial 
setting. The regulatory approval of two vasopressin-receptor antagonists changed all that 
as industry launched a global campaign to sell to clinicians the importance of both chronic 
hyponatraemia as a problem and these new agents as its solution.
Our review identified 33 randomized trials, all save five investigating a vasopressin re-
ceptor antagonist. We found vasopressin receptor antagonists modestly raised serum so-
dium concentration (on average about 4 mmol/L) at the cost of a 10% increased risk of 
the rise being too rapid. To date little evidence from RCTs exists for a favourable effect on 
mortality, quality of life or any other truly patient-important health outcome. Studies con-
tributing to the review included mostly participants with mild to moderate hyponatraemia 
(mean serum sodium concentration at study level ≥123 mmol/L). Meta-regression revealed 
a modifying effect of the serum sodium concentration at baseline, with lower values associ-
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ated with larger increases and correspondingly more people with increases that were too 
rapid according to current standards. Extrapolation of meta-regression data would suggest 
higher increases, but possibly higher risks of rapid correction as the baseline serum sodium 
decreases. Although no study reported osmotic demyelination, it is unclear what would 
happen if vasopressin receptor antagonists were used on a larger scale and in people with 
sodium concentrations below those included in the RCTs that contributed to the review.  
As hyponatraemia can develop in a variety of settings, it is not unreasonable to assume 
the effect of vasopressin-receptor antagonists may be different for different underlying 
conditions. There are two reasons for believing any differential effect of vasopressin re-
ceptor antagonists may be limited. First, metaregression did not indicate that the cause 
of hyponatraemia modified the effect of vasopressin receptor antagonists on change from 
baseline in serum sodium concentration or any of the other outcomes. Second, the major-
ity of studies that included participants with different underlying conditions, conducted 
some form of subgroup analysis. None showed appreciably different results according to 
the underlying condition.
Clinical practice guideline on the diagnosis and treatment of hyponatraemia 
Aiming for harmonisation across disciplines, European Renal Best Practice decided to 
collaborate with the European Society of Intensive Care Medicine (ESICM) and the Euro-
pean Society of Endocrinology (ESE). It turned out to be a very fruitful partnership. Interac-
tions between methodologists and clinicians in a truly multidisciplinary team safeguarded 
a commonality in view and resulted in a clinical practice guideline with the power to tran-
scend the confines of individual subspecialty implementation. 
The guideline suggested a diagnostic pathway that should allow reasonable discrimina-
tion between underlying causes so as to guide appropriate treatment. The main deviation 
from earlier algorithms was an initial reliance on urinary biochemical parameters and de-
emphasis of volume-status. Contrary to common belief, even nephrologists seem poor at 
assessing fluid balance [23]. 
When it came to treatment, we attempted to resolve an ever resurfacing problem caused 
by treatment strategies essentially being dependent on the speed with which hyponatrae-
mia develops. Focussing immediate decision-making on assessable symptoms rather than 
an estimate of time-frame removed at least some of the ambiguity earlier guidelines have 
been criticised for. 
Extensive external review has suggested broad acceptance of the guideline content, 
with selected members of the ESICM, ESE and ERA-EDTA indicating recommendations 
were felt to be clear, acceptable and implementable [20]. Still, as it often is multifactorial, 
hyponatraemia remains a complex topic and no guideline can hope to fully disentangle 
the intricacies of differential diagnosis and treatment. Some of the champions of vasopres-
sin receptor antagonists continue to have their reservations. They argue that if you accept 
important associations between hyponatraemia and adverse outcomes, and acknowledge 
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even mild hyponatraemia may cause, albeit mostly subtle symptoms, then how can a guid-
ance group advize against the one treatment that has proven efficacy in raising serum sodi-
um concentration? The answer lies in the a priori relative importance assigned to individual 
outcomes. For each intervention question, the guideline development group compiled a 
list of outcomes, reflecting both benefits and harms of alternative management strategies. 
They ranked the outcomes as critically, highly or moderately important according to their 
relative importance in the decision-making process. As such, patient-important health out-
comes (reduction in all-cause mortality or improvement in quality of life, cognitive and gen-
eral functional status) related to hyponatraemia and the treatment of hyponatraemia were 
considered critical. Owing to their surrogate nature, the outcomes ‘change in serum sodium 
concentration’ and ‘correction of serum sodium concentration’ were considered less impor-
tant than the critically and highly important clinical outcomes. What is essential, is that all 
this happened before the data were collected and critically assessed.  To date, clinically im-
portant outcomes remain insufficiently investigated in trials. The limited data we do have, 
suggest vasopressin receptor antagonists have little or no benefit on these outcomes for 
people with hyponatraemia. We do not debate whether vasopressin receptor antagonists 
are able to increase serum sodium concentration, because they do, at least in the short term. 
However, that by itself may not translate into an appreciable benefit, however much we 
would like it to. In the context of intervention studies, a surrogate is a measurable outcome 
such as a laboratory test, which responds to an intervention (e.g. lowering of cholesterol 
with statins) and is causally associated with a clinically important outcome (e.g. reduction in 
mortality with statins) [24]. Investigators often use surrogates instead of important health 
outcomes because surrogates can substantially reduce the cost, sample size and duration 
of a randomized trial. However, not all are valid proxies of clinically important outcomes. It is 
true that in acute and profound hyponatraemia, the evidence from observational studies is 
so overwhelming that we readily accept that increasing the serum sodium concentration is 
life-saving. It is also true that a chronically low serum sodium concentration is strongly and 
consistently associated with increased mortality and risk of bone fractures [18]. However, 
there is currently insufficient evidence that aside from affecting the surrogate (e.g. increase 
in serum sodium concentration with a vasopressin receptor antagonist) treatment in case 
of chronic hyponatraemia also changes the patient-centred outcomes downstream of the 
surrogate in the same causal pathway (e.g. reduction in mortality as a consequence of rais-
ing serum sodium concentration with a vasopressin receptor antagonist). In addition, the 
price paid for a 5 mmol/L increase in 290/1000 additional people, is an additional 29 having 
an increase exceeding 10-12 mmol/L/day, putting them at risk for osmotic demyelination 
syndrome. Although none of the participants in any of these randomised trials developed 
osmotic demyelination syndrome, in fact none were expected to. Although incidences are 
currently impossible to estimate, they are undoubtedly very low. Yet, it is precisely the fear 
of this rare but dramatic complication that has caused front-line clinicians to be extremely 
careful in the process of correcting hyponatremia.  Throughout the guideline development 
process, the group tried to stick to the adagio ‘Primum non nocere’. 
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General conclusion
Evidence-based practice of Nephrology is often challenged by a lack of high-quality evi-
dence on the benefits and harms of tests and interventions. The studies conducted for this 
thesis predominantly highlight how limited the data for informed decision making some-
times are. It clearly limits the extent to which one can expect systematic reviews to provide 
insights beyond those provided by the individual studies and one may ask whether such 
studies are worth conducting at all. Of course, any attempt to answer the question some-
how leads to a catch-22 situation, where utility can only be assessed ad-hoc and decisions 
have to be made regardless of whether or not high quality evidence exists. 
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Guideline development is hampered by the availability and quality of evidence
With this thesis I set out to contribute to evidence based practice by showing what worked and what didn’t for various conditions in clinical nephrology. In-stead, this exercise mostly revealed just how little we know of the diagnostics 
and therapeutics we use to prolong or improve the lives of the people we treat.
Unbiased and precise estimates of effect typically call for sizable randomised controlled 
trials. But such trials are costly and ill-afforded by most. As a consequence, the market is 
increasingly dominated by industry seeking to promote new – and often expensive - phar-
maceuticals or devices. Interventions are compared with placebo – to obtain regulatory 
approval – or with control groups that are likely to produce ‘sure wins’ [1-3]; they measure 
surrogate rather than patient-important outcomes [4, 5]; and often stress the benefits and 
underplay the harms [6-10]. They often do not aim to entirely answer the questions that are 
relevant for clinical care. The way in which society values the achievements of independent 
researchers is partly responsible for this evolution. Novelty ignites excitement, begets sci-
entific esteem, and is honoured both professionally and financially. Studies examining new 
tests and treatments are more thrilling to conduct, more likely to be read and thus more 
likely to be published than studies evaluating the benefits and harms of existing ones. As a 
consequence, existing – often less costly – alternatives often remain below the radar.  
Where attempts are made to objectively examine what truly matters to patients, we are 
often limited by how researchers conduct and report their research. There is insufficient 
agreement on what outcomes matter, unsatisfactory guidance on how they should be 
measured and excessive variability in how they are reported. It makes effectively collating 
the research that ís being done a tremendously challenging task with results that are often 
very difficult to interpret. Given the costs involved in conducting clinical studies, this lack of 
standardisation is a luxury we cannot afford. 
Conclusions are highly dependent on what we do in the face of uncertainty
Clinical practice guidelines are often faulted for offering inconsistent recommendations 
and the suppliers of evidence remain a convenient culprit to blame. Still, methodological 
issues aside, it may not be so much a problem of the evidence we have, than what we do 
in the face of its absence. Consider a shortage of data on harms. If an intervention has a 
suggested benefit, do you believe withholding it does people disservice, or do you fear the 
unknown risk? This dilemma may explain some of the controversy we have seen around 
treatment of hyponatraemia with the ‘vaptans’ and the different viewpoint held by at least 
some of the American experts compared with the European guideline group.  A witty col-
laborator nicely captured the sentiment by stating: ‘It’s what separates us from one another; 
in case of uncertainty, the Americans went west. We just stayed put.’ In that sense, it may 
be more of a philosophical dispute than a methodological one, and possibly a much more 
difficult one to resolve.
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Future perspectives
If we are adamant about resolving some of the raised concerns, we need to generate 
more evidence targeted at answering the questions that are truly relevant for clinical care. 
Guideline organisations need to work with systematic review groups and both should be 
involved in setting the research agenda while safeguarding it from industry lobby.   
If we believe clinical practice recommendations have the ability to improve quality of 
care – it is an ethic premise for developing guidelines - then we need to spend more time 
and effort in bringing them to the bed-side. Research into the effectiveness of implementa-
tion strategies is paramount to ensuring restricted funds are allocated wisely. 
Thus far, guideline development organisations have seldom integrated health-economic 
data into the equation. Yet, in an environment where resources are becoming exceedingly 
scarce, it is a responsibility physicians cannot continue to evade. Equally, guideline organi-
sations need to address it too. Constructive integration of health-economics should aim to 
help understand key economic trade-offs between alternative management strategies, by 
summarising evidence for resource use, costs and cost-effectiveness from economic evalua-
tions conducted in different settings and at different times, placed in the context of the best 
available evidence for management effects. It requires collaborative views on how health-
economic data should be collated and incorporated into supranational decision-making. It 
requires guideline development groups to expand their methodological support to include 
people trained in health-economic synthesis. Be it difficult as it may, recommendations 
made without any reference to the implications for the sustainability of healthcare systems, 
are recommendations made into the void. 
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